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Abstract
One hundred and ninety five thousand abortions were performed in Britain in 1989, a
rate of 13 per 1000 women of reproductive age. Data from England and Wales
indicates that 35% of women undergoing abortion in 1989 were at less than nine
weeks gestation, a stage when menstrual induction can readily be performed. The
method of abortion in almost all these women was vacuum aspiration, but there is
increasing interest in menstrual induction, whereby early pregnancy can be terminated
medically without the need for surgical intervention. The development of the
progesterone antagonist mifepristone offers the possibility of a safe method of
menstrual induction (in combination with a prostaglandin), which is effective and has
minimal side effects. The minimum effective dose, and the mechanism of action of
mifepristone are however unknown. The work in this thesis has investigated these two
questions further.
When the efficacy and side effects of three different doses of mifepristone: 200 mg,
400 mg and 600 mg followed 48 hours later by 1 mg gemeprost in women of < 56
days amenorrhoea were compared, all three regimes were equally effective, with a
mean complete abortion rate of 98%. There were no differences in the incidence of side
effects between the three groups. In contrast, a lower complete abortion rate of 87%
was seen in women at the same gestation following gemeprost alone (1 mg 6 hourly to
a total of 3 mg) (p<0.01). In a randomised comparison between the two methods,
there was a significantly greater requirement for analgesia following the use of
gemeprost alone (p<0.02).
The effects of a new prostaglandin (misoprostol) which could be used in combination
with mifepristone were also studied. A significant increase in uterine tone was
observed 30-120 minutes after 200-600 (ig misoprostol alone (p<0.01); in women
pretreated 48 hours earlier with 200mg mifepristone, an increase in uterine contractility
measured in Montevideo units was observed 30 minutes after 200-600 (ig misoprostol
(p<0.01). Eighteen out of twenty one women aborted using 200 mg mifepristone
followed 48 hours later by 200-1000 (ig misoprostol.
In the second part of this thesis, the mechanism of action of mifepristone has been
investigated. In vitro studies have already shown that the addition of mifepristone to
culture medium results in an increased ability of decidua to generate PGF2a in culture.
In the studies described here, decidua harvested from women pretreated in vivo with
mifepristone showed a similar increase in ability to generate PGF2a- This increase was
inhibited by co-administration of indomethacin in vivo. Uterine activity measurements
showed an increase in uterine activity following mifepristone in vivo, but co¬
administration of indomethacin failed to inhibit this increase. The increase in uterine
activity seen following mifepristone is likely, therefore, to be due to mechanisms
other than an increase in decidual prostaglandin production.
Finally, when the effects of mifepristone on the cervix were studied in primigravidae
of eight to twelve weeks gestation, it was found that mifepristone significantly reduced
the median total force required to dilate the cervix from 4 mm to 10 mm, from 93
Newtons in a control group to 47 Newtons in a group of women pretreated with 200
mg mifepristone 36 hours earlier (p<0.0005). There was no difference in the ability of
the cervix to generate PGE2 and PGF2a in tissue culture between the groups.
In summary therefore, the minimum effective dose of mifepristone to induce abortion
in combination with prostaglandin is still to be established. The mechanism of action of
mifepristone is similarly unclear, but appears to involve mechanisms other than an




" the world needs a Fifth Freedom - freedom from the tyranny of
civilised man's excessive fertility". (Baird, 1965).
" No developed country has brought down its birth rate without a
considerable recourse to abortion and it appears unlikely that
developing countries can ever hope to see any decline in their fertility
without massive resort to induced abortion". (Potts et al, 1977).
Innovations in methods of abortion have implications not only for individual women,
but also for the world's population as a whole. In the United Kingdom, since the
1967 Abortion Act allowed induced abortion under certain specified circumstances, the
number of abortions performed has increased steadily each year. In Scotland in 1990,
10,000 abortions were performed, giving an abortion rate (the number of abortions
performed per 1000 women of reproductive age) of 9.1 (Scottish Home and Health
Department, 1991). In England and Wales the abortion rate is higher at 13.4 (Office of
Population Censuses and Surveys, 1990). Worldwide it has been estimated that some
40-60 million abortions are performed each year (Tietze and Henshaw, 1986), with an
estimated maternal mortality of 200 000 per year from induced abortion alone (Mahler,
1987). In the U.K, the mortality from induced abortion is low, with only two maternal
deaths being recorded following induced abortion (legal or illegal) during the triennium
1985-1987, the most recent period for which the Report on Confidential Enquiries into
Maternal Mortality is available (Department of Health et al, 1991). This gives a rate of
4.2 deaths per million legal abortions. The method of abortion used depends on the
gestation. Data collected on all abortions performed in NHS hospitals in England and
Wales in 1985 indicates that medical abortifacients (mainly prostaglandins) were used
in 56% of cases at 13-19 weeks gestation, whereas for abortions performed on
women of less than 9 weeks gestation, surgical methods were used in 98% of cases
(Office of Population Censuses and Surveys, 1986). The unpopularity of medical
abortion (or menstrual induction) in the early first trimester relates primarily to the side
effects of the agents used, which are thought to be excessive in comparison with the
relatively straightforward procedure of vacuum aspiration under general or local
anaesthetic. However, with the development of an effective antiprogesterone
(mifepristone), interest has been rekindled in menstrual induction and medical
abortion.
Part 1:
Methods of menstrual induction.
The unpopularity of medical abortion in early pregnancy amongst providers of abortion
services is not shared by women using these services. In a study performed in
Sweden, women of up to 49 days amenorrhoea requesting legal termination of
pregnancy were offered a choice between vacuum aspiration, and medical abortion
(using vaginal prostaglandins) at home or in hospital. The majority (43/51) opted for
medical abortion, despite an awareness that this would probably be more painful than
vacuum aspiration (Rosen et al, 1984). In another study using intramuscular
sulprostone as an abortifacient in women with a mean menstrual delay of 17 days,
89% of the women who had previously also undergone surgical termination of
pregnancy stated a preference for medical abortion (Csapo et al, 1980). Similar data
has been obtained following the use of antiprogesterone and prostaglandin. In the
U.K, 95% of women seeking abortion at less than 56 days of amenorrhoea, who were
offered a choice of either medical abortion using mifepristone and gemeprost or
vacuum aspiration opted for medical abortion. Following the procedure 89% found
the procedure acceptable and 10 out of the 13 women who had previously also
undergone surgical abortion stated a preference for medical abortion should a future
abortion be required (Urquhart and Templeton, 1988).
Menstrual induction (medical abortion within a few weeks of the first missed menses)
is potentially more straightforward than medical termination at a later gestation.
Spontaneous abortions before the eighth week of pregnancy are often complete,
probably due to a lack of anchoring villi which develop later in pregnancy, suggesting
that menstrual induction at this early stage of pregnancy is unlikely to be complicated
by incomplete abortion. Where blood loss following medical termination has been
measured, it is proportional to gestation (Rodger and Baird, 1989). The work in this
thesis concentrates on the methods and mechanisms of action of medical abortion in
women of up to 56 days amenorrhoea. In the first three chapters, the use of
prostaglandins for menstrual induction, either alone or in combination with the
antiprogesterone mifepristone, is investigated. The literature on the use of
prostaglandins and the antiprogesterones for early medical abortion is reviewed below.
The uterotonic effects of prostaglandins have been apparent since an active substance
in the seminal plasma (Kurzrok and Lieb, 1930), later termed "prostaglandin"
(Von Euler, 1935) was first discovered, but it was not until after the prostaglandins
were isolated and their structure delineated that this effect could be exploited for
fertility control. The use of natural PGF2a as an abortifacient was first described in the
early 1970s in women in the late first and early second trimester; complete abortion
was achieved in 13/15 women following intravenous administration of PGF2a (50
|ig/min) (Karim and Filshie, 1970), and in 3/11 women following intravenous PGE2
(l-10mcg/min) or PGF2a (10-50 pg/min), or subcutaneous PGF2a (5 mg 3 hourly)
(Roth Brandel et al 1970). The first description on the use" of prostaglandins for
menstrual induction was the use of PGF201 as a continuous intravenous infusion (up
to 300 pg/min) for 7 hours to twelve women of up to 17 weeks gestation (Wiqvist and
Bygdeman, 1970). Abortion occurred in all seven women of up to nine weeks
gestation within 24 hours, and in three of the other five women after a second course
of treatment the following day. The apparent increased effectiveness in the earlier
stage of pregnancy was attributed to decreased cervical resistance and a more
vulnerable vascular connection between the conceptus and the uterus at this early stage
of pregnancy. This complete abortion rate of 100% in early pregnancy was not
achieved by other workers. In another study, thirteen women reporting menstrual
delay of between 6-18 days (34-47 days of amenorrhoea) were given PGF201
intravenously (50 pg/min) for 8 hours 20 minutes (Wentz and Jones, 1973). Nine
out of the thirteen women were subsequently found to have been pregnant (by
measurement of hCG by radioimmunoassay, with a sensitivity to 5 IU/1).
Five patients aborted completely, but four continued to have a positive immunological
pregnancy test following treatment. Histological evaluation of products of conception
obtained at uterine evacuation from these latter four women showed severe
trophoblastic damage. The authors concluded that caution should be exercised in the
use of PGF2a as a post conceptive agent for fertility control, because of lack of
reliability of the method and because of concern about adverse effects on the pregnancy
should the pregnancy continue. In addition, abortion was not an inevitable
consequence of vaginal bleeding, so that follow up was necessary to determine
outcome.
One of the advantages ofmenstrual induction over surgical termination of pregnancy is
that the potential for selfmedication exists. In an attempt to find a method which would
allow this, other routes of administration of prostaglandin have been explored. Vaginal
PGF2a in THAM solution was administered to nine women of between 34-40 days
amenorrhoea every 2-4 hours for 24 hours, up to a total dose of 1100 mg PGF2a
(Corlett et al, 1972). Three out of nine women aborted completely. Evidence of
adequate absorption into the systemic circulation was confirmed by finding a two to
eight fold increase in serum prostaglandin levels during treatment. Although there was
a fall in the concentration of 17-hydroxyprogesterone, a marker of luteal function,
following treatment, this occurred only after a fall in serum hCG, suggesting that
prostaglandins did not induce luteolysis directly. Variable rates of success of between
50 and 80% have been achieved by other groups, using vaginal prostaglandins within
a few weeks of the first missed period (Sato et al, 1973; Bolognese and Corson, 1973;
Tredway and Mishell, 1973; Jones et al, 1974), although gastrointestinal side effects
were noted to be a problem in most of these studies. Again, the lack of efficacy and
poor correlation between vaginal bleeding and eventual abortion meant that follow up
was necessary.
A modification of the use of prostaglandins for early pregnancy termination was
suggested by Csapo, who proposed that the mechanism of action of prostaglandins in
inducing abortion was biphasic. The initial effect was to promote uterine activity,
resulting in suppression of the endocrine function of the fetoplacental unit, and
withdrawal of progesterone, which in turn increased spontaneous uterine activity
(Csapo and Pulkinnen, 1979a). The success of prostaglandin in abortion therefore
depended on the initial "prostaglandin impact" (Csapo et al, 1972). Although this was
initially described in women of nine weeks gestation (i.e after the luteoplacental shift),
it also appeared to operate in early pregnancy, with the insult to the endocrine function
of the fetoplacental unit leading to luteolysis. From these observations, it seemed
sensible to administer prostaglandins as a bolus. Thereafter the above mechanism
would ensure the development of uterine activity without further doses of
prostaglandin being given. Clinical studies used intrauterine administration of
prostaglandins, so that a large dose of the drug could be given directly to the target
organ. Complete abortion rates of 91% (in twenty two women at a mean of 11 days of
missed menses following a single intrauterine injection of 5 mg PGF2a) (Csapo et al,
1973a), and 100% (65 women with a mean of eleven days of missed menses given
either 5 mg PGF2a [n=50] or lmg PGE2 [ n=15] ) (Moscary and Csapo, 1973) were
achieved. Similar success rates were found following intrauterine prostaglandin
therapy by other investigators (Karim 1973; Ylikorkala et al, 1974). An American
group had a lower complete abortion rate of 65%, using a similar protocol at a slightly
later gestation of 38-47 days amenorrhoea and felt that the incidence of side effects (up
to 35%), including hypertension and haemorrhage, and septic abortion in those who
failed to abort completely made the method unsuitable for routine use (Lichtman et al,
1974). Despite the apparent success of extraovular prostaglandin for menstrual
induction, some disadvantages of the regime were becoming obvious. In all the above
studies - with the exception of one (Karim, 1973), premedication was required and the
route of administration precluded self administration. Side effects were greater than
experienced with vacuum aspiration. In a comparison between intrauterine PGF2a
(5 mg) and vacuum aspiration under intramuscular analgesia alone, in 200 women of
up to 56 days amenorrhoea the incidence of vomiting in the prostaglandin treated group
was 30%, significantly greater than in the group undergoing vacuum aspiration (9%),
although the rate of complete abortion was high in each group, and only one patient
(in the vacuum aspiration group) failed to abort completely (Ragab and Edelman,
1976).
When prostaglandins are administered via a route which involves systemic absorption,
repeated high doses have to be given because of the short half life of the natural
prostaglandins in the circulation. The development of a synthetic prostaglandin, with
an alkyl group at CI5 such that oxidation at C15 did not occur, and thus had increased
activity (Bundy et al, 1971) offered a prostaglandin which could be given once only.
The effects of 15 methyl PGF2a on uterine contractility were found to be 100-400
times greater than that of the natural compound, depending on the route of
administration (Karim and Sharma, 1972). The abortifacient effects of 15 methyl
PGF2cx and PGE2 were initially demonstrated in the late first, and second trimesters,
with a complete abortion rate of 91% (Lauersen and Wilson, 1975a; Lauersen and
Wilson, 1975b). When 15-methyl PGF20C was used for menstrual induction, complete
abortion was achieved in 8/9 women (Lauersen and Wilson, 1976) and 32/34 women
(Fylling and Jerve, 1977), of up to 60 days gestation following multiple or single
intramuscular injections respectively. The latter study also investigated the effects of
vaginal therapy with the synthetic prostaglandin, this having the advantage that it could
be given at home. Thirty women were given the first dose of prostaglandin in hospital,
and subsequently self administered further doses at home. All aborted completely.
Many other investigators also reported their results with vaginal 15-methyl PGF2a
therapy, and initially promising success rates were achieved with complete abortion
without further therapy, of between 70-94% in women up to 61 days from the last
menstrual period (Bygdeman et al, 1976, Ylikorkala et al, 1976; Zoremthangi et al,
1976; Hamberger et al, 1978; Lauersen and Wilson, 1980). However, 15-methyl
PGF200 did not constitute an ideal abortion method, since repeated doses were
necessary, making non compliance a problem. Gastrointestinal side effects were still a
significant feature, occurring in up to 50% of patients, and premedication was still
required in all but two (Zoremthangi et al, 1976; Lauersen and Wilson, 1980) of the
above studies. A long acting suppository of 15 methyl PGF201 has been developed
which gives a sustained release of prostaglandins (Spilman et al, 1976). In women of
less than 50 days amenorrhoea, the complete abortion rate following a single vaginal
pessary was dose dependent. 120 out of 128 women aborted following a single 3 mg
dose (Green et al 1978). Although compliance was not a problem with this regime,
gastrointestinal side effects were still excessive, and the development of a regime
giving consistent results remained elusive. In addition, objective measurement of blood
loss showed a mean blood loss during abortion of 131 ml, and a mean blood loss
during menstruation 2-4 months later at the upper limit of normal, perhaps reflecting
continued presence of trophoblast (Hamberger et al, 1978). Notwithstanding these
problems, vaginal 15-methyl PGF2a has become the method of choice for early
abortion in some countries (Population Information Program, 1980).
Introduction of methyl groups at CI6 has generated prostaglandins which are more
resistant to oxidation of the 15 hydroxy group, thus increasing in vivo activity. These
compounds are called the "third generation" prostaglandins. Four have been
extensively investigated for their use in pregnancy termination: 16 phenoxy-tetranor
PGE2 methyl sulphonylamide (sulprostone); 16, 16 dimethyl PGE2; 16, 16 dimethyl
PGEi methyl ester (gemeprost); and 9-deoxo 16,16 dimethyl 9 methylene PGE2 (9
methylene PGE2).
These compounds were first administered as extraovular injections, and a complete
abortion rate of 95% achieved in a study of 240 women of up to 6-14 days menstrual
delay following a single 50 p.g dose of sulprostone into the uterine cavity
(Karim et al, 1977). Intramuscular administration of sulprostone induced complete
abortion in 94-100% of women of less than 49 days amenorrhoea (Csapo and
Pulkkinen, 1979b; Csapo et al, 1980, Fleicher et al, 1982; Bygdeman et al, 1983). In
the largest of these studies, 90 women with a mean menstrual delay of 17 days were
given repeated intramuscular injections of 500 (ig sulprostone every 4 hours to a
maximum of 2 mg. The complete abortion rate was 96% and the incidence of
vomiting and diarrhoea was 26% and 10% respectively (Csapo et al, 1980).
16, 16 dimethyl PGE2 has been administered as a vaginal suppository; abortion rates
of 87-100% have been achieved following up to 4 mg in divided doses in women of
less than 56 days amenorrhoea (Lundstrom et al, 1977; MacKenzie et al, 1978).
Gastrointestinal side effects were reported by up to 50% of patients. The advantages of
the newer prostaglandins were indicated by the greater efficacy and lower incidence of
gastrointestinal side effects in women of a similar gestation treated with vaginal 16,
16, dimethyl PGE2 compared to vaginal 15-methyl PGF201 although a randomised
comparison was not performed (MacKenzie et al, 1978). Vaginal administration of
16, 16, dimethyl PGEi (1 mg every 1-3 hours; up to 5 mg) induced abortion in 87%
of patients with up to 49 days of amenorrhoea (Smith and Baird, 1980). Finally,
9 methylene PGE2 has also been administered vaginally, complete abortion occurring
in 92-98% of women, depending on the dose (Bygdeman et al, 1983).
Several trials have compared menstrual induction using one of the third generation
prostaglandins to vacuum aspiration under local or general anaesthesia.
Menstrual induction using vaginal administration of up to 3.6 mg of 16, 16 dimethyl
PGE2 (Lundstrom et al, 1977), up to 5 mg of 16, 16 dimethyl PGEi (Smith and
Baird, 1980), up to 120 mg 9-methylene PGE2 (Rosen et al, 1984) or up to 1.5 mg
intramuscular sulprostone (World Health Organization Task Force, 1987) was shown
to be as effective as vacuum aspiration either under local anaesthesia or under
premedication only. Premedication before menstrual induction was not given
routinely in any of these studies, but between 12% and 30% of women undergoing
menstrual induction required an injection of opiate analgesia, and most investigators
highlighted the greater incidence of gastrointestinal side effects in these women,
compared to those undergoing vacuum aspiration. In the largest of these studies,
involving 473 women, mean duration of bleeding was 9 days in the prostaglandin
treated group compared with 4 days in the vacuum aspiration group (p<0.001)
(World Health Organization Task Force 1987). Similar trends were observed in the
other three studies. Objective measurement of blood loss shows a mean loss of 70-85
ml in women treated with prostaglandin, vacuum aspiration under local anaesthesia or
vacuum aspiration under general anaesthesia, with no significant differences between
the groups (Smith and Baird, 1980).
Progesterone is essential for the maintenance of early pregnancy in humans.
In a study on removal of the corpus luteum (the main source of progesterone in early
pregnancy prior to the luteoplacental shift) uterine activity developed in all eleven
women who underwent lute-ectomy at a mean of 50 days gestation, and seven out of
eleven women aborted completely (Csapo et al, 1973b). In another group of seven
women who also underwent lute-ectomy, but received progesterone replacement
(200 mg intramuscular per day), the pregnancy continued apparently unaffected in all
seven. In contrast, oestradiol replacement therapy failed to prevent abortion following
lute-ectomy (Csapo et al, 1973c), demonstrating that the luteal hormone which inhibits
uterine activity and maintains pregnancy is progesterone rather than oestradiol.
Compounds which reduce levels of endogenous progesterone have long been sought
as abortifacients. The synthesis of progesterone can be blocked by a variety of
synthetic gestagens and indeed by progesterone itself in vitro (Shinada et al, 1978).
However, this effect cannot be exploited therapeutically because of the intrinsic
progestational activity of these compounds. The group of 3(3 hydroxysteroid
dehydrogenase inhibitors, epostane, trilostane, azastene and cyanoketone (Sterling
Winthrop) inhibit progesterone production but have no agonistic activity themselves;
several studies have investigated the use of epostane for menstrual induction. Despite
initially promising results (Birgerson et al, 1987; Crooij et al, 1988) this work has not
been continued, partly because of the controversy surrounding medical abortifacients.
An alternative approach is to block the action of progesterone at the receptor, using an
"antiprogesterone" with a chemical structure sufficiently similar to the natural hormone
for adequate binding to the receptor, but with some modification which confers
antagonistic activity. R2323 (gestrinone) is a trienic steroid which binds to the
progesterone receptor and exerts a pronounced antiprogestinic effect. When given to
women after ovulation but before implantation it also results in a decrease in serum
progesterone and oestradiol 17(3 (Mora et al, 1975). When given for three days
around the time of ovulation it can be used as a contraceptive, with a Pearl index of
9.6% including user failures (Sakiz et al, 1974) although its contraceptive effect in the
luteal phase is very weak (Mora et al, 1975). However, decrease in progesterone and
oestradiol levels is inhibited by the presence of hCG, and thus it is ineffective as an
abortifacient after implantation. Other antiprogestational compounds, ORF 9371 and
anordrin, have also been investigated as abortifacients, but are not useful clinically
either because of low efficacy in vivo, or because of androgenic side effects
(Healy,1985). The discovery that some lip aryl steroids have antigluocorticoid and
antiprogestogenic activity has generated a series of compounds which can be used as
abortifacients, including mifepristone (Roussel Uclaf), ZK 987 34 and ZK 98 299
(Schering AG) (Teutsch, 1985) (Figure 1.1). A single report into the use of
ZK 98734 as an abortifacient in women has been published (Kovacs et al, 1989).
The data on the use (of ZK 98 734) ofmifepristone is more extensive, and is reviewed
below.
Figure 1.1.
Structure of progesterone and antiprogesterone.
In the first clinical study of mifepristone in human pregnancy, eleven women of less
than 56 days amenorrhoea requesting legal termination of pregnancy were given
mifepristone 200 mg/day for 4 days (Herrmann et al, 1982). Eight women aborted
completely, there was one incomplete abortion and two ongoing pregnancies.
Although the overall success rate with mifepristone alone seemed promising, the
patient with an incomplete abortion bled heavily and required a blood transfusion.
Fortunately this has been an infrequent occurrence in subsequent trials. Further trials
have confirmed similar success rates, with complete abortion occurring in around 60%
in women of up to eight weeks gestation (Sitruk-Ware et al, 1985; Vervest and
Haspels, 1985; Shoupe et al, 1986; Cameron et al, 1986; Mishell et al, 1987;
Birgerson and Odlind, 1988). Modification of the regime of administration, and of
the total dose given does not improve efficacy. However when treatment is restricted
to women within 14 days of the first missed menses, a higher complete abortion rate of
84-85% can be achieved (Couzinet et al, 1986; Ulmann, 1987). The inverse
relationship between gestation and complete abortion rate is also illustrated in a study
including women of 56-70 days amenorrhoea, treated with 200 mg mifepristone daily
for a total of 4 days; only 3 out of 9 women at this later gestation aborted completely
following treatment (Vervest and Haspels, 1985). Within each study, there appeared
to be few differences between women who abort completely and those who do not.
Plasma levels of mifepristone were the same in groups of responders and non
responders (Couzinet et al, 1986; Mishell et al, 1987), although in a group of women
of less than 49 days amenorrhoea, low (3hCG levels (<15,000 IU/1) and small
gestational sac diameters (<10 mm) were found to correlate best with a successful
outcome (Sitruk-Ware et al, 1990).
The abortion rate following mifepristone alone in the first trimester is therefore
insufficient for routine clinical use. Earlier studies on lute-ectomy have shown that
progesterone withdrawal not only induces uterine activity, but also sensitises the uterus
to the action of oxytocic agents (Csapo et al, 1973b). Following progesterone
inhibition with mifepristone, an increase in uterine activity and an increased sensitivity
to exogenous prostaglandins can be demonstrated (Bygdeman and Swahn, 1985;
Swahn and Bygdeman, 1988). This effect can be exploited to improve on the complete
abortion rate achieved using mifepristone alone and was initially demonstrated in a
study of 34 women of up to 49 days amenorrhoea treated with mifepristone 25 mg b.d
for 4 days, and 0.25 mg sulprostone intramuscularly on the fourth day, 32 of whom
aborted completely (Bygdeman and Swahn, 1985). The complete abortion rate of 94%
is similar to the success rate seen using sulprostone alone for menstrual induction
(Bygdeman et al, 1980), but pretreatment with mifepristone allows one sixth of the
dose of sulprostone to be used. The improved abortion rate when mifepristone is
used in combination with prostaglandins, compared to the use of mifepristone alone,
has been confirmed in other studies using a combination of mifepristone and
sulprostone, with abortion rates of 89-95% achieved in women of less than 50 days
amenorrhoea (Swahn and Bygdeman, 1989; World Health Organization Task Force,
1989). Pretreatment with mifepristone for 3 days prior to treatment with sulprostone
appears to be as effective as pretreatment for 4-6 days. Other prostaglandin analogues
have also been used in combination with mifepristone. Abortion rates of 94-100%
(Cameron et al, 1986; Rodger and Baird, 1987; Dubois et al, 1988; UK Multicentre
Trial, 1990), can be achieved in women given 0.5-1.0 mg gemeprost 48-72 hours after
mifepristone. There was no significant difference in abortion rates between the smaller
and larger dose of gemeprost used (0.5mg or l.Omg) (Rodger et al, 1989).
The use of a prostaglandin administered orally in combinatiort with mifepristone has
potential advantages. Firstly, the oral route of administration is more acceptable than
vaginal or intramuscular routes. Secondly, it allows for the possibility of self
administration. However, the combination of oral PGE2 (l-2mg) and mifepristone (25
mg bd for four days) was initially no more successful than that of mifepristone and
placebo (Swahn et al, 1989), with an overall complete abortion rate of 59%. One of the
newer prostaglandins, 9 methylene PGE2 seems to be more active orally, with an
abortion rate of 95% achieved using 600 mg mifepristone followed 3 and 4 days later
by 10 mg 9-methylene PGE2 (Swahn et al 1990). Another oral prostaglandin
(misoprostol) marketed for the treatment of peptic ulcer has also been used following
pre treatment with 600 mg mifepristone, and an overall complete abortion rate of 95%
achieved, in women of less than 49 days amenorrhoea (Aubeny and Baulieu, 1991).
Since the combination of mifepristone and prostaglandin allows a smaller total dose of
prostaglandin be given compared to the use of prostaglandin alone for menstrual
induction, prostaglandin related side effects are reduced. Mifepristone alone appears
to cause few side effects other than vaginal bleeding. Following large doses of
mifepristone (400 mg/day for four days) headache occurs in up to 30% of women
(Shoupe et al, 1986) and nausea and vomiting in up to 80%. However, these latter
are common pregnancy symptoms, so that only a small proportion of these symptoms
may be attributable to mifepristone (Cameron et al, 1986;
World Health Organization Task Force, 1989; World Health Organization Task
Force, 1990). Whilst the stimulatory effects of mifepristone on uterine activity may
induce abdominal cramps, opiate analgesia is not required. When mifepristone is
followed by a prostaglandin, prostaglandin related gastrointestinal side effects and
abdominal pain (presumably due to increased uterine activity) become a problem. In
a study of over 500 women given mifepristone and gemeprost, 26% and 13% of
patients reported vomiting and diarrhoea respectively as a new symptom in the
4 hours following prostaglandin treatment, and 28% required opiate analgesia
(UK Multicentre Trial, 1990). In a large French trial of over 2000 women, the
reported incidence of vomiting and diarrhoea was 15% and 7% respectively, and the
overall requirement for opiate analgesia was 1% (Silvestre et al, 1990). However,
some of these women were given premedication and so these data are likely to
underestimate the side effects ofmifepristone. The requirement for opiate analgesia is
related to prostaglandin dosage (Silvestre et al, 1990), and since smaller doses of
prostaglandins are as effective as the larger doses used in these studies
(Rodger et al, 1989; Silvestre et al, 1990), this offers a method of reducing side effects
without compromising efficacy. Median blood loss during abortion using
mifepristone and gemeprost up to 56 days amenorrhoea has been found to be 81 ml in
a series of 13 women (range 32-222 ml) (Cameron et al, 1986) and 71 ml in a series of
206 women (range 14-512 ml) (Rodger and Baird, 1989). Duration of amenorrhoea
has a major influence on blood loss, such that the median blood loss in 7 women of
between 56-63 days amenorrhoea was 154 ml (range 84-341 ml) (Rodger and Baird
1989). The requirement for blood transfusion was 0.1% in the first 10 000 women
treated in France from October 1988 (Aubeny, 1990).
If menstrual induction is to be more widely adopted, it should be shown to be at least
as safe as vacuum aspiration. Few studies have compared the long term effects of
menstrual induction and vacuum aspiration. In an analysis of 132 women in their
second pregnancy who had previously undergone menstrual induction with intrauterine
prostaglandin, the prematurity rate was 8% (Moscary and Csapo, 1978). The authors
compare this to Hungarian data showing a greater prematurity rate (of 13-20%) in
women who have previously undergone therapeutic abortion, mostly by dilation and
curettage (Csapo, 1973). However, a randomised comparison was not performed, and
accepted data fails to demonstrate an increased prematurity rate following termination
of pregnancy in the first trimester (World Health Organization Task Force, 1979).
There is no data on the long term effects of menstrual induction using a regime of
prostaglandins and mifepristone.
Increasing experience with the use of mifepristone and a prostaglandin for menstrual
induction has shown the combination to be safe and effective. However, the minimum
effective dose of mifepristone in combination with prostaglandin is unknown. In
Chapter 2, the results of a double blind randomised trial comparing a single dose of
200 mg, 400 mg or 600 mg mifepristone in combination with a single lmg dose of
gemeprost are reported. Where mifepristone is unavailable, or contraindicated, there is
a need for another effective agent for menstrual induction. Chapter 3 describes a study
to determine the efficacy and side effects of a new regime of gemeprost (a PGEi
analogue) for menstrual induction, and the efficacy of this compared to menstrual
induction with 200-600 mg mifepristone and 1 mg gemeprost. In Chapter 4, a study to
quantify the effect of the orally active prostaglandin misoprostol on uterine activity in
early pregnancy is reported, and the efficacy of misoprostol for early abortion, either
alone or in combination with mifepristone, investigated.
Part 2:
Mechanism of action of mifepristone in menstrual induction.
Although the importance of progesterone in maintaining early pregnancy, and the
development of uterine activity often sufficient to induce abortion when progesterone is
removed (as in lute-ectomy) is clear, the mechanism of action of mifepristone in
inducing abortion is unknown. At least three mechanisms may operate, either alone or
in combination. Firstly, there is evidence that mifepristone causes ultrastructural
changes in the endothelium of decidual capillaries (Schindler et al, 1985).
Baulieu has proposed that this is evidence of vascular damage induced by
mifepristone, leading to bleeding, and detachment of the conceptus (Baulieu, 1985).
Secondly, administration of mifepristone results in the generation of spontaneous
uterine activity (Bygdeman and Swahn, 1985; Swahn and Bygdeman, 1988), and an
increased sensitivity to exogenous oxytocic agents. This latter effect accounts for the
increase in complete abortion rate when mifepristone is followed by a small dose of
prostaglandin which would be ineffective when used alone. Thirdly, mifepristone
provokes cervical dilation and ripening, so that a reduced force is necessary to dilate
the cervix following treatment with mifepristone compared with placebo (Rldestad et
al, 1988). In vivo these effects could act in combination, so that mifepristone would
induce decidual damage and separation of the conceptus, and expulsion of the products
of conception would be engendered by spontaneous uterine activity and reduced
cervical resistance. A further mechanism has been proposed, arising from observations
that mifepristone inhibits trophoblastic production of (3hCG and progesterone in vitro
(Bischof et al, 1986, Das and Catt, 1987), and from evidence that mifepristone inhibits
progesterone production from granulosa cells in vitro (DiMattina et al 1986).
However, during abortion induced by mifepristone and prostaglandin, hCG and
progesterone levels fail to decline until prostaglandin is given and the conceptus is
expelled (World Health Organization Task Force, 1989), suggesting that mifepristone
does not have any direct effect on production of these hormones in vivo.
It is unclear whether the effects ofmifepristone in early pregnancy described above are
direct effects, or whether they operate via an intermediate mechanism. Mifepristone has
been shown to stimulate decidual prostaglandin production in vitro (Smith and Kelly,
1987) and ifmifepristone also stimulates uterine prostaglandin production in vivo, this
would explain many of the observed effects of mifepristone in vivo. In Chapter 5,
the effects of mifepristone on decidual prostaglandin production in vivo have been
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investigated. Firstly, it is appropriate to review the synthesis and metabolism of the
prostaglandins, and the known effects of progesterone and the antiprogesterone













Synthesis of prostaglandins from membrane phospholipids.
Prostaglandin synthesis and metabolism is illustrated in Figure 1.2. The first step in
prostaglandin production is the liberation of arachidonic acid mainly from cell
membrane phospholipids, this reaction being catalysed primarily by phospholipase A2
( PLA2). Free arachidonic acid is then converted (under the influence of the cyclo-
oxygenase enzyme system) to one of the cyclic endoperoxides (PGH2 and PGG2),
these are then quickly converted into the primary prostaglandins PGF2a and PGE2.
Metabolism of PGF2a and PGE2 proceeds via oxidation at CI 5 under the action of
15-hydroxyprostaglandin dehydrogenase, followed by reduction of the double bond
between C13 and C14 under the action of reductase, to give a 15 keto, 13 14
dihydro derivative (Grden 1986). Progesterone may influence prostaglandin
production at a number of sites in this pathway. There is evidence that progesterone
has a priming effect on prostaglandin production by laying down stores of arachidonic
acid which can be used as a precursor for prostaglandin production. In vitro
pretreatment with progesterone and arachidonic acid results in a subsequently greater
ability of the tissue to generate PGF2a and PGE2 compared with pretreatment with
arachidonic acid alone (Kelly et al, 1986a). The evidence that this effect also operates
in vivo can be inferred from studies on persistent proliferative endometrium (taken
from women with heavy irregular menses, suggesting the presence of anovulatory
cycles, and a lack of exposure to progesterone) which has a lower endogenous
concentration of PGF201 than normal secretory endometrium (Smith et al, 1982),
although when persistent proliferative endometrium was incubated with arachidonic
acid, production of PGF2a and PGE2 increased to that of normal secretory
endometrium. The authors concluded that persistent proliferative endometrium has the
same synthetic capacity as secretory endometrium, but lacks endogenous arachidonic
acid required as a precursor for prostaglandin synthesis. Paradoxically, progesterone
has a direct inhibitory effect on prostaglandin synthesis. PGF2a and PGE2 production
from both secretory and proliferative endometrium in organ culture is decreased by the
addition of 5-500 ng/ml progesterone to the culture medium (Abel and Baird, 1980).
Similar effects of progesterone on PGF2a production were seen using isolated
fragments of proliferative endometria in tissue culture (Kelly and Smith, 1987a).
The inhibitory effect of progesterone was not overcome by the addition of arachidonic
acid suggesting that progesterone inhibits prostaglandin synthetic activity.
Similar mechanisms appear to operate in the myometrium (Jeremy and Dandona,
1986). Progesterone may also inhibit prostaglandin production via an increase in
lysosomal membrane stability (Dawood, 1981), thus reducing availability of PLA2.
The inhibitory effect of progesterone on prostaglandin production which has been
demonstrated in vitro also appears to operate in vivo during pregnancy, with a decrease
in decidual prostaglandin production in both intrauterine (Maathuis and Kelly, 1978)
and ectopic pregnancy (Abel et al, 1980), although a similar inhibitory effect of
progesterone does not appear to operate in the second half of the menstrual cycle
(Maathius and Kelly, 1978).
Prostaglandin synthesis and metabolism may be linked such that pathophysiological
processes resulting in increased prostaglandin production also result in decreased
prostaglandin metabolism, and vice versa (Hoult and Moore, 1979). In vitro,
progesterone not only inhibits prostaglandin synthesis, but also increases
prostaglandin metabolism: pretreatment of stromal cells in tissue culture with
progesterone increases the conversion of PGE2 and PGF2a to their 13,14 dihydro
15 keto metabolites (Kelly et al, 1986a). The stimulatory effect of progesterone on
prostaglandin metabolism also operates in vivo. The activity of endometrial
15-hydroxyprostaglandin dehydrogenase is highest during the secretory phase of the
menstrual cycle when progesterone dominates, and low in anovulatory cycles, where
progesterone is lacking (Casey et al, 1980). In pregnancy between 5 and 14 weeks
gestation, there is a close correlation between placental 15-hydroxy prostaglandin
dehydrogenase activity and the placental progesterone concentration
(Falkay and Sas, 1978).
Several studies have investigated the effects of the antiprogesterone mifepristone on
prostaglandin production in vitro. Mifepristone stimulated PGF2« and PGE2
production from endometrial stromal cells in tissue culture (Kelly et al, 1986a) and
this increase was competitively inhibited by progesterone. When separated decidual
glandular cells from pregnant women in the first trimester were cultured in vitro with
mifepristone, an increase in PGF201 production compared with control was also seen
(Smith and Kelly, 1987). This occurred both in the presence and absence of
arachidonic acid, suggesting an effect ofmifepristone on the cyclooxygenase enzyme.
In contrast to these findings, and the findings expected by extrapolation from the action
of progesterone in vitro, incubation of fragments of secretory endometrium with
mifepristone alone resulted in a significant decrease in PGF2a and PGE2 production,
suggesting that mifepristone acted as a progesterone agonist in this situation (Kelly and
Smith, 1987b). The reasons for these apparendy contradictory findings are not clear.
Few studies on the effects of mifepristone administered in vivo on prostaglandin
production have been published. In recent studies on the effect of oral mifepristone in
pregnant women, there was no increase in serum levels of prostaglandin metabolites
24-48 hours after mifepristone administration, either in the first
(Hill et al, 1990a) or in the second (Hill et al, 1990b) trimester. The authors conclude
that mifepristone in vivo has no effect on decidual prostaglandin production. However,
since mifepristone inhibits prostaglandin metabolism in addition to stimulating
prostaglandin production in vitro, a mifepristone-induced increase in decidual
prostaglandin production may not result in increased prostaglandin metabolite levels in
the serum. Data using the guinea-pig model, thought by some to be a good model
for the action ofmifepristone in the human (Elger et al, 1986), supports in vitro work
suggesting an inhibitory effect of mifepristone on prostaglandin metabolism in vivo. A
recent study using this model shows that a single 10 mg dose of mifepristone in vivo
inhibited the subsequent ability of the myometrium / decidua and of the chorion to
metabolise prostaglandins in vitro (Kelly and Bukman, 1990),«although there was no
significant effect of mifepristone pretreatment on the capacity of these tissues to
generate prostaglandins in tissue culture.
In general, therefore, progesterone inhibits decidual prostaglandin production, and
mifepristone stimulates prostaglandin production in vitro. In vivo effects of
mifepristone on prostaglandin production are yet to be fully determined, although there
was no increase in peripheral prostaglandin metabolite levels following treatment with
mifepristone. In Chapter 5, the results of a study to determine the effects of
mifepristone in vivo by measuring the ability of decidua harvested from women
pretreated with mifepristone to generate prostaglandins in culture are reported.
Mifepristone also stimulates uterine activity, and in Chapter 6 the mechanism of action
of this effect is investigated further. Firstly, it is appropriate to consider the physiology
of uterine contractility, and the mechanism of action of progesterone and the
prostaglandins on the inhibition and stimulation respectively of uterine activity. The
stimulation of uterine activity during pregnancy depends on the transformation of the
uterus from a quiescent to an actively contracting organ. The functional units of
uterine activity are the billions of small muscle cells which make up the myometrium.
Individual cells are 2-10 p.m wide and 50-800 (im long, and are arranged as bundles of
10-50 cells, oriented along the long axis of the bundle (Finn and Porter, 1975). These
compose the myometrium, with its two distinct layers of smooth muscle, the inner
circular layer and the outer longitudinal layer. Communication between individual
smooth muscle cells is achieved through "gap junctions". These intercellular channels
allow the passage of inorganic ions and small molecules of less than 1.6-2.0 nm
diameter (Schwarzmann et al, 1981).
The stimulation of uterine activity involves the generation of an action potential in an
individual muscle cell, and the conversion of this action potential into a contractile
force. In addition, for uterine activity to be effective in dilating the cervix and expelling
uterine contents, the myometrium has to function as a syncitium. Propagation of the
action potential into other muscle cells, and the orderly spread of uterine activity
throughout the uterus is also required, so that a wave of contraction can impart
directional force to the uterine contents. Uterine activity is controlled through
myogenic, neurogenic and hormonal mechanisms. The intrinsic properties of the
uterine smooth muscle are such that the uterus is able to contract spontaneously in the
absence of any other input. Although the myometrium is innervated by post
ganglionic fibres from the autonomic nervous system, neurogenic mechanisms are
thought to play little if any part in the control of uterine activity. However, the
observation that adrenergic nerves disappear near term during human pregnancy
(Thorbert et al, 1979), suggests that neurogenic mechanisms may be more important
than previously thought. The predominant controlling factors in the regulation of
uterine activity appear to be hormonal. In general, progesterone and relaxin inhibit
uterine activity, whereas oestrogen and oxytocin stimulate uterine activity.
The prostaglandins are a heterogeneous group, some of which (PGF2a, PGE2)
stimulate and others (PGI2) inhibit uterine activity (Challis and Lye, 1986).
The evidence for the suppressive effect of progesterone on uterine activity has been
discussed in Part 1 of this chapter (Csapo et al, 1973b). The mechanism by which
progesterone may control uterine activity can be inferred from in vitro studies.
Progesterone causes hyperpolarisation of smooth muscle cells in vitro, inhibiting
uterine activity by increasing the change in membrane potential required before an
action potential can be stimulated (Marshall, 1959). Since there is decreased
spontaneous electrical activity in areas of the myometrium overlying the placenta
(Csapo 1969), these effects may also operate in vivo. Progesterone may not only
inhibit action potential formation but also inhibit the conversion of these action
potentials to active contractions by affecting availability of calcium
(Carsten, 1979). Progesterone also appears to inhibit electrical coupling in the
myometrium, as evidenced by an increase in junctional resistance in conditions of
progesterone dominance (Ichikawa and Bortoff, 1970; Bortoff and Gilloteaux, 1980),
presumably by inhibition of gap junction formation. Thus the propagation of action
potentials into other smooth muscle cells, and the orderly spread of uterine activity
throughout the uterus is inhibited. In addition progesterone alters uterine activity via
effects on other oxytocic agents; it inhibits prostaglandin synthesis as discussed in
Part 1, and inhibits the replenishment of oestrogen receptors, thus inhibiting the
stimulatory effects of oestrogens on uterine activity (Clark and Peck, 1979).
The effect of prostaglandins on uterine contractility are mediated by mechanisms
controlling intracellular calcium levels. Prostaglandins stimulate intracellular calcium
release (Grosset and Mirroneau, 1977) and inhibit active calcium extrusion from the
cell (Popescu et al, 1984) both of which effects increase the resting tension of the
smooth muscle cell.
Chapter 6 describes a study to determine whether the mechanism of action of the
antiprogesterone mifepristone in stimulating uterine activity depends mainly on an
increase in uterine prostaglandin production, or on other mechanisms, by using
indomethacin to inhibit endogenous prostaglandin production in women treated with
mifepristone.
In addition to its effects on the myometrium and endometrium, mifepristone also
induces cervical softening and dilation (World Health Organization Task Force, 1990;
Cohn and Stewart 1991), an action which will contribute to its abortifacient effect.
For abortion to occur, the cervix has to efface and dilate under the influence of uterine
contractions. "Ripening" of the cervix reduces the force required for this, either when
generated in vivo from uterine activity or artificially with cervical dilators. Either in
early pregnancy to facilitate surgical abortion, or in late pregnancy to induce labour,
cervical ripening can be induced pharmacologically by agents such as prostaglandins
(Calder et al, 1977), oestrogen (Gordon and Calder, 1977), relaxin (MacLennan et al,
1980) or laminaria tents (Johnson, 1989). The physiological mechanisms underlying
cervical ripening are not clear, but may involve changes in collagen and
glycosaminoglycan concentrations in the cervix.
The human cervix is composed of collagen fibres, elastin, a matrix of proteoglycans
containing glycosaminoglycan (GAG) chains extending out from a protein core,
cellular elements dominated by smooth muscle cells and fibroblasts, and water
(Dobson, 1988). The relative proportions of these substances change during
pregnancy, with an increase in water content with increasing gestation (Uldbjerg et al,
1983a), and a greater collagen content (expressed as a proportion of the dry weight of
the cervix) in pregnant compared with non - pregnant women (Danforth et al, 1974;
Granstrom et al, 1989). Both these effects reduce the mechanical strength of the
tissue. During cervical ripening, histological changes in cervical collagen can be
observed, with a lower proportion of intact collagen fibres in dilated cervices, using
those from non pregnant women as a control (Junqueira et al, 1980). The mechanism
of collagen breakdown during cervical ripening is not certain, but may involve
collagenolysis induced by collagenase, generated by fibroblast and leucocytes;
and leucocyte elastase, from polymorphonuclear leucocytes (Uldbjerg et al 1983b).
Leucocyte elastase increases steadily during pregnancy and is at a maximum post
partum (Uldbjerg et al, 1983b). In addition, the ability of the cervix to breakdown a
synthetic DNP-peptide having the same amino acid composition as the
collagenase-sensitive part of the tropocollagen molecule increases during pregnancy,
suggesting increasing collagenase activity (Uldbjerg et al, 1983b). Although direct
evidence is lacking, it seems likely that cervical ripening is associated with activity of
proteolytic enzymes particularly that of collagenase, leading to collagen breakdown
and, therefore, a decrease in mechanical strength of the cervix. Changes in the
glycosaminoglycan concentration of the cervix may also contribute to cervical ripening,
with an increase in keratan sulphate (associated with a decrease in diameter of collagen
fibrils, [Borcherding et al, 1975]), an increase in hyaluronate concentrations
(associated with an increase in tissue compliance, [Bryant et al, 1968]), and a fall in
chondroitin sulphate (associated with a reduction in rigidity of cervical tissue, [Bryant
et al, 1968]) being observed during pregnancy (Von Maillot et al, 1979).
Biochemical changes in the cervix are also observed during pharmacologically induced
cervical ripening. Prostaglandin E2 increases DNP-peptide hydrolytic activity, and
therefore by inference collagenase activity (Uldbjerg et al, 1983b), and alters the
proportions of GAGs in cervical tissue (Norstrom, 1984). Intravenous administration
of the oestradiol precursor dehydroepiandrosterone sulphate increases cervical
compliance. This change is associated with an increase in collagenase activity in vivo
(Mochizuki and Tojo, 1980), although in vitro, oestradiol appears to inhibit
collagenase activity (Wallis and Hillier, 1981). The reasons, for this difference are
unclear, but may be due in part to infiltration of leucocytes containing collagenase in
vivo (Basset, 1962) an effect which cannot occur in vitro. In the sheep, progesterone
concentrations correlate with cervical resistance (Fitzpatrick and Dobson, 1979).
Possible mechanisms are via a reduction in collagenase activity (Jeffrey and Koob,
1980) or via leucoytic migration (Dobson, 1988). Lastly, the stimulatory effects of
relaxin on cervical softening (MacLennan et al, 1980) may be mediated via changes in
fibroblast activity, since relaxin appears to stimulate mitosis of fibroblasts in culture
(McMurtry et al, 1980).
Although the ripening effect of mifepristone on the cervix is well established, few
studies have investigated the mechanism of this. Extrapolating from the effects of
mifepristone on the decidua (Chapter 5) and myometrium (Jeremy and Dandona,
1986), it is tempting to speculate that mifepristone stimulates cervical prostaglandin
production. This would account for the known effects of mifepristone on the cervix.
The limited evidence available, however, fails to show an increased bioconversion of
radiolabeled arachidonic acid in vitro, by cervical biopsies taken from women
pretreated with mifepristone in vivo (Rldestad et al, 1990).
In Chapter 7 of this thesis, the results of a quantitative study to compare the effect of
mifepristone versus placebo on the force required for cervical dilation, and studies to
determine the role of cervical production of prostaglandins, and collagen and
glycosaminoacid breakdown are described.
In summary, the work in this thesis aims to investigate further the methods and
mechanisms of action of agents used for menstrual induction, principally those of the
antiprogesterone mifepristone.
Chapter 2:
The use of mifepristone (three different doses) and
gemeprost to induce abortion in women of up to eight weeks
amenorrhoea.
Introduction
The use ofmifepristone in combination with gemeprost provides an effective agent for
menstrual induction. Since mifepristone was made available in France in October
1988, over 80,000 women of up to 49 days amenorrhoea have been treated, in a
protocol using a single 600 mg dose of mifepristone followed 48 hours later by a
prostaglandin (usually sulprostone). Mifepristone was granted a product licence in the
UK by the Committee of Safety of Medicines in the summer of 1991, for medical
termination of pregnancy up to a maximum gestation of 63 days. The data sheet
recommends a dose of 600 mg mifepristone followed 36-48 hours later by 1 mg
gemeprost. Experience in the UK shows a complete abortion rate of 94% can be
achieved with this latter protocol (UK Multicentre Trial, 1990). The minimum effective
dose of mifepristone in combination with gemeprost is, however, unknown. Previous
studies have shown no differences in efficacy between 400 mg, 500 mg or 600 mg
mifepristone (Rodger and Baird, 1987); and a WHO supported trial has shown that
small doses of mifepristone (5 x 25 mg) were as effective as a single 600 mg dose
when followed by 0.5 - 1 mg gemeprost (World Health Organization Task Force,
1991). Although mifepristone itself is reported to induce few side effects, the use of an
unnecessarily large dose ofmifepristone has both cost and toxicological implications.
In this chapter, the effects of 200 mg, 400 mg or 600 mg mifepristone each followed
48 hours later by 1 mg of gemeprost, are compared. This study was part of a
multicentre trial under the auspices of the WHO, the results of which have not yet been
published.
Methods
One hundred and fifty women of < 56 days amenorrhoea undergoing legal termination
of pregnancy were randomised to receive either 200 mg, 400 mg or 600 mg oral
mifepristone (Roussel Uclaf) followed forty eight hours later by 1 mg of vaginal
gemeprost (a PGEi analogue). Women were followed up one, two, six and ten weeks
after mifepristone or until the next menstrual period. Completeness of abortion was the
main outcome measure. In cases of incomplete abortion or ongoing pregnancy, the
uterus was evacuated surgically. The protocol was approved by the local Reproductive
Medicine Ethical Subcommittee.
Recruitment.
General Practitioners and Family Planning Clinics in the area were asked to refer
pregnant women of < 56 days of amenorrhoea requesting therapeutic abortion, who
had grounds for termination of pregnancy under the 1967 Abortion Act. Patients were
initially seen in the gynaecology outpatient clinic. Their reasons for requesting
termination of pregnancy were ascertained, and they were counselled in the usual
manner. A full history was taken and general physical and pelvic examination
performed. A cervical smear was taken if appropriate, a high vaginal swab taken for
bacteriological culture and endocervical swab taken for culture for chlamydia. Once the
decision was made to terminate the pregnancy, women who met the study criteria were
offered medical termination of pregnancy using mifepristone and gemeprost. Details
of the study were given both verbally and in the form of an information sheet. Written
consent was obtained and patients were informed of their right to withdraw from the
study without prejudice to their future medical care. An admission date was scheduled
for mifepristone administration at the patient's convenience, usually on the same day or
the day following the clinic visit.
Mifepristone administration.
On admission (day 1), details of the patient's menstrual cycle, the date of the last
menstrual period, and previous obstetric and medical history were recorded on a data
sheet. Women were specifically asked if they had had any one of six common
pregnancy or prostaglandin related side effects since their last menstrual period
(nausea, vomiting, dizziness, fatigue, lower abdominal pain and breast tenderness) for
comparison before and after mifepristone and after prostaglandin. Blood pressure,
pulse rate, height and weight together with details of physical examination were
recorded. A pelvic ultrasound examination was performed, mean gestational sac
diameter, fetal crown rump length (if present) and the presence or absence of the fetal
heart was noted. Blood was taken for typing of the patient's blood group,
haemoglobin and serum human chorionic gonadotrophin estimation.
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Exclusion criteria for the study were :
age less than sixteen
recent irregular menstrual cycles
menstrual delay of less than seven or more than twenty-eight days
ectopic pregnancy
chronic disease affecting the respiratory, gastrointestinal, endocrine,
genitourinary, neurological or cardiovascular system
contraindications to mifepristone or prostaglandins
history of thromboembolism
regular use of prescription drugs or the oral contraceptive pill in the
cycle before conception or the conception cycle
A single oral dose of 200 mg, 400 mg or 600 mg of mifepristone was given.
The mifepristone dosage was allocated in a randomised fashion, randomisation being
performed by the World Health Organization in Geneva. The patients and investigator
were blind to the randomisation. Patients were allocated to numbered bottles of tablets
each containing a mixture of placebo tablets and tablets containing 200 mg mifepristone
in order of recruitment into the study. The bottles of tablets were made up by the
WHO in Geneva, or with total dose of 200 - mg, 400 mg or
600 mg mifepristone randomly distributed between them. Fifty bottles of each type
were prepared and the tablets were swallowed with water after the patient had fasted
for at least one hour. Women were allowed home immediately after taking the tablets,
given a menstrual diary card to record the pattern of vaginal bleeding and asked to
avoid the use of non steroidal anti-inflammatory drugs.
Prostaglandin administration
On readmission forty eight hours after mifepristone administration (day 3), details of
vaginal bleeding, blood pressure and pulse rate were recorded, and blood taken for
measurement of haemoglobin and serum human chorionic gonadotrophin The
pregnancy / prostaglandin related symptom questionnaire was repeated. A single
gemeprost pessary (1 mg) was inserted into the posterior vaginal fornix. Patients were
asked to remain in bed for one hour after prostaglandin administration, and were then
encouraged to mobilise or to sit up as they wished.
Following prostaglandin administration, blood pressure, pulse rate and temperature
were recorded hourly. The presence or absence over the preceding hour of the series of
pregnancy / prostaglandin related symptoms was recorded. Analgesia was given as
required, either oral paracetamol, oral or intramuscular dihydrocodeine, or
intramuscular diamorphine (with cyclizine) as appropriate. Most patients who
requested pain relief were given a mild analgesic initially, and then opiates if
necessary. A few patients in more severe pain were given diamorphine as an initial
analgesic. Non steroidal anti-inflammatory drugs were avoided because of theoretical
inhibitory effects on the action of mifepristone and gemeprost via effects on
prostaglandin production and metabolism. Many patients were aware when abortion
occurred, or passed products of conception into a bedpan. Otherwise, patients were
examined at the end of four hours to determine whether abortion had occurred, from
examination of uterine size and of the vagina for products of conception. Patients were
then allowed home if well and accompanied by an adult, some patients, especially
those who had been given narcotic analgesia, stayed in hospital for a further few
hours. Immunoprophylaxis (250 IU IgG to the rhesus D antigen) was given to
rhesus negative patients. A follow up appointment was given for day 8 (ie one week
after mifepristone administration). Women were asked to use non-hormonal methods
of contraception until the first menstrual period after treatment
Follow up.
At the follow up examination (day 8), the menstrual diary card was reviewed and the
incidence of complications and requirement for medical attention or drug therapy
noted. Blood pressure and pulse rate were recorded and pelvic examination performed.
Blood was taken for measurement of haemoglobin and serum human chorionic
gonadotrophin. The patient was given a further follow up appointment for one week
later.
At the second follow up appointment (day 15), a similar protocol was employed, and
in addition, a pelvic ultrasound scan was performed. Those patients with an ongoing
pregnancy (rising serum human chorionic gonadotrophin and a gestational sac of
increasing diameter on pelvic ultrasound scan with or without an active fetal heart), or
a missed abortion (near constant level of serum human chorionic gonadotrophin, a
gestational sac on ultrasound scan and no fetal heart activity) underwent surgical
uterine evacuation. Those few patients with an incomplete abortion (slowly falling
serum human chorionic gonadotrophin and products of conception visible in the uterus
on ultrasound scan) were managed conservatively or underwent surgical termination of
pregnancy, depending on their clinical condition.
Patients were seen again on day 43 and 71 until abortion was complete, and
menstruation had occurred. The duration of bleeding and date of menstruation were
noted. Once bleeding had stopped, patients were asked to compare the whole bleeding
episode compared with their normal menses.
Blood samples.
Haemoglobin and serum hCG concentrations were measured by the Haematology
Laboratory of the Royal Infirmary of Edinburgh, and the Reproductive Endocrine
Laboratory in the Centre for Reproductive Biology respectively.
Data calculation
When follow up on all the patients was complete, data was entered into the "Excel"
programme on an Apple Macintosh computer. The randomisation code was broken.
Data on the fifty patients in each group were compared with each of the other two
groups using "CLR anova" and "Statview 512".
Statistics.
Normally distributed data (weight, height, duration of amenorrhoea, and haemoglobin)
were compared using analysis of variance. Kruskal Wallis testing was used for
continuous data which were not normally distributed (interval to vaginal bleeding
following mifepristone and before prostaglandin, time to abortion and change in
haemoglobin and human chorionic gonadotropin levels). Categorical data was
analysed using the Chi squared test. Continuous data were plotted prior to analysis to
determine the type of distribution of the data. In some instances (age, sac diameter,
duration of vaginal bleeding and interval to next menses) the data were log
transformed before analysis to generate a normal distribution. Serial data on the same
patients have been compared using a paired t test for normally distributed data
(haemoglobin) or the Wilcoxon Rank Sum test for data which were not normally
distributed (human chorionic gonadotroph^). For normally distributed data, the mean
value and the 95% confidence intervals have been quoted. For data analysed using non
parametric methods, the median and the range of values have been quoted.
Results.
Patient characteristics
There were no significant differences between the three treatment groups in terms of
patients characteristics on admission to the study (Table 2.1a and b).
Table 2.1a
Characteristic 200 mg 400 mg 600 mg
Age (years) 27.3 (25.7 - 28.9) 29.2 (25.8 - 30.2) 25.8 (24.0 - 27.6)
Height (cm) 164(162- 166) 164(163- 166) 165 (164- 167)
Weight (kg) 61.1 (58.7 - 63.4) 60.0 (58.0 - 62.1) 61.6 (59.0 - 64.2)
Gestation (days) 46.7 (45.3 - 48.2) 47.3 (45.9 - 48.8). 47.8 (46.3 - 49.2)
Parous 40% 58% 48%
Previous live birth 32% 52% 38%
Characteristics of patients in each of the three treatment groups -
200,400 or 600 mg mifepristone - mean (95% C.I), or percentage.
Table 2.1b
Characteristic 200 mg 400 mg 600 mg
Sac diameter
(mm) 18.3 (16.6 - 20.1) 20.0 (17.6 - 22.7) 21.5 (19.5 - 23.8)
Fetal heart seen 66% 66% 55%








Results of investigations on patients in each of the three treatment groups, 200 , 400 and 600 mg
mifepristone; mean sac diameter (95% C.I), presence of fetal heart on ultrasound scan (% age); mean
haemoglobin (95% C.I) and median human chorionic gonadotrophin level (range) at initial visit.
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Effect of mifepristone
There were no significant differences in the effect of the three mifepristone doses on
vaginal bleeding, change in haemoglobin or on human chorionic gonadotrophin
concentrations (Table 2.2), nor in the effect on pregnancy or prostaglandin related
symptoms (Table 2.5). Fifty-eight percent of women had some vaginal bleeding in the
48 hours interval between mifepristone administration and prostaglandin
administration. Median time (range) to bleeding in those women who did bleed was 29
hours (3-47.5). Serum human chorionic gonadotrophin levels increased significantly
from before to 48 hours after mifepristone (p<0.005).
Table 2.2
200 mg 400 mg 600 mg
Bleeding 56% 58% 60%
Time to bleed (hrs) 32 (12 - 46) 30 (3 - 47) 27 (16-47)
Change in Hb (g/dl) 0.1 (-0.8 - +1.3) 0.0 (-1.6 - +1.4) 0.3 (-0.7 - +1.9)
hCG as (% of
original value)
124% (53-218) 106% (9 - 207) 106% (22 - 245)
Percentage of patients who bled in the forty eight hours after mifepristone, median interval to
bleeding (range) in those who did; median change in haemoglobin concentration (range) over 48 hours
following mifepristone and human chorionic gonadotrophin 48 hours after mifepristone, expressed as a
percentage of the original value.
There was a significant increase in the percentage of patients who had noted abdominal
pain during the forty-eight hours after mifepristone compared with at any time from the
last menstrual period to mifepristone administration (p < 0.02) There was no
significant change in any of the other pregnancy or prostaglandin related symptoms
during this period (Table 2.5). There were no differences between the three treatment
groups in terms of change of symptoms.
Effect of gemeprost and mifepristone.
One hundred and forty seven patients (98%) aborted completely without further
intervention following mifepristone and gemeprost. There were no differences in
abortion rates between any of the treatment groups. There was one ongoing pregnancy
(in a woman who had been given 400 mg mifepristone followed by 1 mg gemeprost).
This was terminated surgically three weeks after mifepristone administration. One
patient (in the 400 mg mifepristone group) underwent surgical uterine evacuation four
weeks following mifepristone administration after being referred to another
gynaecologist with prolonged vaginal bleeding; serial hCG levels had fallen to 39 IU/1
and an ultrasound examination had shown an empty uterus. Products of conception
were not obtained at curettage. A third patient (in the 600 mg group) underwent
diagnostic curettage and sterilisation after 55 days of vaginal bleeding. Histology of the
curettings showed "marked endometritis, occasional foci of decidua but no
trophoblastic villi." Eighty three percent of patients aborted an identifiable gestational
sac within four hours of prostaglandin administration, at a median time (in those
patients who aborted) of 180 minutes after prostaglandin administration (Table 2.3).
Analgesia was required by 55% of patients, and 21% of all patients were given
diamorphine. There were no significant differences between the treatment groups in
terms of products passed or analgesic requirements (Tables 2.3 and 2.4).
Table 2.3
200 mg 400 mg 600 mg
P.O.C. identified 82% 82% 86%
Time to abortion
(mins)
180 (99-255) 180 (80-240) 200 (60 - 240)
Percentage of women in each treatment group in whom products of conception were passed within four
hours of prostaglandin administration, and median (range) time to abortion.
Table 2.4
200 mg 400 mg 600 mg
None 38% 52% 44%
Paracetamol 18% 12% 16%
Codeine 26% 14% 16%
Diamorphine 18% 22% 24%
Analgesia: percentage of women requiring no analgesia (none), paracetamol alone (paracetamol),
codeine ± paracetamol (codeine), diamorphine ± codeine ± paracetamol (diamorpine) in each of
the three treatment groups.
There was a significant increase in the incidence of abdominal pain before to four
hours after prostaglandin administration ( p < 0.002) (Table 2.5). The incidence of
breast tenderness decreased from before to after prostaglandin administration, this
reached statistical significance when symptoms before mifepristone and after




Nausea 64% 67% 66%
Vomiting 23% 24% 33%
Dizziness 27% 27% 35%
Fatigue 72% 69% 75%
Lower abdominal 47% a 61% b 95% c
pain
Breast tenderness 67% d 57% 51% e
Percentage of patients with pregnancy or prostaglandin related side effects from the last menstrual
period to immediately prior to mifepristone administration (before mifepristone), from mifepristone
administration to immediately prior to prostaglandin administration (after mifepristone), and during
the firt four hours after prostaglandin administration (after prostaglandin).
(a < b, p < 0.02; a < c, p< 0.0002 b < c, p < 0.002; d > e, p < 0.005).
Of the one hundred and forty one patients who returned for follow up from day 7 to
day 11 inclusive, there was a significant decrease in haemoglobin and in hCG
concentration ( p < 0.0001) compared with concentrations at initial visit. There were
no significant differences between the treatment groups in this regard (Table 2.6).
Table 2.6
200 mg 400 mg 600 mg
Change in Hb (g/dl)
hCG (as %age of
original value)
-0.6 (-1.9 - +1.2)
3.36 (0.06 - 10.41)
-0.6 (-2.9 - +1.6)
3.95 (0.03 - 152.63)
-0.4 (-2.3 - +0.8)
2.9 (0.31 - 13.18)
Median (range) change in haemoglobin concentration from prior to mifepristone to one week after
mifepristone, median (range) change in serum human chorionic gonadotrophin concentration over the
same period, expressed as a percentage of the original value.
Bleeding.
Data on duration of bleeding following mifepristone and prostaglandin have been
obtained from 142 patients. Data on three patients who underwent uterine curettage
(including the patient with an ongoing pregnancy) have not been included in this
analysis, nor have data on a further five patients who defaulted from follow up before
bleeding had ceased (although two patients in this latter group were known to have
prolonged bleeding). Mean (95% C.I) duration of bleeding in the remaining 142
patients was 13.9 days (12.8-15.2). There were no significant differences in bleeding
duration between the treatment groups. Data on interval from mifepristone to the next
menses were obtained in 137 patients. Eight patients defaulted from follow up before
the scheduled six week visit, one patient attended the six week visit but had not yet
menstruated, and failed to attend thereafter. Data from three patients who underwent
surgical uterine evacuation were not included in the analysis. One patient conceived
again shortly after abortion, prior to menstruation. Mean (95% C.I) interval from
mifepristone to menstruation was 35.8 days (34.5-37.1) with no significant
differences between the treatment groups (Table 2.7).
Table 2.7





13.2 (11.2 - 15.6)
36.2 (34.2 - 38.5)
14.2 (12.6 - 16.1)
37.2 (34.7 - 39.8)
14.4 (12.33 - 16.8)
34.1 (32.3 - 36.1)
Mean (95% C.I) duration of bleeding and interval from mifepristone administration
to the next menses.
Once the bleeding had ceased, patients were asked how the total amount of bleeding
compared with their normal menstruation. Data was obtained from 144 patients (three
patients who defaulted before the bleeding had ceased, and three patients undergoing
surgical uterine evacuation were not included in the analysis). Seventy eight percent of
patients described the bleeding as heavier or much heavier than their normal menses.
There were no significant differences between any of the treatment groups in this
regard (Table 2.8). No patient required a blood transfusion.
34
Table 2.8
200 mg 400 mg 600 mg
Lighter 6.4% 4.3% 2.1%
Same 14.9% 17.0% 19.2%
Heavier 40.4% 44.7% 53.2%
Much heavier 38.3% 34.0% 25.5%
Comparison of bleeding with normal menstruation, percentage of each treatment group.
Discussion
The overall complete abortion rate of 98% in this study is similar to other that of other
large studies on the use of mifepristone and gemeprost in women of up to 49-63 days
amenorrhoea (Rodger and Baird, 1987; Silvestre et al, 1990;
UK Multicentre Trial, 1990). In this study the complete abortion rate was similar in
each of the three treatment groups, suggesting that pretreatment with 200, 400 and
600 mg mifepristone is equally effective, when followed 48 hours later by 1 mg
gemeprost. The similarity in efficacy between the three doses ofmifepristone correlates
with data showing similar plasma levels of the drug 48 hours after a single dose of
between 100 mg and 800 mg in non pregnant women (Heikinheimo et al, 1987), and
only a very minor small differences in plasma concentration of mifepristone in
pregnant women after 50 mg mifepristone compared with 25 mg mifepristone (Swahn
et al, 1986). However, plasma levels of the metabolites of mifepristone are likely to be
greater with the higher dose, and since these metabolites have been shown (at least in
rats) to have biological activity of up to 30% that of the parent molecule (Deraedt et al,
1985), one would expect greater total antiprogestational activity following the higher
dose. In practice, the effectiveness of mifepristone alone as an abortifacient is similar
following different dose regimes (Van Look and Bygdeman, 1989) with duration of
amenorrhoea being the main predictor of success. (Although the regime of
mifepristone used was reported to be the strongest predictor of success in a recent
study of 271 women, each regime included a variable proportion of women given
either prostaglandin or methylergonovine maleate, as a confounding variable [Grimes
et al, 1990]). An increase in uterine activity following mifepristone can be seen with
doses as divergent as 25 mg mifepristone b.d and a single dose of 600 mg
mifepristone, the change in uterine activity having a greater dependence on the time
after treatment, than on the dose of mifepristone used (Swahn and Bygdeman, 1988;
Chapter 6). The group of patients studied here was too small to determine minor
differences in success rates between the different dose regimes, at least one hundred
and thirty women being needed in each treatment group to show (with 90% power)
that either 200 or 400 mg was less effective than 600 mg mifepristone (assuming a
success rate in the 600 mg group of around 98% or greater, and a success rate in the
other groups of 90% or less). Smaller differences in complete abortion rate between
the groups would require even greater numbers to demonstrate any difference.
The complete abortion rates in each of the three groups (200 mg, 400 mg and 600 mg
mifepristone) were 100%, 96% and 98% respectively. If data from the other
participating centres shows similar results, the equivalent efficacy of 200, 400 and 600
mg mifepristone in combination with 1 mg gemeprost can then be claimed more
confidently.
Analgesic requirements seen here were similar to those reported in a recent UK trial
(UK Multicentre Trial, 1990) using 600 mg mifepristone and 1 mg gemeprost, but
higher than those previously reported from this Centre (Rodger and Baird, 1987).
However, this latter study included women given only 0.5 mg gemeprost, which
results in a lower requirement for analgesia than a 1 mg dose (Rodger et al, 1989).
Although the total requirement for analgesia in this study was apparently greater than
the largest published French study (55% compared to 21%), the comparison is not
valid since in the French study, not only were women of 50-56 days amenorrhoea
excluded, but also some women received premedication. Nulliparous women required
a significantly greater amount of analgesia than parous women, the requirement for
opiate analgesia in each group being 33.8% and 8.2% respectively (p<0.0002). This
agrees with previously reported data (UK Multicentre Trial, 1990).
Although the incidence of side effects following mifepristone appears high, when side
effects before and after treatment were compared, only abdominal pain was shown to
increase. An increase in abdominal pain following mifepristone and following
mifepristone and prostaglandin has been seen in other studies (Swahn et al, 1989;
Cameron et al, 1986), and presumably relates (at least in part) to increased uterine
activity. The decrease in breast tenderness following prostaglandin and abortion is
likely to be a response to the fall in the levels of hCG, progesterone and oestradiol
which is seen following this treatment (World Health Organization Task Force, 1989).
Unfortunately, the presence or absence of symptoms was compared over different time
periods. The period of up to 56 days prior to mifepristone was compared with the 48
hour period after mifepristone, and the four hour period after prostaglandin
administration. Since patients were asked about the incidence of symptoms, this
leads to a bias towards no effect ofmifepristone or prostaglandin.
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Haemoglobin concentrations decreased significantly by one week after the start of
treatment. None of the 150 patients studied here required a blood transfusion,
correlating with the known low requirement for blood transfusion (0.1% in the first
10,000 women treated in France from October 1988, [Aubeny 1990]). The duration of
bleeding in this study was similar to that previously published (Rodger and Baird,
1987), and appears to be less when gemeprost is used (as in this study), compared to
the use of mifepristone and sulprostone (Silvestre et al, 1990). The increase in human
chorionic gonadotrophin seen here following mifepristone correlates with results of
other workers (World Health Organization Task Force, 1989; World Health
Organization Task Force, 1991). Other studies have failed to show a significant rise in
human chorionic gonadotrophin 48 hours after mifepristone (Swahn et al, 1989;
Kovacs et al, 1984). Since the natural progression of human chorionic gonadotrophin
is to increase up to eight weeks gestation (Johnson and Everitt, 1988), a control group
of untreated women given placebo would be required for comparison, to determine the
effects of mifepristone in isolation.
The mean interval from mifepristone to next menstruation of 36 days seen here is
similar to the interval previously reported following menstrual induction either with
mifepristone and prostaglandin (Cameron et al, 1986; Swahn and Bygdeman, 1989),
or with prostaglandin alone (World Health Organization Task Force, 1987). Studies
on women after vacuum aspiration or prostaglandin termination of pregnancy in the
first trimester indicate that most ovulate prior to the first menses (Cameron, 1987).
Equivalent data is not available following the combination of mifepristone and
a prostaglandin. However, one subject conceived prior to the first menstrual period
after treatment, indicating that this cycle must have been ovulatory.
In summary, this study has failed to demonstrate any differences in the efficacy or side
effects between 200, 400 or 600 mg mifepristone in combination with gemeprost
1 mg for early therapeutic abortion. Assuming these findings are confirmed when data
from other centres is analysed, the minimum effective dose of mifepristone as an
abortifacient in combination with 1 mg gemeprost is yet to be established.
Since mifepristone and prostaglandin appear to act synergistically, it may be that the
dose of mifepristone can be reduced further only at the expense of an increase in




The use of gemeprost for menstrual induction
Introduction.
The use of prostaglandins to induce menstruation has been reviewed in Chapter 1.
Despite obvious advantages in terms of patient acceptability, menstrual induction has
not become a popular method of abortion in the UK, since the side effects induced by
the prostaglandins are thought to preclude routine use. The "third generation
prostaglandins" have fewer side effects compared to the natural compounds, and
appear to be as effective as vacuum aspiration under local anaesthesia in early
pregnancy (World Health Task Force, 1987). 16, 16, dimethyl PGEi is the only third
generation prostaglandin available in the UK. It is currently licensed for softening
and dilatation of the cervix prior to transcervical intrauterine procedures in the first
trimester, and for therapeutic abortion in the second trimester. The use of this
compound for menstrual induction has previously been described in regimes using
1 mg doses at three hourly intervals, to a maximum of 5 mg (Smith and Baird, 1980,
World Health Organization Task Force, 1982; Cameron and Baird, 1988), and
complete abortion rates of 86-97% achieved. However, the incidence of
gastrointestinal side effects is reported to be as high as 57% (Smith and Baird, 1980)
and up to 53% of patients require opiate analgesia (Cameron and Baird, 1988). The
use of a three hourly regime of gemeprost administration may be inappropriate
however, since plasma levels of gemeprost are maintained for up to six hours after
vaginal administration (Dimov et al, 1983). In an attempt to reduce the side effects
associated with menstrual induction using gemeprost, and to capitalise on the
"prostaglandin impact" which induces endogenous uterine activity and prostaglandin
production following an initial dose of exogenous prostaglandins (Csapo et al, 1972;
Csapo and Pulkkinen, 1979a), a protocol using six-hourly pessary administration was
employed, the results of which are reported in Part 1 below.
Mifepristone is now marketed in France, China and the UK for menstrual induction.
In combination with a prostaglandin it is associated with a high rate of complete
abortion (Chapter 2) and is rapidly becoming the "gold standard" by which other
methods of medical abortion should be judged. When gemeprost is used alone, a
larger total dose of prostaglandin is required to induce abortion, compared with the use
of mifepristone and gemeprost in combination, resulting in greater side effects, and
often associated with lower efficacy. Whilst this is apparent from data on the two
methods published separately, only one small study has compared the two methods
directly, and failed to find any difference in the rate of complete abortion
(Cameron and Baird, 1988). In the second half of this Chapter, the efficacy and the
side effects of the use ofmifepristone (200 - 600 mg) in combination with gemeprost
1 mg, and those of gemeprost alone (1 mg 6 hrly x 3) are compared.
Part 1: The efficacy and side effects of a new regime of gemeprost
for early therapeutic abortion.
Methods.
One hundred and fifty one women of < fifty-six days amenorrhoea, were recruited to
investigate the efficacy of vaginal gemeprost (1 mg six hourly to a total of three
pessaries) for therapeutic abortion. The incidence of complete abortion was the main
outcome measure. The protocol was granted ethical approval by the local Reproductive
Medicine Ethical Subcommittee.
Recruitment.
Women were recruited from those referred by their general practitioner for legal
termination of pregnancy, as described in Chapter 2. Exclusion criteria from the
study were:
gestation more advanced than 56 days as dated from menstrual history,
pelvic examination or ultrasound scan;
a history of asthma;
an inability to stay in hospital overnight or to attend for
follow up visits.
After the usual history, physical examination and counselling, details of the study were
given verbally, and written consent obtained from each participating patient.
Admission and prostaglandin administration.
On the day of admission (day 1), patients were admitted to hospital and details of the
history and physical examination were noted on a data sheet as described in Chapter 2.
A more detailed symptom questionnaire was used than described in Chapter 2, and the
point prevalence rather than the cumulative incidence of symptoms noted. Blood was
taken for blood grouping, estimation of haemoglobin and of human chorionic
gonadotrophin concentrations, and pelvic ultrasound performed. A single pessary of
gemeprost (1 mg) was inserted into the posterior vaginal fornix. Patients were
instructed to remain in bed for the first hour after pessary insertion, and then
encouraged to sit up or mobilise. Blood pressure, pulse rate and temperature were
recorded every three hours. The symptom questionnaire was repeated six hours after
the first pessary and a further 1 mg gemeprost was inserted into the posterior vaginal
fornix, unless the patient had complained of severe abdominal pain, or abortion had
occurred. The process was repeated six hours later and a third pessary given if
necessary. The time at which bleeding and abdominal pain started and the number of
vomiting and diarrhoea! episodes were noted. Analgesia was available as required;
paracetamol, codeine and diamorphine were used in order for increasing severity of
pain. Those patients who required a third prostaglandin pessary were encouraged to
stay in hospital overnight.
Blood was taken 24 hours after prostaglandin administration for repeat serum human
chorionic gonadotrophin estimation. The sanitary protection used by the patients
during their stay in hospital was collected so that an accurate estimate of blood loss
could be made and, in addition, patients were asked to bring the sanitary pads used
during the remainder of the bleeding episode to their follow up appointments. Prior to
discharge, anti D was given to rhesus negative women. A menstrual diary card was
given to record the pattern of vaginal bleeding and a follow up appointment arranged
for one week later.
Follow up.
At follow up (day 8) the patient's clinical condition was reviewed, details of vaginal
bleeding and of any adverse effects were noted, and a physical examination
performed. A pelvic ultrasound scan was carried out, and blood taken for haemoglobin
and serum human chorionic gonadotrophin estimation. This procedure was repeated
on day 15 and day 29, and the total duration of bleeding noted. Patients with an
ongoing pregnancy underwent surgical termination after the two week follow up visit
unless they requested earlier surgery. Women in whom abortion was incomplete by
the second follow up visit (day 15) underwent surgical uterine evacuation. Four
women with an ongoing pregnancy had a further course of pessaries.
Laboratory analysis.
Analysis of blood samples was performed by the appropriate laboratories, as described
in Chapter 2. The calculation of the total amount of blood lost during abortion was
performed from assessment of soiled sanitary protection (Hallberg and Nilsson,
1964).
Statistical methods.
Data were plotted before analysis to determine the distribution. For data which were
normally distributed, or in which log transformation could achieve normality, the mean
and 95% confidence intervals have been quoted, and analysis of variance, or a paired
t test for paired samples from the same patient used to look for differences between
the groups. Otherwise the median and range have been quoted, and non parametric
tests (Mann Whitney, or Wilcoxon Rank Sum for paired data) used to explore the
statistical significance of differences between the groups.
Results.
Patient details.
Characteristics of the patients and results of investigations on the first day of treatment
are shown below (Table 3.1a and 3.1b).
Table 3.1a
Mean (95% C.I)
Age (years) 24.5 (24.0 - 24.8)
Height (cm) 163.8 (162.8 - 164.7)
Weight (kg) 60.9 (59.5 - 62.3)
Gestation(days) 47.4 (46.5 - 48.2)
Parous 38%
Previous live birth 32%
Characteristics of patients on admission day; mean (95% C.I) or percentage.
Table 3.1b
Sac diameter (mm) 18.7 (17.1-20.6)
Haemoglobin (g/dl) 13.1 (12.9-13.2)
hCG (MU/1)* 38,510 (339- 214,900)
Results of investigations, mean (95%CI) or * = median and range.
Abortion rate.
One hundred and thirty two of the one hundred and fifty one patients (87%) aborted
completely by the second follow up visit. Nineteen patients (13%) required further
intervention, including four patients who opted for a further course of pessaries.
Three of these four women aborted completely. Sixteen patients, therefore, required
uterine evacuation. Only nine patients had an ongoing pregnancy at the time of further
intervention, the others had a diagnosis either of missed abortion (seven patients) or
incomplete abortion (three patients). Eighty six patients (57%) were given all three
pessaries, 43 (28%) were given two pessaries and twenty one patients (14%) were
given one pessary. One patient became transiently hypotensive but failed to abort after
one gemeprost pessary. A further half pessary was given and abortion occurred
shortly thereafter without incident.
Side effects.
All patients bled following prostaglandin treatment, at a median time of 300 minutes,
(range 90-765 minutes) after the first gemeprost pessary. All but five patients
experienced abdominal pain prior to abortion, at a median time of 195 minutes (range
0-540 minutes) after prostaglandin administration. Fifty eight (38%) patients vomited
following prostaglandin treatment, and sixty one (40%) had diarrhoea, with a median
of 0 (range 0-5) and 0 (range 0-6) episodes respectively. There was a significant
increase in abdominal and pelvic pain following the first prostaglandin pessary, and a
significant decrease in breast tenderness (Table 3.2).
Fifty four patients (36%) required opiate analgesia, 50 (33%) were given codeine ±
paracetamol, and 11 (7%) received paracetamol alone. Thirty six (24%) patients did
not require analgesia. There were no significant differences in analgesic requirements
between parous and nulliparous women. Data on duration of bleeding was available
on 106 patients who aborted following the prostaglandin pessary course. (The first
twenty four patients were treated as a pilot group and followed up only until abortion
was found to be complete. Of the 127 patients remaining, 112 aborted completely,
but six defaulted from follow up before the bleeding had ceased.) Mean (95% C.I)
duration of bleeding in these women was 13.6 days (12.3-15.0). Median blood loss
as assessed from measurement from the sanitary pads was 28 ml (range 2-237 ml).
Table 3.2
Time in relation
to first pessary 0 6 hrs 12 hrs Significance
Headache 7% 5% 4% ns





Nausea 32% 37% *#$00r-H ** p <0.02
Vomiting 9% 22% 6% ns
Indigestion 7% 5% 5% ns
Abdominal 10% 22% * 21% ** " * p <0.02
distension ** p <0.02
















Diarrhoea 3% 21% * 9% *p <0.0002
Constipation 9% 5% 3% ns










Faintness 8% 10% 6% ns
Tiredness 43% 46% 49% ns
Dysuria 3% 4% 3% ns
Hot flushes 1% 15%* 10% ** p <0.002
p <0.002
Point prevalence of pregnancy / prostaglandin related symptoms at time 0, 6 and 12 hours
after the first prostaglandin pessary, statistical significance of the difference compared with
time 0 are shown in the right hand column.
To determine whether there were any factors which might predict outcome,
characteristics of "successful" patients (those who aborted completely without further
intervention) and "unsuccessful" patients (those who required either a further pessary
course or surgical uterine evacuation) have been compared (Table 3.3). Successful
patients were significantly taller and lighter than those who failed to abort (p<0.05),





Age (yrs) 25.6 24.3 ns
(24.2 - 27.1) (22.3 - 26.42)
Height (cm) 163.9 157.87
°
p <0.05
(162.8 - 164.9) (146.3 - 169.5)
Weight (kg) 61.3 68.1 p <0.05
(59.3 - 63.3) (57.5 - 78.7)
Gestation (d) 47.7 45.0 ns
(46.8 - 48.6) (42.7 - 47.4)
Parity 45% 32% ns
Initial hCG 38,960 31,150 ns
(IU/1). (339 - 214,000) (706- 136,500)
Data at recruitment mean (95%C.I) except for parity (percentage) and initial hCG (median and range)
When the response to treatment is compared, successful patients were found to bleed
significantly earlier following the prostaglandin pessary (p<0.05) and to require
stronger analgesia during abortion (p<0.003) than unsuccessful patients






Vomiting episodes 0 (0-5) 0 (0-3) ns
Diarrhoeal episodes 0 (0-6) 0 (0-4) ns
Minutes to bleeding 300 (90 - 720) 360 (165-765) p <0.05
Minutes to 195 (20 - 540) 180 (110-420) ns
abdominal pain
Median (range) number of vomiting and diarrhoeal episodes in patients who required further
intervention to achieve complete abortion, compared with those who did not; interval from
insertion of the first prostaglandin pessary to abdominal pain and vaginal bleeding.
Table 3.5
Analgesia "Successful" patients "Unsuccessful" patients
None 19% 58%
Paracetamol 8% 0%




Analgesic requirements in patients who aborted following the prostaglandin course compared
with those who did not (p<0.003 between successful and unsuccessful patients).
Follow up data shows a greater decrease in hCG concentration (expressed as a
percentage of the original hCG concentration) both at 24 hours and at seven days after
prostaglandin administration in women who aborted completely following treatment
(Table 3.6). Blood loss as assessed from menstrual pads was significantly greater in
women who aborted following therapy (although since collection of menstrual pads
ceased once the patient underwent surgical curettage this is not an accurate assessment






hCG after 24 hours 34.1 (7.8 -126.7) 58.9 (28.5 - 103.2) p <0.0001
hCG after 7 days 1.7 (0.5 - 113.6) 90.7 (0.9 - 277.0) p <0.0001
Change in Hb -0.3 (-1.6 - +1.0) -0.5 (-1.4- +0.2) ns
Blood loss (mis)
from pads
34 (2 - 237) 10 (5 - 69) p <0.01
Median (range) change in haemoglobin and serum hCG concentrations at 24 hours and or 7 days
after prostaglandin treatment, and blood loss during abortion as assessed from the menstrual pads.
hCG concentrations are expressed as a percentage of the original value.
Part 2: A randomised comparison between the use of mifepristone and
gemeprost and gemeprost alone in early therapeutic abortion.
Methods.
One hundred and seventy women of < 56 days gestation requesting therapeutic
abortion were randomised to treatment either with mifepristone (200-600 mg) in
combination with gemeprost (1 mg); or gemeprost alone (1 mg 6 hrly to a total of five
pessaries) in order that the efficacy of the methods could be compared The main
outcome measure was the number of complete abortions. The protocol was approved
by the local Reproductive Medicine Ethical Subcommittee. Eighty five women were
treated in each group. Their details have also been reported separately (in Chapter 2,
and in Part 1 of this Chapter) as part of larger studies into the use of mifepristone in
combination with gemeprost, and gemeprost alone. They are reported again here in
order to compare the efficacy and the side-effects of the two methods.
Women were recruited from those referred by their general practitioner, as described in
Chapter 2. Only women who fitted the inclusion criteria for both the study described in
Chapter 2, and the study described in Chapter 3, Part 1 were included. Details of the
study, and of the plan to randomise patients to one or other treatment were discussed
with the patient, and consent obtained. Treatment was allocated by opening a sealed
envelope containing directions as to one or other protocol. The envelopes were
prepared in advance, so that an equal number of patients were recruited to each group
over the course of the study. Once allocated to a therapeutic group, treatment was
followed as described for each of the groups separately. Follow up on women treated
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with prostaglandin pessaries alone was extended until the date of the next menstrual
period following prostaglandin administration.
Results
Characteristics of patients in each group at recruitment are jshown in Tables 3.7a
and 3.7b. There were no significant differences in the groups for any of the
parameters shown.
Table 3.7a
Mifepristone and gemeprost Gemeprost alone
Age (years) 25.9 (24.7 - 27.2) 27.0 (25.6 - 28.5)
Height (cm) 164.4 (163.1 - 165.7) 163.8 (162.5 - 165.0)
Weight (kg) 60.0 (58.4 - 61.5) 61.6 (59.7 - 63.5)






Previous abortion 29% 25%
Characteristics of patients in each of the two treatment groups on the first days of treatment, mean
(95%C.I), or percentage. No significant differences between the groups.
Table 3.7b.
Mifepristone and gemeprost Gemeprost alone
Haemoglobin (g/dl) 13.1 13.1
(12.9 - 13.2) (12.9 - 13.3)
hCG (IU) 43,870 38,510
(1,038 - 191,000) (1,389 - 210,700)
Sac diameter on scan (mm) 19.6 19.5
(17.9 - 21.5) (17.8 - 21.5)
Results of investigations on the first day of treatment - median (range).
The combination of mifepristone and gemeprost was significantly more effective in
inducing a complete abortion than the use of gemeprost alone, with complete abortion
rates of 83/85 (98%) and 74/85 (87%) respectively (p<0.01). Details of the failures in
each group have been described in Chapter 2, and Part 1 of this Chapter.
Analgesic requirements were significantly greater in the group of women treated with
gemeprost alone (p<0.02), (Table 3.8). Total duration of bleeding and interval to the
next menses were similar in both groups (Table 3.9). The patient's subjective
assessment of the amount of bleeding was greater in women treated with mifepristone
and gemeprost compared to women treated with gemeprost alone (p<0.01),
(Table 3.9). Levels of hCG (expressed as a percentage of the original value) were
greater on day 8 in the group of women treated with the combination of mifepristone
and gemeprost, compared with the group of women treated with gemeprost alone
(p<0.0001). There was no difference in the change in haemoglobin in women treated
with mifepristone and gemeprost, compared to women treated with gemeprost alone
(Table 3.10).
Table 3.8
Analgesia Mifepristone and gemeprost Gemeprost alone
None 41% 22%
Paracetamol only 11% 7%




Difference in analgesic requirements in the two treatment groups,
(p <0.02 between the two groups).
Table 3.9
Mifepristone and gemeprost Gemeprost alone








13.7 (12.2 - 15.6)





13.1 (11.7 - 14.8)





Effect of different treatments on duration of bleeding, interval to menses and amount of bleeding
compared with menstruation.(** = p<0.01 between the treatment groups). .
Table 3.10
Mifepristone
and gemeprost Gemeprost alone
hCG (% of original value)
Change in Hb (g/dl)
2.9% (0.0 - 42.5)***
-0.6 (-2.3 - +1.6)
1.8% (0.5 - 157.7)***
-0.3 (-1.4- +2.8)
Change in hCG and haemoglobin on day 7-11 median and range; (*** = p<0.0001).
Discussion
The complete abortion rate seen here is similar to that reported by other groups using a
three hourly regime of prostaglandin administration for menstrual induction, where
abortion rates of 86% in a study of 358 women (World Health Organization Task
Force, 1982), and 87% in a study of 30 women (Smith and Baird, 1980) were
achieved. A higher complete abortion rate of 97% has been achieved in a small
sample of thirty women at the same gestation (Cameron and Baird, 1988). Although
a comparison was not made here, the complete abortion rate of 87% seen in this study
compares poorly to the complete abortion rate of 99.3% in a study of over 15,000
women undergoing suction termination of pregnancy at less than eight weeks gestation
(Tietze and Lewit, 1972). In a previous study comparing gemeprost for menstrual
induction with vacuum aspiration under general anaesthesia, the latter method is
associated with a significantly higher rate of complete abortions (Smith and Baird,
1980).
The rationale behind a vaginal route of administration of prostaglandins is to reduce
unwanted side effects, experienced when prostaglandins are given via other routes.
However, this approach is not entirely successful, as the increase in nausea,
abdominal distension, flushing and diarrhoea following the first prostaglandin pessary
indicates. The use of a smaller dose of prostaglandin in this study has not resulted in a
reduction in the incidence of vomiting and diarrhoea compared with other studies
(Smith and Baird, 1980; World Health Organization Task Force, 1982; Cameron and
Baird, 1988) although the analgesic requirement seen here was lower than in women
of the same gestation given gemeprost three hourly (Cameron and Baird, 1988).
Analgesic requirements in parous women were not significantly different from those in
nulliparous women, in contrast to the data on women undergoing therapeutic abortion
using mifepristone and prostaglandin (Chapter 2). The reasons for the different effect
of parity on analgesic use in the two groups are not clear, but may represent a greater
contribution of endogenous prostaglandin production to uterine activity and pain in
women following mifepristone and prostaglandin, compared to women treated with
prostaglandin alone. Median blood loss, as assessed from sanitary protection, was less
than previously reported (Smith and Baird, 1980). Any measurement of blood loss
using this method is an underestimate of the actual blood loss unless every pad has
been included. However no patient in this study bled sufficiently heavily to require a
blood transfusion.
The lower mean weight of women who aborted following treatment suggests that the
dose/kg and/or the plasma profile of gemeprost is important, perhaps resulting in a
greater "prostaglandin impact" in women who aborted successfully following
gemeprost (Csapo et al, 1972). Despite a greater mean height in women who aborted
following gemeprost alone, there was no significant difference in body mass index
(weight/height2, Quetelet's index). This contrasts with published data on the predictors
of failed attempted abortion with the antiprogestin mifepristone, with or without
prostaglandin (Grimes et al, 1990). Surprisingly, there was no significant difference in
mean gestation in women who aborted compared with those who did not. The earlier
interval to bleeding and the increased analgesic requirement in women who aborted
following prostaglandin therapy suggests a greater sensitivity to prostaglandin in this
group.
The randomised comparison between treatments shows mifepristone and gemeprost to
be more effective in inducing complete abortion than gemeprost alone. These results
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contrast to a non randomised study of 49 patients, where no difference in abortion rate
was seen following either mifepristone 150 mg daily for four days with 1 mg
gemeprost on the third treatment day, or gemeprost 1 mg three hourly to a total of five
pessaries (Cameron and Baird, 1988). There are other advantages of the mifepristone
and prostaglandin combination compared to prostaglandin treatment alone.
Most women undergoing termination of pregnancy using gemeprost alone who
required all three pessaries had an overnight stay in hospital. This was not a feature of
termination of pregnancy using mifepristone followed by gemeprost. Staying in
hospital overnight is not only inconvenient for many women, but has obvious cost
implications. In addition, the requirement for analgesia (which correlates with the
painfulness of the procedure) is significantly less following mifepristone and
prostaglandin than prostaglandin alone.
A lower hCG concentration (expressed as a percentage of the original value) was seen
seven days after the start of treatment in the gemeprost alone group, compared to the
mifepristone and gemeprost group, despite the fact that the former group included a
greater proportion of women with an ongoing pregnancy or missed abortion.
This reflects the time of abortion in the two groups. In women treated with gemeprost
alone, a significant decrease in hCG concentrations can be seen twenty-four hours
after treatment, whereas in women given mifepristone and prostaglandin, hCG levels
are greater forty-eight hours after mifepristone than at the time of mifepristone
administration. It is not until prostaglandin is given and abortion occurs that hCG
levels decline in this latter group. The change in hCG concentration seven days after
prostaglandin administration in each group would, in retrospect, have been a more
appropriate comparison.
Amongst women who aborted following treatment, there were no significant
differences between the groups in terms ofmean duration of bleeding or the interval to
the next menses following mifepristone and gemeprost, compared with following
gemeprost alone. The median change in haemoglobin concentration seven days after
the start of treatment was similar in each group. In contrast, the patients' subjective
report of bleeding compared with their normal menstruation (in women who aborted
completely) indicates a significant trend towards heavier bleeding in the mifepristone
and gemeprost group (p<0.01). However, the main difference lies in the fairly subtle
distinction between "heavier bleeding" and "much heavier bleeding" compared to
normal menstruation, and may therefore be artefactual. Indeed, when the data were
grouped into two categories, bleeding heavier than menstruation, or bleeding the same
or lighter than menstruation, there were no significant differences between the two
treatment groups.
In summary, the combination of mifepristone and prostaglandin is more effective than
the use of prostaglandin alone in termination of early pregnancy, and results in fewer
side effects. The duration of bleeding and interval to next menses in women who do
abort is similar, suggesting an analogous process of abortion in each case.
Chapter 4 :
The effects of misoprostol, an orally active prostaglandin on
uterine activity and early pregnancy, both alone and in
combination with mifepristone.
Introduction
The comparison of the use of mifepristone and gemeprost for menstrual induction with
the use of gemeprost alone (Chapter 3) shows clearly that the mifepristone-gemeprost
combination has advantages both in terms of increased efficacy, and reduced side
effects. Mifepristone has been used in combination with both vaginal
(Rodger and Baird, 1987) and intramuscular (Bygdeman and Swahn, 1985)
prostaglandins. However, neither of the commonly used prostaglandins are ideal. The
recent reports of cardiovascular compromise and even death from myocardial infarction
following the use of mifepristone in combination with intramuscular sulprostone
(Anonymous,1991) are probably related to high peak levels of sulprostone in blood
following injection. The formulation of gemeprost in a vaginal pessary requires it to be
refridgerated prior to use, and absorption from the vagina is variable between
individuals. In addition, gemeprost has been reported to induce cardiovascular
complications (Kalra et al, 1989). Studies on the available oral prostaglandins have
shown natural PGE2 (1-2 mg) to be no more effective than placebo, in combination
with mifepristone for menstrual induction (Swahn et al, 1989), and although
9-methylene PGE2 is more active orally, it has to be given in solution, a formulation
which is unsuitable for routine use (Swahn et al, 1990). Recently, misoprostol
(Cytotec™, G.D.Searle), an orally active prostaglandin ([15-S]-15-methyl-PGE2
methyl ester) marketed for the treatment of peptic ulcer has been used in combination
with mifepristone in women of less than 49 days amenorrhoea (Aubeny and Baulieu,
1991), and an abortion rate of 95% achieved. It was claimed that the structure of
misoprostol results in fewer gastrointestinal side and increased oral activity compared
with other prostaglandins (Dajani et al, 1975; Collins et al, 1985). In this Chapter, the
results of a study undertaken to determine the effects of misoprostol alone on uterine
tone and contractility in pregnant women at an early gestation (< 56 days amenorrhoea)
are reported. Misoprostol (200-1000 fig) was also given to women pretreated with
mifepristone (200 mg), to determine whether enhanced sensitivity to misoprostol could
be seen following mifepristone. The clinical effects of the combination therapy as an




Seventy-three women of < 56 days amenorrhoea scheduled for legal termination of
pregnancy were recruited, as described in Chapter 2. A full history and physical
examination were performed, and blood taken for analysis of blood group and
haemoglobin estimation prior to recruitment. An ultrasound scan was performed to
confirm gestation. Women in whom the gestation was uncertain, or who were
suspected of having an ectopic pregnancy were not recruited. The protocol was
approved by the Reproductive Medicine Ethical Subcommittee of Lothian Health
Board, and all women gave informed consent to participation. Women were recruited
into one of three groups, and treated as described below.
Group 1
Twelve women scheduled for suction termination of pregnancy were recruited to
determine the effect of differing doses of misoprostol on uterine activity. Women were
admitted in the morning for operation in the afternoon. On admission, an intrauterine
pressure transducer was inserted into the uterus, via the cervix. Details of the
equipment used, and of the method of transducer insertion are given below. After a ten
minute period of equilibration, a thirty minute baseline recording was made of uterine
activity. Thereafter, a single dose of misoprostol was given orally to each patient, and
intrauterine pressure recorded over the following three hours. Three women were
given one 200 qg misoprostol tablet, six women received two misoprostol tablets (total
dose 400 |ig), and the remaining three women received three misoprostol tablets (total
dose 600 |J.g). At the end of the monitoring period, the pressure transducer was
removed, and the patient transferred to theatre for suction termination of pregnancy
under general anaesthesia in the usual manner. Post operatively, the patient's condition
was reviewed, she was given an injection of anti D if necessary and discharged on the
evening of admission if well, with contraceptive advice.
Group 2
A further forty women who had opted for surgical termination of pregnancy were
recruited to determine whether misoprostol alone was sufficient to induce abortion.
On admission to the study, blood was taken for measurement of serum human
chorionic gonadotrophin, and details of the size of the gestational sac, and of the
presence or absence of fetal heart activity on ultrasound scan were noted. A single oral
dose of misoprostol (400 |ig) was given, and following this the women were allowed
home. Seven days later, the patient was readmitted to hospital. Clinical assessment,
an ultrasound scan and measurement of serum human chorionic gonadotrophin levels
were used to determine whether there was an ongoing pregnancy, an incomplete or a
complete abortion. The pregnancy was then terminated by suction termination under
general anaesthesia in the usual manner.
Group 3
Twenty one women were recruited to determine the effect of mifepristone and
misoprostol on uterine contractility in early pregnancy (<56 days amenorrhoea) and to
assess the clinical outcome of this therapy. On the first day of the study, a single oral
dose of mifepristone (200 mg) was administered. Forty-eight hours later, the patient
was readmitted. A pressure transducer was inserted into the uterus via the cervix, as
described below. After a ten minute equilibration period, baseline intrauterine pressure
was recorded over thirty minutes, to determine the effect of mifepristone alone.
A single oral dose of misoprostol was then given. Four women received 200 (ig
misoprostol (one tablet), ten received 400 (ig misoprostol (two tablets) and seven
received 600 fig misoprostol (three tablets). Intrauterine pressure monitoring was
continued either for a further three hours or until abortion occurred, whichever was the
shorter time period. Patients were examined three hours after misoprostol
administration to determine whether abortion had taken place. In three of the women
receiving 600 \ig misoprostol, a further dose of 400 jig misoprostol was given
following examination since no products of conception had been passed vaginally.
Surgical termination of pregnancy was not performed at the end of the recording period
for any of the women in group 3 but they were allowed home and a follow up
appointment was scheduled for one and two weeks later, to ensure that abortion was
complete. Complete abortion was defined as an empty uterus on ultrasound scan and
falling concentrations of human chorionic gonadotrophin. Women in whom abortion
was not complete by the second follow up were scheduled for surgical termination of
pregnancy. Women in each of the groups completed a short symptom questionnaire
before and three hours after misoprostol administration.
Intrauterine pressure recordings.
Equipment
Intrauterine pressure was measured with a flexible catheter tipped with a pressure
transducer (Gaeltec Ltd, Dunvegan, Isle of Skye, Scotland) (pressure range 0 - 300
mmHg). This was connected to an amplifier and thence to a pen recorder.
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Transducer insertion
Under sterile conditions, the cervix was visualised with the aid of a vaginal speculum,
the catheter was grasped with a pair of sponge forceps and passed through the cervical
canal into the uterus. When resistance to further insertion was felt at a depth of around
8-10 cm, the catheter was withdrawn 1-2 cm so that it would be lying free in the
uterine cavity. The other end of the catheter was then connected via an amplifier to a
pen recorder. A vaginal tampon was inserted to hold the catheter in place, and the
catheter taped to the patient's leg. A mark was made on the paper when the intravenous
prostaglandin was administered.
Calibration
Prior to each insertion the transducer and amplifier were calibrated as follows.
The system was zeroed at atmospheric pressure, i.e when the transducer was free in
air, a pressure of 0 was recorded on both the amplification system and the pen
recorder. The transducer was then placed at the bottom of a column of water at a
depth of 43 cm (equivalent to a pressure of 31.6 mmHg). The gain on the amplifier
was adjusted so that this pressure resulted in a deflection of 31.6 mm on the pen
recorder. When high intrauterine pressures were experienced, the sensitivity of the
system was halved by halving the sensitivity of the pen recording system so that the
records were kept on one page. The paper was allowed to run at a speed of 5 mm/min.
The pressure transducer was sterilised prior to insertion into the patient by immersing
in 2% glutaraldehyde solution ("Cidex") for 10 minutes.
Calculation of uterine activity
The measurement of uterine activity is the subject of much debate. In abortion, as in
labour at term, regular contractions of the uterus result in cervical dilation and
expulsion of uterine contents. With the development of pressure transducers small
enough to be inserted into the uterus, the measurement of intrauterine pressure is now
relatively straightforward (Steer et al, 1978), although some authors feel that insertion
into a fluid filled cavity ie the intra-amniotic rather that the extra-amniotic space is
necessary (Gibb, 1989). The conversion of intrauterine pressure into units to quantify
uterine activity is more complex. Following much work on the relationship between
uterine activity in different states of pregnancy and in labour, a group of workers in
Uruguay introduced the Montevideo Unit (Caldeyro Barcia et al, 1957).
A Montevideo unit is the mean active intrauterine pressure (ie. the mean increase in
uterine pressure over baseline pressure) multiplied by the number of contractions in a
ten minute period. From a series of recordings they have produced reference values
for normal labour at term. Alexandria units (El-Sahwi et al, 1967) are a modification
of this measurement, but also take into account the mean duration of the contraction, so
that one Alexandria Unit is the average amplitude of uterine contractions, multiplied by
the duration in minutes and the frequency of contractions in ten minutes.
This modification has not been found to be helpful in clinical practice (Gibb, 1989).
An alternative approach to the calculation of uterine activity is to calculate the area
bounded by the curve of intrauterine pressure and the line of zero pressure, since this
area is proportional to uterine work (Bourne and Bum, 1927). - Uterine Activity Units
are based on this approach, one Uterine Activity Unit being the area bounded by a
uterine pressure of 1 mmHg for 1 minute (Hon and Paul, 1973).
No single method of quantifying uterine activity is ideal. The units described above
are primarily designed to measure uterine activity in labour at term, and not during
abortion in early pregnancy. For the studies described in this thesis, a method of
quantifying the effects of the prostaglandins and of mifepristone ± prostaglandins on
uterine activity in early pregnancy was required. Small doses of prostaglandins result
in an increase in uterine tone (and therefore an increase in Uterine Activity Units), but
do not result in discrete uterine contractions (and therefore no increase in uterine
activity measured in Montevideo units), or abortion. In contrast, mifepristone results in
the development of discrete uterine contractions, which lead to abortion in a proportion
of women. The measurement of uterine contractility in Montevideo units discriminates
best between the pattern of uterine activity seen before and after mifepristone.
In addition, it may be that discrete uterine contractions are more important in
overcoming cervical resistance and expelling the uterine contents than a general
increase in uterine tone, and that pressures below basal pressure may not play such an
active part (Gibb, 1989).
For these reasons, a different method of calculating uterine activity has been employed
to determine the effects ofmifepristone with or without prostaglandins, and the effects
of small doses of prostaglandins alone on uterine activity. No attempt has been made to
compare uterine activity following mifepristone ± prostaglandins with that following
prostaglandins alone on a quantitative basis. For women treated with prostaglandins
only uterine tone at varying times after prostaglandin administration has been
calculated. For women pretreated with mifepristone ± prostaglandins, uterine activity
has been calculated in Montevideo units. A review of the literature indicates that other
workers have used a combination of Montevideo units and Total Pressure Area
(a modification of uterine activity units: 1 TPA = area bounded by an intrauterine
pressure of 1 mmHg over 10 minutes) to measure uterine activity following
mifepristone in the first trimester (Swahn and Bygdeman, 1988) and Uterine Activity
Units have been used to measure uterine activity following mifepristone in the second
trimester (Hill et al, 1990b). Montevideo units have also been used to quantify uterine
activity in the first trimester following epostane, a progesterone synthetase inhibitor
(Webster et al, 1985a), although following epostane in the second trimester, Uterine
Activity Units were used (Selinger, 1988). Despite the assertion that a pressure tip
transducer is unsuitable for measurement of extra-amniotic pressure, both studies to
measure uterine activity following mifepristone quoted above have used this method.
Both an increase in TPA and Montevideo Units has been observed following
mifepristone in the first trimester (Swahn and Bygdeman, 1988). Having decided to
use Montevideo Units to quantify uterine activity following mifepristone, no reports of
an objective scoring system for discriminating between single contractions, the noise
of the recording system and an increase in baseline intrauterine pressure when
calculating uterine activity from actual pressure traces were found. The following
system was therefore devised to reduce observer bias:
1. Any increase in uterine activity lasting for more than one minute was considered
to be a change in baseline tone rather than a single contraction. These changes in
baseline tone were not included in the calculation of Montevideo Units.
2. To distinguish a contraction from electrical "noise" in the system, we considered
an increase in tone as a contraction, only if the amplitude of the increase was
more than twice that of the variability around the baseline, and if the increase in
tone lasted for one minute or less.
3. For an episode of increased uterine pressure where the pressure dipped towards
the baseline but did not reach it before rising again to a further peak, we
considered this as two separate contractions only if the difference between the
pressure trough and the baseline was < 20% of the difference between the
smaller peak and the baseline. Otherwise this was considered as one contraction
provided it lasted less than one minute) with the greatest peak of intrauterine
pressure taken as the amplitude of contraction.
In practice all significant increases in intrauterine pressure which appeared to be
contractions were included by this system. It is possible that contractions of low
amplitude would not have been included under this system, but the contribution of
these contractions to the total score in Montevideo units would not have been great.




The effects of the dose ofmisoprostol, and of time after misoprostol administration on
intrauterine tone or on uterine activity in women pretreated with mifepristone were
determined by analysis of variance using Newman-Keuls procedure using the "CLR
Anova programme" on an Apple Macintosh Computer. The data were log
transformed before analysis. The geometric mean and 95% CI (or median and range)
of the data have been quoted, the Statview programme was used to calculate these
parameters.
Results
The characteristics of the women recruited to each group are shown in Table 4.1.
Table 4.1.






Group 1 29 (19 - 38) 50 (42 - 56) 6/12
Group 2 26 (17 - 42) 49 (39 - 56) 26/40
Group 3 25 (18- 35) 50 (39 - 56) 17/21
Characteristics of the women recruited to each group.
Group 1. (Misoprostol alone).
Following misoprostol, there was an increase in intrauterine pressure in ten out of
twelve patients, but despite this increase in intrauterine tone, regular uterine activity did
not develop (Figure 4.1). In the other two patients (both treated with 400 fig
misoprostol), misoprostol failed to effect any change in intrauterine pressure. The
change in intrauterine pressure following misoprostol administration was analysed
both with respect to time and dose of misoprostol. Analysis of the effect of time after
misoprostol administration on mean intrauterine pressure (all three doses of
misoprostol) showed a greater mean intrauterine pressure at 30, 60 and 120 minutes
after misoprostol administration, compared with the- pretreatment value
(Table 4.2). Comparison of different doses of misoprostol shows a greater
intrauterine pressure in women given 600 fig misoprostol, compared with women





























































Intrauterine pressure in mmHg (geometric mean and 95% C.I) at different time points after each
of three different doses ofmisoprostol, and mean intrauterine pressure for all three doses combined.


























0 30 ~60 120 minutes
Time after misoprostol
a 200|lg, n=3 • 400pg, n=6 ■ 600pg, n=3
Mean intrauterine pressure following three different doses of misoprostol.
P values show overall significance of the differences in pressure.
(Data also shown in Table 4.2)
No patient given misoprostol alone developed prostaglandin related side effects such as
nausea, vomiting or diarrhoea. One patient (who had received 400 pg misoprostol)
developed mild abdominal pain which was relieved by paracetamol. Three other
patients reported abdominal pain on direct questioning but did not require analgesia.
Group 2: (Clinical efficacy of misoprostol alone).
Twenty one of the forty patients had some bleeding in the seven days following the
administration of misoprostol, although only two (42 and 44 days amenorrhoea)
aborted completely, 6 and 72 hours respectively after prostaglandin intake.
The remainder required surgical evacuation seven days later due to ongoing pregnancy
(thirty two women), or incomplete or missed abortion (six women). Side effects were
few with only one woman having either diarrhoea or vomiting. Ten women felt
abdominal discomfort in the four hours following misoprostol, of whom three
described the pain as severe.
Group 3. (Misoprostol pretreated with mifepristone).
In the group treated with mifepristone, there was the expected increase in uterine
contractility compared to those in Group 1 (Figure 4.3), although a quantitative
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analysis was not made. There was a further increase in uterine activity (in
Montevideo units) following prostaglandin (Table 4.3). The significance of the
increase during different time epochs (all three doses of misoprostol combined) is
shown in Figure 4.4.
Figure 4.3
10mlns
Intrauterine pressure tracing after three different doses of misoprostol








































Uterine activity in Montevideo units (geometric mean and 95% CI) in women pretreated with 200 mg
mifepristone, during various time epochs before and after misoprostol administration.
There were no significant differences in uterine activity between the three doses of
misoprostol. In four women uterine recordings were not possible due to technical
reasons. In three of the remaining seventeen women, the recording was terminated
prematurely before 90 minutes due to passage of the fetus (two of the women in the
600 fig group and one in the 200 fig group). In eighteen of the twenty one women,
complete abortion occurred following treatment with misoprostol and mifepristone. Of
the remaining three women who required surgical evacuation, two (one given 200 fig
and one given 400 \ig misoprostol in combination with 200 mg mifepristone) were
found to have an ongoing pregnancy at a follow up visit fourteen days later. The third
woman (given 400 jig misoprostol in combination with 200 mg mifepristone) passed
a gestational sac and placental tissue following misoprostol and appeared to have an
empty uterus one week later. However, she was subsequently admitted to another
hospital with continuing vaginal bleeding. An ultrasound scan showed the presence of
some material in the uterus and uterine evacuation was therefore performed.
Unfortunately the material obtained was not sent for histological evaluation.
Side effects of the combination therapy were not troublesome. Three patients vomited
following misoprostol but one had vomited earlier that day and reported an
improvement in symptoms after taking misoprostol. None of the women had
diarrhoea, nine women (two following 200 fig misoprostol, six following 400 fig
misoprostol, and one following 600 fig misoprostol) required analgesia in the form of
paracetamol or dihydrocodeine and three (two following 400 fig misoprostol and one
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Uterine activity following mifepristone and three different doses of misoprostol.
Discussion.
The effects ofmisoprostol on uterine tone as shown above are qualitatively similar to
those seen with other prostaglandins. When the natural prostaglandins are given orally
early in the second trimester, a high incidence of side effects occurs at doses sufficient
to effect a change in uterine tone (Karim, 1971). In this study, misoprostol resulted
in a significant increase in uterine tone without marked side effects. The low incidence
of side effects with the use of misoprostol is in keeping with previously published
reports. In one study only 8.5% of patients receiving 400 |ig misoprostol per day for
the treatment of peptic ulcer complained of diarrhoea over a four week period
(Sontag et al, 1985). Misoprostol is known to have some uterine effects. In a study
of pregnant women of 9-12 weeks gestation, 800 fig of misoprostol induced vaginal
bleeding in 45% of women, and partial or complete abortion in 11% of women within
12 hours of tablet administration (Rabe et al, 1987). In the UK the Committee on
Safety of Medicines has urged caution regarding the use of misoprostol in pre and post
menopausal women, and advise against its use in women who are pregnant, or who
are planning a pregnancy, because of the risk of provoking uterine activity (Committee
on Safety of Medicines, 1989).
Although misoprostol induced an increase in uterine tone when given alone, only eight
out of forty women bled or aborted, indicating that it would have little use as an
abortifacient at this dose. Six women had either a missed or incomplete abortion and
required surgical evacuation as well as the thirty-two women with ongoing
pregnancies. Fetal malformations have been reported in babies bom to women who
have taken misoprostol in early pregnancy in an unsuccessful attempt to induce
abortion (Fonseca et al, 1991). There is insufficient data to determine whether these
abnormalites are due directly to misoprostol, but clearly misoprostol alone is
ineffective as an abortifacient. The increased effectiveness in women who had been
pretreated with mifepristone reflects the increased sensitivity to prostaglandins induced
by antigestagens (Bygdeman and Swahn, 1985).
The observed increase in uterine activity following misoprostol in women pretreated
with mifepristone (RU 486) are qualitatively similar to the effects of other
prostaglandin analogues, whether administered by the intramuscular
(Bygdeman and Swahn, 1985) or oral route (Swahn et al, 1990). Clinical
effectiveness of the mifepristone and misoprostol therapy cannot be fully evaluated
from this small study, but the fact that complete abortion occurred in eighteen out of
twenty-one patients is encouraging. The success rate in this study was lower than that
reported in a larger study of 100 women of <49 days amenorrhoea where a complete
abortion rate of 95% was achieved using 600 mg mifepristone followed 48 hrs later
with 400 (ig misoprostol (Aubeny and Baulieu, 1991).
Another orally active prostaglandin, arbaprostil, a PGE2 analogue (15 (R)15 methyl
PGE2) which is used to treat peptic ulcers has been shown to have little or no effect on
uterine activity or baseline uterine tone when a single dose (similar to that
recommended for treatment) was given to pregnant women in the first trimester
(Euler et al, 1989). At larger doses (1200 jig and over) vaginal spotting was induced in
some women, but the incidence of side effects in association with this dose of
prostaglandin were high.
In summary, oral misoprostol increased uterine tone in women in early pregnancy, but
only resulted in bleeding and abortion in 20% of women. In contrast, in women
pretreated with 200 mg mifepristone there was a striking increase in contractility and
eighteen out of twenty-one women aborted completely. The side effects associated
with the administration ofmisoprostol were minimal. Opiate analgesics were required
by only 14% of women following mifepristone and misoprostol, compared with 21%
of women following mifepristone and gemeprost (Chapter 2) at the same gestation. It
is not clear whether the apparent lower incidence of side effects following mifepristone
and misoprostol simply relates to a lower total dose of prostaglandin, and whether the
same effect could be achieved by using a lower dose of gemeprost in combination with
mifepristone. Further work is required to determine the clinical efficacy ofmifepristone
and misoprostol in women of up to 56 days amenorrhoea, and to compare the use of
misoprostol with a bio-equivalent dose of other prostaglandins.
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Chapter 5:
The effects of mifepristone in vivo on decidual prostaglandin
production
Introduction
The data presented in Chapters 2 and 4 demonstrate that mifepristone is an effective
abortifacient when used in combination with an exogenous prostaglandin. It also
stimulates uterine activity in early pregnancy (Bygdeman and Swahn, 1985), but the
mechanism of action ofmifepristone in inducing these effects is uncertain. An increase
in decidual prostaglandin production could explain both effects. There is good
evidence that progesterone inhibits decidual prostaglandin synthesis, both in vitro and
in vivo (see Chapter 1). In vitro studies have shown an increase in decidual
prostaglandin production following the addition ofmifepristone to decidual glandular
cells in culture (Smith and Kelly, 1987). However, in vivo studies, where an
increase in prostaglandin metabolite levels in the peripheral circulation have been used
as an index of decidual prostaglandin production, have failed to show a demonstrable
increase in decidual prostaglandin production 24-48 hours after 600 mg mifepristone in
vivo both in the first and early second trimester (Hill et al, 1990a; Hill et al, 1990b).
This Chapter describes results of a study to determine whether treatment with
mifepristone in vivo results in an increase in decidual prostaglandin by obtaining
decidua from women pretreated in vivo with mifepristone, and examining the ability of
the tissue to generate prostaglandins in culture in vitro.
Methods
Patients
Forty-five women with a normal intrauterine pregnancy of less than 56 days
amenorrhoea undergoing legal termination of pregnancy were recruited into the study.
All women had grounds for termination of pregnancy under the 1967 Abortion Act.
The study was described in detail to the patients and written informed consent obtained
prior to enrolment. The protocol was approved by the Reproductive Medicine Ethical
Subcommittee of Lothian Health Board. On recruitment, full clinical history was taken
and physical examination performed. A scan was performed to confirm an intrauterine
pregnancy of < 56 days gestation. Mifepristone ± indomethacin was given, and
surgical termination performed under general anaesthesia as described below. Women
were detained in hospital for four hours post operatively. Thereafter they were
allowed home with contraceptive advice, and anti D if appropriate. All women were
seen for routine follow up one week after abortion.
Treatment
Women were allocated into one of eight groups: a control group received no treatment
prior to surgical termination of pregnancy (n=5), three groups were given 600 mg (3
tablets) of mifepristone 24 hours (n=5), 36 hours (n=4) or 48 hours (n=3) prior to
termination of pregnancy. A second cohort of women were also included in the
randomisation but in addition received indomethacin in the form of a rectal
suppository 100 mg every 12 hours from the time of administration of mifepristone.
One group of women were given indomethacin alone, 100 mg PR every 12 hours from
48 hours before surgery, the last dose being given 12 hours before pregnancy
termination (n=5). The remaining three groups of women were given mifepristone and
indomethacin, with the last dose of indomethacin given 12 hours prior to surgical
termination so that a total number of 2, 3, or 4 doses of indomethacin were given to
women treated with mifepristone 24 hours (n=5), 36 hours (n=4), or 48 hours (n=3)
prior to surgical termination respectively.
Operation
At operation under general anaesthesia, the vulva and vagina were cleansed with
Betadine (povidone-iodine 10%), and draped to provide a sterile operative area.The
cervix was dilated using Hegar dilators to a diameter of 8mm. Decidua was obtained
by gentle curettage from the side wall of the uterus, and placed in liquid nitrogen (for
measurement of endogenous levels) or ice cold transport media (as described below)
for removal to the laboratory and subsequent tissue culture. Pregnancy termination was
completed using suction curettage.
Materials
Mifepristone {RU486 (17a hydroxy 11 (3 - [4 dimethyl amino phenyl] 17p -[1-
propynyl] estra 4, 9 dien-3-one)} tablets (200 mg each) were a gift from Miss Angela
Davey, Roussel Laboratories Ltd, Uxbridge U.K. RPMI 1640 medium (Gibco Ltd,
Paisley, Scotland, UK) was supplemented with 200 mg/ml gentamicin and fungizone
2 (ig/ml (both from Sigma Chemical Co., USA ) and used as "transport medium".
Tissues were cultured in "complete medium": RPMI 1640 supplemented with 2 |!g/ml
fungizone and 50 mg/ml gentamicin with 5%(v/v) calf serum (Gibco Ltd, Paisley,
Scotland, UK) which had previously been stripped with charcoal (1 mg/ml).
Progesterone (Sigma Ltd, Poole, Dorset, UK) 50 ng/ml or 500 ng/ml was added to
complete media in some of the wells. Mifepristone (175 ng/ml) (Roussel Laboratories
Ltd, Uxbridge U.K) and progesterone (50 ng/ml) was added to complete media in a
fourth set of wells
Extraction of endogenous prostaglandins
A portion of decidua was stored in liquid nitrogen until analysis. When ready to be
assayed the tissues were removed from the liquid nitrogen. A piece of decidua
weighing approximately 60 mg was homogenised in 5 ml ice cold ethanol at full speed
(Polytron) for 5 seconds to extract the prostaglandins. After homogenisation, a 1 ml
aliquot of the homogenate was spun at 12000 g for 2 minutes. An equal volume of
methyl oximating solution (0.12M methoxyamine hydrochloride and 1.0M sodium
acetate, pH 5.6-5.8 ) was added to 0.5 ml of the supernatant. The sample was then
stored until ready to be assayed in the manner described below.
Culture of decidua
On arrival at the laboratory, the decidua was washed twice in complete medium. The
tissue was then divided into small pieces of around 1mm3. Several pieces were then
placed into each of 12 wells of a 24 well culture plate (Nunc, Denmark) with 1 of
complete medium, medium supplemented with progesterone to a final concentration of
50 ng/ml or 500 ng/ml, or medium supplemented with progesterone and mifepristone
to a final concentration of 50 ng/ml and 175 ng/ml respectively. Three replicates of
each culture treatment were used. The culture plates were sealed with micropore tape
and placed in an incubator at 37°C in 95% air and 5% CO2. Media was changed daily
and the spent media stored at room temperature after the immediate addition of methyl
oximating solution in a 1:1 ratio. At the end of three days of culture, protein content
of each of the wells was measured using the protein estimation technique of Lowry
(Lowry et al, 1951).
Assay procedures
1. Prostaglandin radioimmunoassay
The prostaglandins were first converted to their methyl oxime derivative using the
methyl oximating solution described above. Conversion is >95% when samples are
treated at 20°C overnight. Radioimmunoassay using antisera to the methyloxime
derivatives was performed. Cross reactivities of the antisera were as follows: PGF2a
antisera with PGFia, 7.2%; PGF3a, 2.9%; PGF2p, 3.5%; PGE2, 1.1%; 6-oxo
PGFia,1.05%; 13,14-dihydro PGF2a, 1.0%, all other prostaglandins <0.2%; PGFM
antisera (raised against the 13,14- dihyro-15-keto PGF2a derivative) with 15-keto
PGF2a, 4.0%; 13,14-dihydro-15-keto PGF2a, 2.0%; 6,15-dioxo-13,14
dihydroPGFia, 0.35%; PGD2, 13,14-dihydro-15-keto PGE2, 0.12%; 0.08%;
PGFia, 0.07%; PGE2, 0.04%; all other prostaglandins <0.01%; PGE2 antisera with
PGEi, 53%; PGE3, 31%; 20 methyl PGE2, 31%; 19-hydroxy PGEi, 17.8%; 19-
hydroxy PGE2, 3.7%; 20-hydroxy PGE2, 3.7%; 8 iso PGE2) 2.9%; 15-keto PGE2,
0.25%; all other prostaglandins < 0.2%. Cross reactivity was determined by the
amount of prostaglandin that caused 50% of inhibition of binding of the appropriate
labelled prostaglandin to the antibody (Kelly et al, 1986a; Kelly et al 1986b; Kelly et
al, unpublished data). The sensitivity of the assay (the amount distinguishable from
zero with a 95% confidence limit) was 2 pg. Intra-assay and interassay coefficients of
variation were 11% and 14% for PGF2a, 12% and 13% for PGE2, and 7.3% and
13.3% for PGFM. Prostaglandin results were expressed in ng as a ratio of the protein
content of the tissue, expressed in milligrammes or grammes.
2. Protein quantification
Protein content of the tissue was measured by the method of Lowry et al (1951).
This involves reaction of the protein with copper in alkali, and then the reduction of the
phosphomolybdic-phosphotungstic reagent by the copper treated protein. The optical
density of the sample is then read in a spectrophotometer at a wavelength of 640 nm.
The colour change is dependent on the amount of protein present and can be compared
with a standard curve of bovine serum albumin of known concentration. A
disadvantage of the Lowry assay is that the amount of colour varies slightly with
different proteins, however, in this situation, where mixed tissue protein is being
measured, and an absolute value of protein content is not required, this variation is not
a serious drawback.
Statistics
Statistically significant differences were found using analysis of variance using
Newman Keuls procedure. Within subject variables were analysed using analysis of
variance using the t-test. The data was log transformed before analysis to normalise the




The "endogenous concentrations" of PGF2a in the decidua were greater in tissue
harvested from women 24 hours after treatment with mifepristone in vivo than 36 or
48 hours after mifepristone in vivo (p<0.05) (Figure 5.1). There was no significant
effect of mifepristone in vivo on decidual concentrations of PGE2 (Figure 5.2) or
PGFM (Figure 5.3). Decidual prostaglandin concentrations in women pretreated with
mifepristone and indomethacin for 24 hours were apparently lower than those in
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1. Effect of duration of culture on prostaglandin production
To determine the effect of duration of culture on prostaglandin production,
prostaglandin production from control tissues (ie in the absence of in vivo treatment)
on each day of culture was compared. (Figures 5.4; 5.5; 5.6). PGF2a production
from decidua harvested from women in the control group was greater on the second
and third day of culture than the first day, when cultured in complete medium only
(p<0.05) or in 50 ng/ml of progesterone (p<0.01) (Figure 5.4). This increase in
PGF2a production with duration of culture was not seen in decidua cultured either in a
larger dose of progesterone (500 ng/ml) or in the presence of progesterone (50 ng/ml)
and mifepristone (175 ng/ml) combined. There was no significant change in decidual
PGE2 or PGFM production with increasing duration of culture from the control group
whatever the culture media used (Figures 5.5 and 5.6).
2. Effect of progesterone and mifepristone in vitro on prostaglandin
production
To determine the effect of progesterone and mifepristone in vitro, prostaglandin
production from decidua harvested from women in the control group was compared
under different culture conditions. Similarly, prostaglandin production from decidua
harvested from women pretreated 24 hours earlier with mifepristone was compared
under different culture conditions. The production of prostaglandins from decidua
from women in the control group was low and unaffected by the addition of
progesterone or progesterone and mifepristone to the medium (Figures 5.4; 5.5; and
5.6). However, in women pretreated with mifepristone 24 hours previously, the
addition of progesterone (500 ng/ml) to the culture medium resulted in a significant
reduction in PGF2a production by day 3 of culture ( p<0.05) (Figure 5.7). A lower
dose of progesterone (50 ng/ml) had a smaller inhibitory effect on PGF2a production,
suggesting a dose related suppression of PGF2a production by progesterone, although
statistical significance could not be established for this. The addition of mifepristone
(175 ng/ml) and progesterone (50 ng/ml) together to the culture media had a
significantly greater inhibitory effect on PGF2a production than 500 ng/ml
progesterone alone, such that prostaglandin production from decidua cultured with
mifepristone (175 ng/ml) and progesterone (50 ng/ml) was lower than prostaglandin
production from decidua cultured either with 500 ng/ml progesterone, or in control
media only, on day 2 and day 3 of culture (p<0.01). Different culture media had no
significant effects on PGE2 or PGFM production from decidua either from women in
the control group, or the from women treated with mifepristone 24 hours previously
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Prostaglandin production in culture from decidua harvested from women treated 24 hrs previously
with mifepristone, (geometric mean and 67% CI)-
3. Effect of mifepristone (with or without indomethacin) in vivo.
To assess the effects of pretreatment with mifepristone in vivo on the output of
prostaglandins in vitro, decidual explants were cultured for 24 hours in the presence of
progesterone (50 ng/ml) which simulated the concentration seen in plasma in
pregnancy. The production of PGF2a was significantly higher in women pretreated
with mifepristone 36 hours previously, but had declined to control levels in the group
pretreated with mifepristone for 48 hours (Figure 5.10). PGE2 production in vivo
was unaffected by pretreatment with mifepristone in vivo for 24 hours (Figure 5.11).
PGFM production was significantly decreased by 24 hours after mifepristone in vivo
(p<0.01), but significantly increased by 36 hours after mifepristone in vivo
(p <0.0.5) (Figure 5.12). The ratio of PGFM to PGF2a shows a biphasic response
with a decrease in PGFM production 24 and 36 hours after mifepristone in vivo, and
an increase in PGFM production 48 hours after mifepristone in vivo.
Co-administration of indomethacin during mifepristone pretreatment inhibited the
increase in PGF2a (p<0.01) and PGFM (p<0.05) production seen following
pretreatment with mifepristone alone for 36 hours (Figures 5.10 and 5.12). There was
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Prostaglandin production in culture (supplemented by 50 ng/ml progesterone) from decidua harvested
following mifepristone in vivo (geometic mean and 67% CI).
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Discussion
The measured concentrations of prostaglandin (as "endogenous levels" in the first part
of this study) do not correspond to the levels of prostaglandin in the tissue in vivo;
rather they reflect the ability of the decidua to generate prostaglandins in response to
the trauma of collection (Grden, 1979). Maximal PGF2a concentrations were seen 24
hours after mifepristone in vivo, in contrast to maximal production of PGF2a in
culture which was seen 36 hours after mifepristone in vivo. The reasons for this
difference are unclear, but may relate to a difference between the amount of
intracellular prostaglandin which can be extracted and measured after homogenisation
of the tissue, and the ability of the tissue to secrete prostaglandin from intact cells into
the surrounding culture medium.
The low decidual prostaglandin production in culture from women in the control
group is in keeping with previous reports on decidual prostaglandin production in
pregnancy (Maathuis and Kelly, 1978; Abel et al, 1980). The increase in
prostaglandin production with duration of culture (from decidua from women in the
control group) when cultured in the absence of steroid hormones may reflect a
decreasing effect of endogenous progesterone. This hypothesis is supported by the
lack of a change in prostaglandin production over duration of culture either when
progesterone is added to the culture medium, or in women pretreated with mifepristone
24 hours previously, where the effects of endogenous progesterone are already
antagonised by mifepristone in vivo. The addition of progesterone to the culture
medium inhibited decidual prostaglandin production by the third day of culture only in
women pretreated with mifepristone in vivo, and not in the control group. It may be
that prostaglandin production is already maximally suppressed by the effect of
endogenous progesterone in the control group. The inhibitory effects of progesterone
in vitro on prostaglandin production from decidua in culture is in keeping with
previous data on the effects of progesterone on endometrial prostaglandin production
(Abel and Baird, 1980; Kelly and Smith, 1987).
In vitro treatment with mifepristone and progesterone inhibited prostaglandin
production in women pretreated with mifepristone in vivo. These results are surprising
since mifepristone, as a progesterone antagonist, might be expected to stimulate
prostaglandin production in vitro.Stimulatory effects of mifepristone in vitro on
decidual prostaglandin production have previously been demonstrated from decidual
glandular cells (Smith and Kelly, 1987) and from endometrial stromal cells
(Kelly et al, 1986a) in culture. In the former study, the increase in prostaglandin
production was seen both in the presence and absence of arachidonic acid, suggesting
an effect of mifepristone on the cyclo-oxygenase enzyme. In contrast, incubation of
fragments of secretory endometrium with mifepristone alone resulted in a significant
decrease in PGF2a production by the third day of culture, compared with controls,
suggesting that mifepristone can act as a progesterone agonist in vitro (Kelly and
Smith, 1987b). However, an equimolar concentration of progesterone was a greater
inhibitor of prostaglandin production, and when equimolar concentrations of
mifepristone and progesterone were added together to the culture medium,
mifepristone partially antagonized the inhibitory effects of progesterone on PGF2tt
production. There were no significant effects of mifepristone in vitro, either alone or
in combination with progesterone on decidual prostaglandin production in the same
system (Kelly and Smith, 1987b). In the study described here, the addition of
mifepristone and progesterone in vitro to decidua harvested from untreated women had
no significant effect, confirming the data from Kelly and Smith. When decidua
harvested from women pretreated 24 hours earlier with mifepristone was cultured, the
greater inhibitory effect of mifepristone and progesterone together, compared with a
similar concentration of progesterone alone, may reflect action of mifepristone as a
(partial) progesterone agonist in vitro.
Decidua from women pretreated in vivo with mifepristone for 36 hours released more
PGF2a in culture than decidua from women in the control group. Other groups have
used peripheral levels of prostaglandin metabolites as an index of uterine prostaglandin
production, and have failed to show an increase 24-48 hours after mifepristone in
vivo, either in the first (Hill et al, 1990a) or the second trimester (Hill et al, 1990b).
Similarly, no change in peripheral PGFM levels has been seen following the
progesterone synthetase inhibitor epostane (Webster et al, 1985a). However, the data
presented here suggest that mifepristone inhibits prostaglandin metabolism in addition
to increasing prostaglandin synthesis, resulting in a decreased production of PGFM
after pretreatment with mifepristone for 24 hours in vivo. It is unlikely, therefore, that
peripheral serum levels of PGFM reflect in vivo decidual prostaglandin production
following mifepristone.
Although pretreatment with mifepristone for 36 hours resulted in increased PGF2a
production, this was not seen 48 hours after mifepristone treatment in vivo. Since
clinically, bleeding and abortion may occur at this time even prior to the action of
exogenous prostaglandins, the lack of decidual prostaglandin production at this time is
surprising. There are several possible explanations. Firstly, although progesterone
inhibits prostaglandin production, there is evidence that progesterone is required for
the accumulation of arachidonic acid, the precursor of prostaglandin production.When
endometrial stromal cells are incubated with arachidonic acid, a subsequendy increased
ability to generate prostaglandins is seen only when the cells are coincubated with
progesterone (Kelly et al, 1986a). In vitro, the synthetic capacity of persistent
proliferative endometrium is lower than that of normal secretory endometrium until
arachidonic acid is added to the incubation media, suggesting that persistent
proliferative endometrium and normal secretory endometrium have the same synthetic
capacity, but that the low endogenous concentrations of PGF2a in the former arise
from lack of an endogenous precursor (Smith et al, 1982). In women pretreated with
mifepristone for 48 hours, the stores of arachidonic acid may be depleted through
conversion into prostaglandins, and lack of replacement in the antiprogestogenic
environment. Further prostaglandin production may be limited 48 hours after
mifepristone in vivo through lack of the precursor arachidonic acid. An alternative
explanation may be that the decidua is partially necrotic by this stage, at least when
viewed at the ultrastructural level (Schindler et al, 1985), so that the amount of
functional tissue capable of prostaglandin production is reduced.
PGFM production in women pretreated with mifepristone in vivo for 24 hours was
reduced, despite a non significant increase in the precursor PGF2a- The ratio of
PGFM to PGF2a which represents the ability of the tissues to catabolise PGF2a was
reduced 24 and 36 hours after mifepristone in vivo, compared to control tissues. These
data suggest an inhibitory effect of mifepristone on prostaglandin metabolism. In
vitro data suggests that progesterone stimulates prostaglandin metabolism (Kelly et al,
1986a), and mifepristone has been shown to inhibit prostaglandin metabolism in
glandular decidual cells (Smith and Kelly, 1987). The net effect of mifepristone in vivo
in stimulating prostaglandin production and inhibiting prostaglandin metabolism is to
increase local decidual concentrations of prostaglandins. These effects on
prostaglandin production and metabolism are in accord with the theory that
pathophysiological processes which stimulate prostaglandin production inhibit
metabolism, and vice versa (Hoult and Moore, 1979). In the clinical situation, when
exogenous prostaglandins are given in combination with mifepristone, a decrease in
prostaglandin metabolism would be particularly important and may explain the
increased sensitivity to exogenous prostaglandins, but not oxytocin, seen following
mifepristone.
It has been assumed that mifepristone stimulates prostaglandin production via its
progesterone antagonistic effects. However, mifepristone is also a glucocorticoid
antagonist (Philibert et al, 1981). The glucocorticoids are known to stimulate uterine
prostaglandin production. Preincubation of dispersed endometrial cells in culture with
Cortisol (5xl0~7 - 5xlO~5M) resulted in a dose dependent decrease in the ability of the
tissues to generate PGF in response to stimulation by histamine (Skinner et al, 1984).
It is likely, however, that it is the antiprogestogenic effect of mifepristone which
influences prostaglandin production and not its antiglucocorticoid effect.
Progesterone shows inhibitory action on PGF production by proliferative endometrium
in tissue culture at concentrations where Cortisol has no effect (Kelly and Smith,
1987a) and under in vitro systems where mifepristone stimulates prostaglandin
synthesis, the antiprogestin ZK 98734 (which has very little antiglucocorticoid activity)
had similar effects (Smith and Kelly, 1987; Kelly and Smith, 1987b).
Indomethacin is one of the group of non steroidal anti-inflammatory drugs and acts via
inhibition of the cyclo-oxygenase enzyme to inhibit prostaglandin production (Lands
and Hanel, 1983). The observed effects of indomethacin in inhibiting the mifepristone
induced increase in prostaglandin production are in accordance with this. This will be
further considered in the next Chapter when the effects ofmifepristone with or without
indomethacin on uterine activity are studied.
Summary
The observed effects of progesterone in vitro (and by inference in vivo) in inhibiting
decidual prostaglandin production is in accordance with the known effects of
progesterone. The inhibitory effect of mifepristone and progesterone on decidual
prostaglandin production in vitro is more difficult to explain, but may reflect partial
agonist activity of mifepristone, which has been demonstrated by other workers
(Gravanis et al, 1985). In vivo, mifepristone clearly stimulates decidual prostaglandin
production, but this increase can be inhibited by indomethacin.
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Chapter 6:
Effects of mifepristone in vivo (with or without
indomethacin) on uterine activity.
Introduction
Mifepristone stimulates uterine activity in pregnant women in the first and second
trimester ( Bygdeman and Swahn, 1985; Hill et al, 1990b) and sensitises the uterus to
the action of exogenous prostaglandins (Bygdeman and Swahn, 1985). Progesterone
withdrawal (Csapo et al, 1973b), and the use of inhibitors of progesterone synthesis
(Webster et al, 1985a'> Webster et al, 1985b) also have the same effect.
The mechanism of action of this increase in uterine activity is as yet unclear.
The inhibitory effects of progesterone on uterine activity act through various
mechanisms (as reviewed in Chapter 1). The antiprogesterone mifepristone is known
to stimulate gap junction formation in rat myometrium (Garfield and Baulieu, 1987),
and to stimulate decidual prostaglandin in the human (Chapter 5), both of which effects
will contribute to an increase uterine activity. In this Chapter, the results of a study to
determine whether mifepristone also simulated uterine activity when decidual
prostaglandin production was inhibited is described. Uterine activity was measured 24-
48 hours after mifepristone administration, both when mifepristone was given alone
and in conjunction with indomethacin. Uterine activity in the two groups was then
compared. The contribution of the increase in decidual prostaglandin production to the
increase in uterine activity seen following mifepristone could therefore be assessed.
Methods
Patients
Patients recruited for the protocol described in Chapter 5 were included in the study.
The protocol was approved by the Reproductive Medicine Ethical Subcommittee of
Lothian Health Board, and written informed consent obtained from each patient, prior
to enrolment in the study. Patients were randomised to treatment with mifepristone
(± indomethacin) in one of eight groups as described in Chapter 5: a control group
(n=8), three groups treated with 600 mg mifepristone 24 hours (n=8), 36 hours (n=6)
or 48 hours (n=6) prior to surgical termination of pregnancy. Five women were treated
with indomethacin alone (100 mg PR every 12 hours) from 48 hours prior to surgical
termination of pregnancy, the last dose being given 12 hours prior to surgery.
A further three groups of women were given mifepristone (600 mg) and indomethacin
(100 mg PR every 12 hours from the time ofmifepristone administration, the last dose
being given 12 hours preoperatively) either 24 (n=5), 36 (n=6) or 48 (n=5) hours prior
to surgical termination respectively. Following measurement of uterine activity,
surgical termination of pregnancy was performed as described in Chapter 5. After a
four hour recovery period, women were allowed home if well, with anti D if
necessary, and seen for follow up one week later.
Intrauterine pressure recordings
Intrauterine pressure was recorded for one hour immediately prior to surgical abortion.
The equipment used, the method of catheter insertion and the method of calibration
were as described in Chapter 4. Half way through the monitoring period, an
intravenous injection of 10 p.g of PGE2 (Prostin E2, Upjohn) was administered, to
determine the sensitivity of the uterus to exogenous prostaglandins.
Calculation of uterine activity
Uterine activity was calculated in Montevideo units. The reasons for this, and the
system used for identifying contractions are described in Chapter 4.
Statistics
Significant differences in uterine activity between the groups were found using
analysis of variance using Newman Keuls procedure. The data was log transformed
before analysis to normalise the distribution. A paired t test was used to determine the
significance in the increase in uterine activity following prostaglandin E2 injection.
Graphs show geometric mean and 67% CI for clarity.
Results
Uterine activity following mifepristone, with or without indomethacin, prior to
treatment with exogenous prostaglandins is shown in Figure 6.1 (expressed in
Montevideo units) and Figure 6.2 (four actual traces chosen at random). Technical
problems with the recording apparatus precluded uterine activity measurement in five
patients, so that results are based on tracings from 7 patients in the control group, and
6, 6, and 5 patients pretreated with mifepristone for periods of 24, 36, and 48 hours
respectively. Tracings were obtained from 5 women in each of the four groups treated
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Uterine activity in women of < 56 days gestation, (a) Control, (b) Treated with indomethacin 100 mg
bd for 48 hrs. (c). 36 hrs after mifepristone 600 mg. (d) 36 hrs after mifepristone 600 mg and
indomethacin 100 mg bd.
Uterine activity was significantly greater in the three groups pretreated with
mifepristone than in the control group (p<0.01). An increase in uterine activity was
seen in four out of six women 24 hours after mifepristone, and in all women 36 and 48
hours after mifepristone. Within the group of women pretreated with mifepristone,
duration of pretreatment had no significant effect on uterine activity. There was no
difference in uterine activity when indomethacin and mifepristone were given,
compared to uterine activity following mifepristone alone, for each treatment duration.
There was no change in uterine activity measured in Montevideo Units following
10 |ig of PGE2, either in the control group, or group pretreated with mifepristone
alone.
Discussion
The mechanism of uterine contractility and its regulation, with particular reference to
the role of progesterone, has been reviewed in Chapter 1. Both the antiprogestin
mifepristone, and the progesterone synthetase inhibitor epostane stimulate uterine
activity. In a study to determine the effect of epostane on uterine activity, twenty
women of 8-11 weeks gestation, were randomly allocated to receive epostane 100 mg
tid for three days, or to receive placebo tablets (Webster et al, 1985a). After treatment
a Foley catheter was inserted in to the uterus, the balloon inflated with 2 ml of fluid
and pressure changes recorded through a fluid column in the catheter. Uterine activity
was greater in the epostane treated group compared with the placebo treated group.
There was a significant inverse correlation between uterine activity 60 minutes after
catheter insertion, and post treatment serum progesterone levels. In another study
epostane resulted in a dose dependent increase in sensitivity to exogenous
prostaglandin given in the form of a prostaglandin E2 pessary, with a partial increase
in uterine sensitivity following 100 mg epostane t.i.d for three days, and a consistent
increase in uterine sensitivity to prostaglandin E2 following epostane 400 mg daily for
3 days (Webster et al, 1985b). In the second trimester, treatment with epostane
resulted in increased uterine activity compared to control women, and increased uterine
sensitivity to exogenous prostaglandins but not to exogenous oxytocin
(Selinger, 1988). Pretreatment with mifepristone also increases uterine activity in the
first (Bygdeman and Swahn, 1985; Swahn and Bygdeman, 1988) and second
trimester (Hill et al, 1990b). An increase in uterine sensitivity to exogenous
prostaglandins, but not oxytocin can be seen following the use of mifepristone in the
first trimester (Swahn and Bygdeman, 1988). When mifepristone 25 mg b.d is
given, an increase in uterine activity can be seen in some women 24 hours after and in
all women 36 hours after mifepristone therapy (Swahn and Bygdeman, 1988).
In non pregnant women in the luteal phase of the menstrual cycle, mifepristone causes
an increase in uterine activity measured in Montevideo Units, but an increase in uterine
sensitivity to exogenous prostaglandins has not been demonstrated
(Gemzell et al, 1990). The progressive increase in uterine activity following
mifepristone described in this Chapter is in accordance therefore with previous work
on the antiprogesterones and progesterone synthetase inhibitors. Interestingly, there
was an increase in uterine activity in four out of six women 24 hours after
mifepristone, but in all women 36-48 hours after mifepristone, and again this is in
agreement with previous data (Swahn and Bygdeman, 1988).
The prostaglandin synthetase inhibitor indomethacin has been shown to inhibit uterine
activity in conditions associated with an increase in prostaglandin synthesis.
In women with dysmennorhoea, indomethacin (100 mg rectally) inhibited uterine
activity within one hour of administration (Lundstrom et al, 1979). Indomethacin has
also been shown to prolong gestation in women in suspected preterm labour,
compared to placebo (Zuckerman et al, 1984). Both of these conditions are associated
with increased prostaglandin synthesis (Willman et al, 1976; Weitz et al, 1986).
Therefore, in situations where an increase in uterine activity is caused by an increase in
prostaglandin production, indomethacin appears to inhibit uterine activity, presumably
by inhibiting endogenous prostaglandin production.
The failure of indomethacin to inhibit the mifepristone induced increase in uterine
activity in this study was surprising. In Chapter 5, indomethacin was shown to
inhibit the mifepristone induced increase in decidual prostaglandin production.
Since indomethacin did not simultaneously inhibit uterine activity this suggests that
factors other than an increase in decidual prostaglandin production are responsible for
the increase in uterine activity seen following mifepristone. There are several possible
explanations for this:
Firstly, mifepristone not only stimulates production of prostaglandins which increase
uterine tone, but has also been shown (in vitro) to antagonise the progesterone
induced inhibition of the uterine relaxant PGI2, in rat myometrium
(Jeremy and Dandona, 1986). When indomethacin is given with mifepristone, the
production of both these prostaglandins may be inhibited, such that the balance
between myometrial stimulation and relaxation is maintained. Secondly, indomethacin
also inhibits prostaglandin metabolism (Hansen, 1976) so that the reduced amount of
PG synthesised is active for longer. Since indomethacin was not added to the culture
media, data shown in Chapter 5 may not reflect PG concentration in decidua in vivo.
Thirdly, some commentators (Kierse, personal communication) have suggested that
uterine contractility is a function of myometrial, rather than decidual prostaglandin
production, and that the effects of mifepristone, with or without indomethacin, may
not be the same in the myometrium as in the decidua. By extrapolation from labour at
term, the main source of the increase in prostaglandin levels in both amniotic fluid
(Karim and Devlin, 1967) and peripheral plasma (Green et al, 1974) co-incident with
an increase in uterine contractility is unclear, with the decidua
(Karim and Devlin, 1967), the fetal membranes (McDonald et al, 1974) and the
myometrium (Willman and Collins, 1976) all having been proposed. However, since
indomethacin in the regime described here has been shown to inhibit uterine activity in
conditions associated with increased prostaglandin production, one would expect
indomethacin to inhibit uterine activity stimulated by any drug acting via increased
prostaglandin synthesis, wherever the source of the increased prostaglandin production
in the uterus.
The most convincing explanation for the lack of inhibition of the mifepristone induced
increase in uterine activity by indomethacin is that the increase in uterine activity seen
following mifepristone is not due to antagonism of the inhibitory effects of
progesterone on prostaglandin production, but is mediated via antagonism of one of
the other suppressive effects of progesterone on uterine activity (Chapter 1).
Mifepristone appears to stimulate gap junction formation in rat myometrium
(Garfield and Baulieu, 1987) and it is possible that the stimulatory effects of
mifepristone on uterine activity act via this mechanism, rather than via increased
prostaglandin production. Further studies are required to investigate the contribution of
other mechanisms to the mifepristone induced increase in uterine activity.
The lack of a further increase in uterine activity following exogenous prostaglandin
suggests that the dose of prostaglandin used was below the threshold dose. In mid
pregnancy, the threshold dose of a single injection of PGE which stimulates a uterine
contraction is 20 fig (Lundstrom, 1986). A dose of 10 fig of PGE2 was chosen for the
study described here, in the hope that the untreated uterus would not respond, but that
following sensitisation with mifepristone (where an increase in myometrial sensitivity
to intramuscular sulprostone of four fold can be seen) (Bygdeman and Swahn,1985),
an increase in uterine tone might be observed. In addition, we were keen to avoid any
cardiovascular side effects which can be observed following moderate-large doses of
intravenous prostaglandins (Karim et al, 1971). Since in early pregnancy the uterus
is even more refractory to the effects of exogenous prostaglandins, it appears in
retrospect that the dose of PGE2 used in this study to test uterine response was too
small. Further studies using larger doses of PGE2 would be required to determine
whether co-administration of indomethacin inhibits the increased sensitivity of the
uterus to exogenous oxytocic agents.
Chapter 7:
The effects of mifepristone on the cervix in early pregnancy
Introduction
The data presented in Chapter 6 show that mifepristone stimulates uterine activity, an
action which contributes to its abortifacient effect. The effect of mifepristone on the
cervix has also been studied. The largest published study involved 230 primigravidae
of 10-12 weeks amenorrhoea, given 0-100 mg mifepristone in a double blind
randomised fashion 24 and 12 hours prior to surgical termination of pregnancy
(World Health Organization Task Force, 1990). Cervical dilation observed at
operation was significantly greater in women pretreated with mifepristone (mean 6.5
mm) compared to those treated with placebo (mean 5.4 mm). Resistance to further
dilation was assessed subjectively at operation. Significantly greater ease of cervical
dilation was observed in mifepristone treated women, an effect which was dose
dependent. Lower cervical resistance in mifepristone treated patients was also recorded
objectively using a strain gauge in a study of 80 primigravidae of 7-13 weeks
gestation. The sum of the peak force required to insert dilators from 4-10 mm was
84.3N in women given placebo tablets, and 46.0N in women pretreated 30 hours
earlier with 600 mg mifepristone (Cohn and Stewart, 1991). The duration of
mifepristone pretreatment also appears to be important. In a study of 55
primigravidae at 7-10 weeks gestation, the resistance of the cervix to further dilation
was significantly less in a group of women given 100 mg mifepristone 36 and 48
hours prior to termination of pregnancy, compared to women treated with mifepristone
36 and 24 hours prior to surgery (R&destad et al, 1990). A ripening effect of
mifepristone on the cervix has also been observed in other studies where parous and
nulliparous women were studied together, or when non pregnant women were studied
(R&destad et al, 1988; Durlot et al, 1988; Gupta and Johnson, 1990).
Therapeutically, the ripening effect of mifepristone on the cervix can be exploited to
avoid cervical trauma during surgical termination of pregnancy, but it is also likely to
aid the abortion process during medical termination of pregnancy. In this Chapter, the
results of a study to determine the effects of mifepristone on the cervix in early
pregnancy, both in terms of the force required to dilate the cervix further, on collagen,
glycosaminoglycan and neutrophil content, and on the ability of the cervix to generate
prostaglandins in culture are reported.
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Methods
Thirty-five women of between ten and twelve weeks gestation undergoing legal
termination of pregnancy were recruited into the study, and randomised to receive
either a placebo tablet or 200 mg oral mifepristone 36 hours before surgical termination
of pregnancy. At operation, the free passability of the cervix and the force required to
dilate the cervix was measured, and a cervical biopsy taken. The ability of the cervix to
generate prostaglandins in tissue culture, and the glycosaminoglycan and neutrophil
elastase content of the cervix were subsequently assessed. The protocol was approved
by the local Reproductive Medicine Ethical Subcommittee, and was part of a
multicentre trial supported by the WHO.
Protocol
Recruitment
Patients were recruited from those scheduled for suction termination of pregnancy, as
described in Chapter 2. Prior to recruitment, a clinical history, and full physical
examination were performed. Details of the study were given to the patient, and
written consent obtained. Patients were informed of their right to withdraw from the
study should they wish.
Mifepristone administration
On admission to the study, details of the patients menstrual cycle, the date of the last
menstrual period, and previous obstetric and medical history were recorded on a data
sheet. Details of the general physical examination, height and weight were recorded.
A pelvic ultrasound scan was performed and mean gestational sac diameter noted.
Blood was taken for typing of the patient's blood group and haemoglobin estimation.
Exclusion criteria for the study were:
age less than sixteen;
recent irregular menstrual cycles;
ectopic pregnancy;
amenorrhoea of < 70 or > 84 days;
chronic disease affecting the respiratory, gastrointestinal,
endocrine, genitourinary, neurological or cardiovascular system;
contraindications to mifepristone;
regular use of prescription drugs or the oral contraceptive pill
in any of the three months prior to presentation.
Patients were given a single tablet containing either 200 mg mifepristone or placebo.
The study was performed in a double blind randomised fashion, patients being
assigned in order of recruitment to a coded treatment pack made up by the WHO in
Geneva. Women were allowed home immediately after taking the tablets, asked to note
any bleeding and to avoid the use of non steroidal anti-inflammatory drugs. Surgical
termination of pregnancy was scheduled for thirty-six hours after tablet administration.
Termination of pregnancy
On readmission to hospital for termination of pregnancy, a short symptom
questionnaire was completed, and routine clinical observations performed.
Termination of pregnancy was performed in theatre under general anaesthesia, with the
patient in the lithotomy position. After washing the perineum with 10% povidone-
iodine, the operative area was draped with sterile towels, and a bimanual pelvic
examination performed. A Sim's speculum was inserted into the vagina, and the cervix
grasped with two vollsellae. Traction was exerted on the volsellae, and a trucut biopsy
taken of the anterior lip of the cervix, in the sagittal plane, at 75° to the cervical canal
and approximately 1 cm from the external cervical os. The cervical biopsy was divided
into two, one piece placed in "complete" culture media (see Chapter 5) and the other in
formaldehyde. The free passability of the cervix (the maximum size of cervical dilator
which could be passed through the cervix without encountering resistance as judged
clinically) was recorded. The cervix was dilated using a set of cylindrical dilators of
progressively greater diameters, starting with a dilator of 3 pam and increasing by
increments of 1 mm . The dilators were attached to a strain gauge and the peak force
required to insert each dilator through the internal os recorded. The cervix was dilated
to 12 mm (or 10 mm if dilation was proving excessively difficult), and routine suction
termination of pregnancy performed. Blood loss was estimated after sieving the
products of conception and removing fetal and placental tissue.
The duration of the operation, from the start of cervical dilation to completion of
abortion was recorded.
The patient was reviewed six hours post operatively, and a further blood sample taken
for haemoglobin estimation, prior to discharge. A follow up appointment was
scheduled for eight weeks post operatively, and barrier methods of contraception
advised until the next menstrual period.
Follow up
At the follow up visit, details of any post operative complications, the duration of
bleeding and the interval to the next menses recorded. Pelvic examination was
performed, and the patient discharged from further follow up if well.
Cervical biochemistry
A portion of the cervical biopsy was fixed in buffered 4% formaldehyde solution,
dehydrated and embedded in paraffin, to enable 5 micron sections to be cut
longitudinally through each specimen. The sections were then deparaffinised with
xylene, and rehydrated through graded ethanol. The following stains were used:
1. Sirius Red (0.1%) (BDH, UK) in saturated aqueous picric acid for one hour.
The sections were then washed for 2 minutes in 0.01M hydrochloric acid,
dehydrated, washed with xylene and coverslipped with Eukitt (O.Kindler Gmbh
and Co). This stain is specific for polymerised collagen. The dye molecules
attach to the collagen fibrils in such a way that their long axes are parallel,
substantially increasing the birefringencey of the collagen. Thus collagen
concentrations in different biopsies can be compared by measuring the percentage
transmission of polarised light through each specimen (Junqueira et al, 1979).
2. Alcian Blue (0.05%) in 0.025M acetate buffer (pH 5.8) with either 0.06M, 0.5M
or 1,0M magnesium chloride for twelve hours. The sections were then rinsed in
absolute alcohol and washed with xylene, before coverslipping with Eukitt. This
method has previously been used to stain for the major classes of
glycosaminoglycans in the cervix (Scott and Dorling, 1965). The differential
concentrations ofmagnesium chloride provide electrolyte cations which compete
with dye cations for binding sites on tissue polyanions; with the different
glycosaminoglycans responding to different electrolyte concentrations: 0.06M,
0.5M and 0.1M magnesium chloride stain selectively for hyaluronic acid,
chondroitin/dermatan sulphate and keratan sulphate respectively. The intensity of
staining at each magnesium chloride concentration can be used to compare
glycosaminoglycan concentrations in each biopsy, by measuring percentage light
transmission.
3. Immunohistochemical staining was used to measure neutrophil elastase content.
Tissue sections were incubated with 3% hydrogen peroxide in methanol for 30
minutes to inhibit endogenase peroxidase activity, rinsed in distilled water and
incubated for 30 minutes in normal rabbit serum (Dakopatts X902; Dako Ltd,
UK) diluted 1: 5 with Tris buffered saline (TBS). They were then incubated for
30 minutes with sheep polyclonal antibody to human neutrophil elastase
(ICN Biochemicals Ltd, UK), washed in TBS for 2 x 5 minutes, incubated for
30 minutes with 1:2500 rabbit anti-sheep immunoglobulin/biotinylated
(Vector Ltd, UK), washed in TBS 2x5 minutes, incubated with avidin-biotin
complex / horseradish peroxidase (Dakopatts K355; Dako Ltd, UK), washed in
TBS 2x5 minutes and incubated for 5 minutes with peroxidase substrate
(3, 3-diaminobenzidine tetrahydrochloride) solution. Sections were dehydrated,
cleared in xylene and coverslipped with Eukitt. The number of neutrophils in
two random fields of the connective tissue of each biopsy specimen were then
counted excluding those within blood vessels.
Quantitation of material
1. Collagen
Slides were screened under an image analyser (Olympus Cue 2 Analyser System with
386 computer and densitometry software 2.2, Olympus UK), under x40
magnification. Two polarising filters were used, one below the condenser and the
other above the objective lens. A plain area of glass (containing no specimen) was
used as the reference optical density, with the polarising filters set in parallel (100%
light transmission). The polarising filters were then reset at 90° to each other, so that
no light was transmitted. The specimen was then moved under the lens, and the optical
density (% light transmission) of 5 separate areas of around 3500 microns square were
analysed so that the median optical density could be calculated. Since the
birefringency was greater with increasing collagen concentrations, the percentage light
transmission was also greater.
2. Glycosaminoglycan content
Slides were screened as above, but without polarising filters. The instrument was
again calibrated using a plain area of glass to give 100% light transmission. Since
staining is proportional to glycosaminoglycan content, the greater the
glycosaminoglycan content, the lower the optical density.
3. Neutrophil elastase
The number of neutrophils in two random high powered fields of the connective tissue
were counted (magnification x 40). Cells in blood vessels were not included in the
quantification. Mean neutrophil count was recorded.
Cervical prostaglandin production
Cervical biopsies for culture were transported to the laboratory in "complete media" as
defined in Chapter 5. The biopsies were washed in complete media, cut into pieces
weighing approximately 0.25 mg, and divided between two culture wells.
Complete media (1 ml) was added to each well, and the plates incubated overnight
(as described in Chapter 5). At the end of 24 hours of culture, spent media was
removed. Methyl oximating solution (0.5ml) was added to 0.5ml of spent media, and
the sample stored until analysis.
Assay procedures
Prostaglandin concentration of the spent media was measured by radioimmunoassay.
Details of the PGE2 and PGF201 assay were as described in Chapter 5. Prostaglandin E
metabolites were measured by radioimmunoassay to the methyl oxime derivative of
13, 14 dihydro-15-keto PGE2. Again, samples were converted to the methyl oxime
derivative using the methyl oximating solution described in Chapter 5. Conversion is
>95% when samples are treated at 20°C overnight. Cross reactivities to the antisera to
13, 14 dihydro-15-keto PGE2 were: 15 keto PGE2, 11.7%; 15-keto PGF2a, 0.94%;
13, 14 dihydro-15-keto PGF2a, 0.19%; 13, 14 dihydro PGF2a, 0.11%; PGE2,
0.05%; PGE3, 0.03%; PGEi, 0.02%; all other prostaglandins <0.02%. The protein
content of the cervical biopsy was measured by the method of Lowry (see Chapter 5).
Statistics
Normally distributed data: age, gestation, weight, height, haemoglobin concentration,
and optical density in the two groups were compared using analysis of variance.
Age, sac diameter, and prostaglandin levels were log transformed (to generate a
normal distribution) and then compared using analysis of variance. Cycle length,
duration of menstruation, cervical dilation, duration of operation, blood loss, change
in haemoglobin concentration, duration of bleeding, interval to next menses and
cervical resistance in the two groups were compared using Mann Whitney U. The chi
squared test was used to explore the difference in the proportion of women bleeding




On breaking the code at the end of the study, eighteen women were found to have been
treated with the placebo, and seventeen women with 200 mg mifepristone. There were






Age (years) 21.8 (20.0 - 23.9) 20.4 (18.9 - 22.0)
Gestation (days) 74.3 (70.8 - 77.9) 73.0 (70.7 - 75.3)
Weight (kg) 62.8 (59.5 - 66.2) 58.8 (55.8 - 61.7)
Height (cm) 165.0 (162- 168) 163.0 (161 - 165)
Diameter of gestational sac (mm) 47.0 (40.6 - 54.6) 46.2 (42.3 - 50.6)
Haemoglobin (g/dl) 13.2 (12.8 - 13.5) 13.0 (12.6- 13.4)
Cycle length (days) 28 (28 - 35) 28 (28 - 35)
Duration of menses (days) 5 (4-7) 5 (3-7)
Patient characteristics on recruitment, mean and 95% CI, except cycle length and duration of menses.
Although some women of less than 70 days were found to have been recruited on
reviewing the data, since they were evenly distributed between the groups, it was
decided to include them in the analysis. Only two women (both in the mifepristone
treated group) reported vaginal bleeding in the 36 hours after tablet ingestion (ns).
Median (range) cervical dilation at operation in the mifepristpne treated group was
5 mm (2-8), and 6mm (2-9) in the placebo group (ns). Median (range ) total force
required to dilate the cervix from 4-10 mm was 47N (9-120N) in the mifepristone
treated group, compared with 93N (34-247N in the placebo treated group (p<0.0005)
(Figure 7.1). Blood loss, and operating time were similar in the two groups, median
and range in the placebo group of 220 ml (10-600) and 12 minutes (7-25) respectively,
compared with 200 ml (100-350) and 10 minutes (7-20) in the mifepristone treated
group. Fall in haemoglobin concentration was not significantly different between the
groups: 0.6 g/dl in the placebo treated group compared to 0.4g/dl in the group treated
with mifepristone. Median (range) duration of vaginal bleeding and interval from
abortion to the next menses was 7 days (2-15) and 37 days (25-52) in the placebo
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Diameter of dilator
Key:
M pretreatment with placebo, n=17
□ pretreatment with mifepristone, n=14
Force required to insert dilators of various sizes in women treated with placebo or mifepristone:
median and upper limit of range.
Biochemical study.
Mean (95%CI) optical density in each of the groups is shown in Table 7.2. There was
no significant difference in the optical density of stained cervical biopsies between the
group treated with mifepristone and the group treated with placebo. Neutrophil elastase




AB 1.0 95.3% (94.2 - 96.4%)
n = 8
95.9% (94.7 - 97.1%)
n = 8
AB 0.6 82.4% (80.0 - 84.9%)
n = 4
93.2% (88.9 - 97.5%)
n = 7
AB 0.06 87.4% (84.4 - 90.4%)
n = 8
72.4 % (53.0 - 91.8%)
n = 6
PSR 0.54% (0.19 - 0.89%)
n = 8
0.39% (0.07 - 0.70%)
n = 7




Optical density and NPL count. Mean and 95% CI (ns. between the groups).
Prostaglandin production
Prostaglandin concentrations in the spent media were expressed as a ratio of protein
content in the cervical biopsy. There was no significant difference in mean PGE2,
PGF2a or PGEM concentrations between the group pretreated with mifepristone and
the group pretreated with placebo (Table 7.3).
Table 7.3
Placebo Mifepristone
PGE2 1.00 (0.39 - 2.58) 0.87 (0.542 - 1.39)
ng/mg protein n = 6 n = 6
PGF2a 1.80 (0.46 - 7.14) 1.42 (0.51 - 3.93)
ng/mg protein n = 5 n = 6
PGEM 1.41 (0.77 - 2.57) 1.46 (0.097 - 2.19)
ng/mg protein n = 6 n = 6
Mean (95% CI) prostaglandin concentration in media incubated with cervical biopsies
(taken from women pretreated with mifepristone 200 mg or placebo) for 24 hours,
(ns between the groups).
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Conclusion
The data described here confirm the cervical softening effect of mifepristone. The total
force required for cervical dilation in women pretreated 36 hours previously with
200 mg mifepristone was 50% that required for cervical dilation in women pretreated
with placebo. These findings are very similar to those in a study comparing
pretreatment with 600 mg mifepristone or placebo 30 hours prior to cervical dilation,
where the force required for cervical dilation in women treated with mifepristone was
55% that found in women pretreated with placebo (Cohn and Stewart, 1991).
A randomised, quantitative comparison of the cervical ripening effect of different
doses of mifepristone has yet to be performed, although data on the ease of cervical
dilation as assessed subjectively in a multicentre trial has shown a dose related effect of
mifepristone on the cervix (World Health Organization Task Force, 1990).
In contrast to other studies (Durlot et al, 1988; Gupta and Johnson, 1990;
World Health Organization Task Force, 1990; Lefebvre et al, 1990;
Cohn and Stewart, 1991) we failed to demonstrate any significant difference in
cervical dilation between the mifepristone treated group, and the placebo treated group
at the start of surgical termination of pregnancy. The reasons for this are not clear,
but may merely be a consequence of the relatively small sample size employed.
The lack of an effect of mifepristone pretreatment on operating time and blood loss
during operation is in agreement with other studies (World Health Organization Task
Force, 1990; Cohn and Stewart, 1991), although a recent study comparing the effect
of 200 mg mifepristone or 1 mg gemeprost with placebo for preoperative cervical
ripening in women of 63-91 days amenorrhoea showed lower blood loss in both the
active treatment groups, compared with the placebo group (Henshaw and Templeton,
1991).
The data presented here fail to demonstrate differences in cervical collagen, hyaluronic
acid, chondroitin/dermatan sulphate or keratan sulphate concentrations between the
group of women pretreated with placebo, and those pretreated with mifepristone.
This implies that the ripening effects of mifepristone on the cervix are mediated by
effects other than a change in collagen or glysocaminoglycan concentrations. There is
little data available on the effects of the antiprogesterones on cervical collagen orGAG
concentrations in the human. Guinea-pig cervix has been studied in late pregnancy
using an electron microscope to determine the morphological effects of the
antiprogesterone onapristone (ZK 98 299) (Hegele-Hartung et al, 1989).
Following subcutaneous administration of 1 mg onapristone on day 59 of pregnancy,
greater collagen degradation, proliferation of fibroblasts, oedema and
polymorphonuclear leucocyte infiltration was observed in cervical biopsies harvested
16-24 hours after treatment, compared to cervical biopsies from control animals at the
same gestation. The changes observed in the mifepristone treated animals were similar
to those seen during spontaneous cervical ripening in control animals when biopsies
were harvested on day 65 of pregnancy (spontaneous delivery in this species normally
occurring on day 67 of pregnancy). Using electrophoresis and susceptibility to
degradation by specific mucopolysaccharidases to determine concentrations of the
different glycosaminoacids in the cervix of the rat (an animal in whom spontaneous
delivery normally occurs from day 22- 23), greater hyaluronic acid concentrations
were observed in biopsies harvested at 22 days gestation when animals were pretreated
24 hours earlier with 10 mg oral mifepristone, compared with cervical biopsies from
animals pretreated 24 hours earlier with vehicle only (Cabrol et al, 1991). There were
no differences in total glycosaminoglycan, heparan sulphate, dermatan sulphate or
chondroitin sulphate concentrations between the mifepristone and placebo treated
group. Electron microscopic analysis of human cervical tissue harvested shortly after
pretreatment with mifepristone in the first trimester shows dissolution of collagen
fibres, accumulation of mast cells and outgrowth of blood capillaries compared with
cervical tissue harvested from a group of women treated with a placebo
However, the same author has failed to demonstrate any change in cervical tissue
morphology in individual patients, after treatment with mifepristone, using cervical
biopsies harvested from the same patients prior to treatment as a control
(RMestad, 1991). The lack of firm quantitative or qualitative evidence of an effect of
mifepristone on cervical collagen or glycosaminoacid concentration contrasts with data
on the effects of the PGEi analogue gemeprost on cervical biochemistry.
Lower collagen content was observed in biopsies from primigravidae in the first
trimester treated with gemeprost, compared with biopsies from a control group treated
with placebo three hours prior to termination of pregnancy, using quantitative
techniques identical to those described in this Chapter (Greer et al - submitted data,
1991). A modest influx of neutrophils was also observed in the group pretreated with
gemeprost (compared to placebo), but there was no change in glycoasaminoglycan
concentrations. This implies, therefore, that not only does mifepristone induce
cervical ripening via mechanisms other than a change in collagen or glycosaminoacid
concentrations, but that the mechanism of action ofmifepristone in inducing cervical
ripening may differ from that of the prostaglandins. The lack of any effect of
mifepristone pretreatment on the ability of the cervix to generate prostaglandins in
tissue culture as described in this Chapter is not, therefore, surprising.
Cervical biopsies taken from pregnant women have previously been shown to produce
prostaglandins in vitro using a superfusion technique with a trend to an increase in
prostaglandin production during active dilation (Ellwood et al, 1980). An increase in
the ability of the cervix to convert arachidonic acid to PGE2 and PGF2a has also been
demonstrated, with an increase in conversion with increasing duration of pregnancy.
However no correlation has been observed between cervical softening as assessed by
the Bishop score, and the ability of the cervix to convert [^C]arachidonic acid to any
one of the prostaglandins (Christensen et al, 1985). Since prostaglandins ripen the
cervix (Calder et al, 1977) and as mifepristone antagonises the inhibitory effect of
progesterone on prostaglandin production from both the decidua (Chapter 5) and the
myometrium (Jeremy and Dandona, 1986), it might be supposed that the ripening
effect of mifepristone on the human cervix is due to increased prostaglandin
production. The data described here fail to support this hypothesis, and are in
agreement with data showing a (non-significant) trend for a decrease in the ability of
the cervix to convert arachidonic acid to PGF2a and PGE2 following pretreatment with
mifepristone in vivo (100 mg 48 and 36 hours, or 36 and 24 hours prior to biopsy)
(R&destadt et al, 1990). Data on the effects of pretreatment with mifepristone (10 mg
24 hours prior to harvesting tissues) in the guinea-pig show no change in the
prostaglandin synthetic or metabolic activity of homogenised cervical tissue (Kelly and
Bukman, 1990), despite significant effects on amnion, chorion and
myometrium/decidua. Further support to the data shown here that increased
endogenous cervical prostaglandin production does not play a role in the mechanism of
cervical ripening induced by antiprogesterone is evinced by guinea-pig studies in
which the prostaglandin synthetase inhibitor indomethacin was given in conjunction
with the antiprogesterone ZK 98 299, but failed to inhibit cervical ripening (Chwalisz
et al, 1987).
If mifepristone ripens the cervix neither by an increase in cervical prostaglandin
production, nor via a change in cervical collagen or glycosaminoglycan content, it may
have other direct effects on the cervix, possibly by antagonism of the effects of
progesterone. Alternatively, the mechanism of cervical ripening following mifepristone
may be passive, with the active effect being the increase in myometrial contractility
following mifepristone. This is less likely, however, since in none of the human
studies on the effect ofmifepristone as a cervical ripening agent in the first trimester is
uterine activity or abdominal pain a significant feature. In an animal study, neither
myometrial activity nor premature labour was noted in guinea-pigs in whom significant
cervical ripening was induced by mifepristone (Chwalisz et al, 1987).
There is limited data on the effects of progesterone on the human cervix. In vitro
treatment with progesterone inhibits the accumulation of hydroxyproline containing
peptides (used as an index of collagen breakdown) in media of cervical biopsies in
culture from non-pregnant women (Wallis and Hillier, 1981). There is greater but
conflicting evidence on the effect of mifepristone on the cervix in animals. In the
pregnant sheep at term progesterone fails to inhibit cervical softening
(Stys et al, 1978). In the guinea-pig, progesterone blocks the oestradiol 17(3
stimulated increase in collagen (type 1) cleavage products in the cultured cervix of the
non pregnant guinea-pig (Rajabi et al, 1991). In studies in the rabbit, both oestradiol
17(3 and progesterone decreased the level of matrix metalloproteinases such as
procollagenase and prostromelysin, and increased the level of tissue inhibitor of
metalloproteinases in the culture media of rabbit uterine cervical fibroblasts; the overall
effect being an inhibition of cervical collagen breakdown by progesterone and
oestradiol 17(3 (Sato et al, 1991). Although these studies indicate that progesterone
tends to inhibit cervical ripening, an action in accord with the effect of mifepristone as
a cervical ripening agent, none of these studies indicates any mechanism of action of
progesterone on the cervix other than via inhibition of collagen breakdown. If the
action ofmifepristone in the human cervix is to antagonise this effect of progesterone,
one would expect a change in optical density as assessed by the picrosirius red method
in this Chapter. Indeed, since significant cervical ripening was observed in the cohort
of women treated with mifepristone from whom cervical biopsies were analysed,
compared to women treated with placebo from whom cervical biopsies were also
analysed, differences in the dose and duration of pretreatment with mifepristone cannot
be credited with the lack of an effect of mifepristone on cervical collagen or
glycosaminoacid concentrations seen here. The remaining possibilities are either that
the changes in collagen or glycosaminoacid concentration are too subtle to be detected
in a small group of patients by the methods described here; that mifepristone
antagonises some as yet unknown effect of progesterone on the cervix, or that
mifepristone has a direct effect, the mechanism of action of which is again entirely
unclear. Further work is required to elucidate which of these hypotheses is correct.
Chapter 8.
Conclusions.
The data presented here confirm that mifepristone, in combination with a
prostaglandin, is a safe and effective agent for menstrual induction. Data in Chapter
2 shows that the currently recommended dose of mifepristone (600 mg) could be
reduced, with no reduction in efficacy of treatment. The full multicentre data is
required to determine whether any small differences in efficacy exist between the
regimes. Where mifepristone is unavailable or contra-indicated, gemeprost alone can
be used for menstrual induction, but the efficacy of a six hourly regime (to a maximum
of 3 mg) described here is less than that of 200-600 mg mifepristone followed
48 hours later by 1 mg gemeprost, and the side effects in terms of analgesic
requirements are greater. Other prostaglandins can also be used in combination with
mifepristone. Data in Chapter 4 show a dose-responsive effect of the orally active
prostaglandin analogue, misoprostol, on uterine activity and indicate that the
combination of mifepristone and misoprostol could be used for menstrual induction.
The importance of mifepristone pretreatment is indicated by the fact that misoprostol
alone (400 jig) is insufficient to induce abortion. Whether the mifepristone-
misoprostol combination has advantages over mifepristone-gemeprost in terms of
reduced side effects, has yet to be shown in a randomised study.
The mechanism of action of mifepristone in inducing abortion is still unclear.
Whilst the data in Chapter 5 shows that mifepristone in vivo stimulates the ability of
the decidua to generate prostaglandin when subsequently cultured in vitro, inhibition
of this increase in prostaglandin synthetic capacity by co-administration of
indomethacin fails to inhibit the mifepristone stimulated increase in uterine activity
(Chapter 6). An increase in uterine prostaglandin production is not, therefore, an
obligatory part of the mechanism of action of mifepristone in stimulating uterine
activity and it may be that other mechanisms such as an increase in gap junction
formation are more important The data in Chapter 7 demonstrates the ripening effect
of mifepristone on the cervix, but the mechanism of action of this effect is still unclear,
since a change in cervical prostaglandin synthetic capacity, collagen or
glycosaminoglycan production does not seem to be involved.
In summary, therefore, the ideal dose of mifepristone and the type and dose of
prostaglandin for menstrual induction is yet to be determined. The mechanism of
action of mifepristone in inducing menstruation is still unclear, and further work is
required to elucidate this. It is estimated that 64,000 women per year in the United
Kingdom will undergo legal termination of pregnancy at less than nine weeks
gestation. The fact that the mechanism of action of mifepristone in inducing
menstruation is still unclear should not prevent the combination of mifepristone and a
prostaglandin being used to treat these women. All the available evidence indicates
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Mifepristone stimulates uterine activity in pregnant women
in the first trimester. In-vitro studies have shown that the
addition of mifepristone to culture medium increases the
ability of decidual cells to generate prostaglandins. In this
study, pregnant women of <56 days gestation were treated
with mifepristone (600 mg) 24, 36 or 48 h prior to surgical
termination of pregnancy. Another cohort of women were
similarly treated with mifepristone, but also received
indomethacin (100 mg b.d.). Control groups, given
indomethacin alone (100 mg b.d. for 48 h) or no treatment,
were also included. Uterine activity was measured
immediately prior to surgical termination of pregnancy and
the ability of decidua obtained at operation to generate
prostaglandins in culture was measured. Uterine activity was
increased in all groups pretreated with mifepristone, an
increase which was not prevented by co-administration of
indomethacin. In the groups pretreated with mifepristone
36 h previously , the production of prostaglandin F^, (PGF^,)
by decidua in vitro was increased. In the group in whom
indomethacin was given in addition to mifepristone 36 h prior
to the study, there was a marked reduction in the ability of
decidua to generate PGF^. In spite of this suppression, the
increase in uterine activity was similar to the group which
had not received indomethacin. These results suggest that
factors other than an increase in decidual prostaglandin
production are responsible for the increase in uterine activ ity




Mifepristone (RU486) has now undergone extensive clinical trials
for the induction of abortion in early pregnancy and is found to
be very effective in combination with an exogenous prostaglandin
for the termination of early pregnancy (Van Look and Bygdeman.
1989). The mechanism of action of mifepristone in inducing an
increase in uterine activity, increasing sensitivity to exogenous
prostaglandin and in terminating early pregnancy is. however,
unknown. Mifepristone increases prostaglandin synthesis when
added to cultures of endometrial or decidual cells in vitro (Kelly
ei al.. 1986a; Smith and Kelly, 1987).
We have attempted to investigate whether the increase in uterine
activity seen after mifepristone treatment (Bygdeman and Swahn.
1985) is due to an increase in synthesis of prostaglandins by the
uterine decidua. Mifepristone was administered to women in early
pregnancy prior to surgical termination of pregnancy, and
prostaglandin synthesis was inhibited in a proportion of these
patients with the use of indomethacin. Uterine activity was
measured for an hour prior to surgery and then correlated with




Women requesting termination of pregnancy with a normal
intrauterine pregnancy of < 56 days amenorrhoea were recruited
into the study. All women satisfied the conditions of the 1967
Abortion Act. and written informed consent was obtained from
each patient. The protocol had been passed by the Reproductive
Medicine Ethical Subcommittee of Lothian Health Board.
Women were allocated into a control group in = 8) (who
received no treatment prior to surgical termination), or were given
600 mg (three tablets) of mifepristone either 24 (n =8). 36
in = 6) or 48 in = 6) h prior to termination of pregnancy. A
further group of women w ere similarly treated w ith mifepristone
but were also given indomethacin in the form of a rectal
suppository 100 mg every 12 h from the time of administration
of mifepristone. The last dose of indomethacin was given 12 h
prior to surgical termination so that a total number of 2. 3. or
4 doses of indomethacin were given to women treated with
mifepristone 24 in = 5). 36 (n = 6). or 48 (n = 5) h prior to
surgical termination, respectively. Five women were not treated
with mifepristone but were given indomethacin 100 mg rectally
every 12 h prior to pregnancy termination.
The allocation of women into the above groups was
randomized. Intrauterine pressure recordings were made for 1 h
immediately prior to surgical termination, and uterine decidua
collected at termination of pregnancy for culture.
Intrauterine pressure recordings
Equipment
A flexible catheter tipped with a pressure transduce (Gaeltec Ltd,
Dunvegan, Isle of Skye, Scotland) was used (pressure range
0 - 300 mmHgl. This was connected to an amplifier and thence
to a pen recorder.
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Transducer insertion
Under sterile conditions, the cervix was visualized with the aid
of a vaginal speculum, the catheter was grasped with a pair of
sponge forceps and passed through the cervical canal into the
uterus. When resistance to further insertion was felt at a depth
of around 8-10 cm, the catheter was withdrawn 1 -2 cm so that
it would be lying free in the uterine cavity. The other end of
the catheter was then connected via an amplifier to a pen recorder.
A vaginal tampon was inserted to hold the catheter in place, and
the catheter taped to the patient's leg.
Calibration
Prior to each insertion the transducer and amplifier were
calibrated as follows. The system was zeroed at atmospheric
pressure, i.e. when the transducer was free in air. a pressure
of 0 was recorded on both the amplification system and the pen
recorder. The transducer was then placed at the bottom of a
column of water at a depth of 43 cm (equivalent to a pressure
of 31.6 mmHg). The gain on the amplifier was adjusted so that
this pressure resulted in a deflection of 31.6 mm on the pen
recorder. When high intrauterine pressures were experienced,
the sensitivity of the system was halved by halving the sensitivity
of the pen recording system so that the records were kept on
one page. The catheter was immersed in 2% glutaraldehyde
solution ('Cidex'; Surgicos Ltd. Livingston, Scotland) for
sterilization prior to insertion into the patient. The paper was
allowed to run at a speed of 5 rnm/min. Following a 'settling
down' period of 10 min, a 60 min recording of intrauterine
pressure was obtained.
Calculation of uterine activity
Intrauterine recordings were subsequently analysed and expressed
in Montivideo units. Montivideo units (as defined by Caldeyro-
Barcia el al.. 1957) are the mean amplitude of contractions (in
mmHg) multiplied by the frequency in 10 min. We were unable
to find reports of an objective scoring system for discriminating
between single contractions, the noise of the recording system
and an increase in baseline intrauterine pressure when calculating
Montivideo units. We therefore devised the following system to
reduce observer bias:
(i) Any increase in uterine activity lasting > 1 min was
considered to be a change in baseline tone rather than a single
contraction. These changes in baseline tone were not included
in any calculation of Montivideo units.
(ii) To distinguish a contraction from electrical 'noise' in the
system, we considered an increase in tone as a contraction only
if the amplitude of the increase was more than tw ice that of the
variability around the baseline, and if the increase in uterine tone
lasted < 1 min
(iii) For an episode of increased uterine pressure where the
pressure dipped towards the baseline but did not reach it before
rising again to a further peak, we considered this as two separate
contractions only if the difference between the pressure trough
and the baseline w as < 207c of the difference between the smaller
peak and the baseline. Otherwise this was considered as one
contraction (provided it lasted < 1 min) with the greatest peak
of intrauterine pressure taken as the amplitude of contraction.
In practice all significant increases in intrauterine pressure
which appeared to be contractions were included by this system.
It is possible that contractions of low amplitude would not havi
been included under this system, but the contribution of thesi
contractions to the total score of Montivideo units would not havi
been great. Certainly, the score in Montivideo units correlate!
with a naked eye impression of uterine activity.
Termination of pregnancy and tissue collection
The intrauterine pressure transducer was removed immediate!;
prior to operation. Surgical termination of pregnancy wa
performed under general anaesthesia. Under sterile condition
with the patient in the lithotomy position the cervix was dilate*
to 8 mm. and decidua obtained by gentle curettage of the sidi
wall of the uterus. This was placed immediately into ice-colt
transport medium (see below). Uterine evacuation was complete*
using suction in the normal manner. Anti D was given to rhesu:
negative patients. Patients rested for 4 h after the surgica
procedure and were then allow ed to return home if accompanied
A follow-up appointment was scheduled for the following week
Tissue culture
Materials
RU486 (17a-hydroxy 11 *3-[4 dimethyl amino phenyl)
17/5-[ 1 -propynyl] estra 4. 9 dien-3-one) tablets (200 mg each;
were a gift from Roussle Laboratories Ltd. Uxbridge UK RPM1
1640 medium (Gibco Ltd, Paisley, Scotland. UK) was
supplemented with 200 /*g/ml gentamycin and 2 j*g/ml fungisone
both from Sigma Chemical Co. Ltd (Poole, Dorset, England)
and used as 'transport medium". Tissues were cultured in
'complete medium': RPM1 1640 supplemented with 2 /*g/ml
fungisone and 50 /ig/ml gentamycin with 5% (v/v) fetal call
serum (Gibco Ltd. Paisley. Scotland. UK) which had previously
been stripped with 1 mg charcoal/ml.
Methods
On arrival at the laboratory, the decidua was washed twice in
complete medium. The tissue was then divided into small pieces
of around 1 mm'. Several pieces were then placed into each of
3 wells of a well culture plate (Nunclon. Nunc. Denmark) with
1 ml of complete medium. The culture plates were sealed with
micropore tape and placed in a plastic box in an incubator at 37°C
in 957c air and 57c CO:. Media was changed daily and the spent
media stored at room temperature after the immediate addition
of methyl oxamating solution (0.12 M methoxyamine
hydrochloride and 1.0 M sodium acetate. pH 5.6-5.8) in a 1:1
ratio. The decidua was cultured for 3 days, and protein content
of the wells measured at the end of the culture period.
Decidua was cultured from women pretreated with mifepristone
for 24 [n = 5), 36 In = 4) and 48 (n = 3) h and from women
in the control group in = 5). In women treated similarly but with
the addition of indomethacin. the numbers in each group were
5. 5. 4 and 3 respectively.
Assay procedures
Radioimmunoassay of the prostaglandin F2o (PGF;a) content of
the media has already been reported (Kelly et al., 1986b). Protein
content of the culture wells was measured using the protein
estimation technique of Lowry et al.. (1951). PGF2o results are
expressed as mean daily prostaglandin per mg protein.
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Statistics
Statistically significant differences were found by analysis of
variance using the Newman-Keuls procedure. The data were
log transformed before analysis to normalize the distribution.
Results
Mean duration of amenorrhoea at time of operation was 48 days;
at time of treatment with mifepristone ± indomethacin (or at
time of operation in the control group) mean serum oestradiol
was 1930 pmol/1, mean serum progesterone 28.3 ng'ml and mean
serum HCG concentration 44905 IU/1. There was no significant
difference between the treatment groups with respect to the above
variables.
Uterine activity
Effects on uterine contractility of pretreatment with mifepristone
with or without indomethacin are shown in Figure 1 (expressed
in Montivideo units) and Figure 2 (two actual traces chosen at
random). Technical problems with the recording apparatus meant
that uterine activity was not recorded in a total of six patients,
so that results are based on tracings from seven patients in the
control group, and 6,6, and 5 patients pretreated with mifepristone
for periods of 24, 36 and 48 h respectively. Tracings were
obtained from five women in each of the four groups treated with
indomethacin. In some women, vaginal bleeding became apparent
prior to the end of the recording of uterine activity. Since the
catheter was not expelled, these recordings were assumed to be
an accurate reflection of uterine activity and therefore included
in the calculations.
The uterine activity was significantly greater in the three groups
pretreated with mifepristone than in the control group (P < 0.01).
An increase in uterine activity was seen in four out of six women
24 h after mifepristone and in all women 36 and 48 h after
mifepristone. There was no significant difference in uterine
contractility within the three groups of women pretreated with
mifepristone. Addition of indomethacin had no effect on uterine
activity either in the control group of women who did not receive
mifepristone, or in the groups treated with mifepristone. The
apparent overall increase in uterine activity in groups treated with
indomethacin compared to groups not treated with indomethacin
was not statistically significant.
Prostaglandin production
PGF.U production in cultures from decidua from women in each
of the treatment groups is show n in Figure 3. It was not possible
to measure PGF;o in the culture media from two patients due
to limited amounts of sample: one from the group pretreated with
mifepristone alone 36 h previously and one from the group
pretreated with mifepristone and indomethacin for 36 h.
The production of PGF;a by decidua collected from women
pretreated 36 h earlier with mifepristone was greater than in the
control group (P < 0.01). Indomethacin had no effect on
PGF:„ production from decidua from women not pretreated
with mifepristone but inhibited the mifepristone-stimulated
increase in PGF-U production (P < 0.01 in tissue from women
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Fig. 1. Uterine contractility following administration of mifepristone
in vivo (Montevideo units); mean and 95% confidence limits. CHI ,
Not pretreated with indomethacin; ■■ , pretreated with
indomethacin. a < b (P < 0.01); c < d (P < 0.01).
Fig. 3. Daily PGF2u production b\ decidua following mifepristone
in vivo; mean and 95% confidence limits. CD . Not pretreated
with indomethacin; Hi . pretreated with indomethacin. a < b (P
< 0.01).
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Discussion
This study demonstrates that a single dose of mifeptist^e
(600 mg) resulted in an increase in uterine activity. This confirms
the findings of Swahn and Bygdeman (1988) who demonstrated
an increase in uterine activity as early as 24 h after commence¬
ment of treatment of 25 mg mifepristone b.d. In both this study,
and that of Swahn and Bygdeman. uterine activity developed in
some (but not all) patients by 24 h after the start of treatment;
it occurred in all subjects 36 or 48 h after the start of treatment.
It appears from these studies that duration of treatment with
mifepristone may be more important than total dose of
mifepristone for stimulation of uterine activity.
PGF;„ has a well described stimulatory effect on uterine
activity in both pregnant and non-pregnant women (for review
see Lundstrom. 1986). Production of PGF2et by decidual
explants in culture reached a maximum 36 h after pretreatment
with mifepristone. This coincides with the presence of uterine
activity in all subjects, and with the peak of uterine activity
measured in Montevideo units. PGF2c, metabolism is decreased
in women pretreated 24 h previously with mifepristone compared
to metabolism in a control group (Norman era/.. 1991). An
increase in decidual PGF2a production would appear to be
at least partially responsible for the increase in uterine activity
seen at 36 h following treatment with mifepristone. However,
uterine activity was still high 48 h after pretreatment with
mifepristone, whereas PGF2a production from decidua
harvested 48 h after pretreatment with mifepristone was not
significantly increased (compared to control). Some factor other
than increased decidual PGF2q production must therefore
contribute to the increase in uterine activity seen 48 h after
pretreatment with mifepristone. This theory correlates with the
observed effects of indomethacin in this study.
Indomethacin is a non-steroidal anti-inflammatory drug which
inhibits prostaglandin synthesis via an inhibitory effect on the
cycloxygenase enzyme (Lands and Hanel. 1983). Indomethaan
(100 mg rectally) inhibits uterine activity in women with
dysmenorrhoea (Lundstrom et al.. 1979) and arrests premature
labour (Zuckerman et al.. 1984). Both dysmenorrhoea ("Willman
el al.. 1976) and premature labour (Weitz el al., 1986) are
associated with increased prostaglandin synthesis. Therefore, in
situations where an increase in uterine activity is caused by an
increase in prostaglandin production, indomethacin appears to
inhibit uterine activity.
In this study, indomethacin had no effect on the mifepristone-
induced increase in uterine activity despite a significant inhibitory
effect on the mifepristone-induced ability of decidua to generate
PGFia in tissue culture. There are several possible explanations
for this finding.
The inhibitory effects of progesterone on uterine activity are
mediated via hyperpolarization of resting membrane potential,
increased junctional resistance and decreased availability of
intracellular calcium, in addition to inhibition of prostaglandin
production (for review see Garfield et al.. 1988). The effect of
mifepristone on uterine activity may be via antagonism of any
one of these effects. Indeed, mifepristone has been shown to have
a stimulatory effect on gap junction formation in rats (Garfield
and Baulieu. 1987). An increase in the number of gap junctions
may be the major mechanism of action of mifepristone on uterine
activity, with increased prostaglandin production playing only
a minor role.
Secondly, myometrial activity is stimulated by PGF;a and
PGE; but inhibited by PGL (at least in the non-pregnant state)
(see Lundstrom. 1986 for review). In cultured rat myometrial
explants. mifepristone has been shown to increase PGL produc¬
tion (Jeremy and Dandona, 1986). The immediate metabolite of
PGI: is the largest conversion product of radio-labelled
arachidonic acid in homogenates of human myometrium
(Christensen, 1984). In the myometrium, therefore, indomethacin
may inhibit the mifepristone-induced production of this inhibitory
prostaglandin, in addition to its effects on decidual PGF2a
production and thus have no net effect on uterine activity.
Although for obvious reasons we were only able to measure
decidual and not myometrial prostaglandin production, there is
evidence that changes in decidual rather than myometrial
prostaglandin production are largely responsible for the initia¬
tion of uterine contractility during labour at term (Casey and
MacDonald. 1988). It is likely that uterine activity throughout
pregnancy is similarly dependent on decidual and not myometrial
prostaglandin production.
Thirdly, prostaglandin receptors concentrations were not
measured. Indomethacin inhibits prostaglandin production but
may also alter prostaglandin receptor concentration so that the
remaining PGF2a has a proportionally greater effect.
In summary , mifepristone has a stimulatory effect on uterine
activity in early pregnancy. This increase in uterine activity is
associated with an increase in decidual PGF;<1 production in
culture 36 h after pretreatment with mifepristone in vivo.
Indomethacin is unable to inhibit the mifepristone-induced in
uterine activity, despite having an inhibitory effect on the ability
of the tissue to generate PGF2o. This suggests that mechanisms
other than an increase in decidual prostaglandin production
contribute to the abortifacient effect of mifepristone An increase
in myometrial gap junctions in response to mifepristone may be
important.
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EFFECTS OF MIFEPRISTONE IN VIVO ON DECIDUAL
PROSTAGLANDIN SYNTHESIS AND METABOLISM
J.E.Norman; Wen Xuan Wu*; R.W.Kelly»; A.F.Glasier»;
A.S.McNeilly*; and D.T.Baird
University of Edinburgh Department of Obstetrics and Gynaecology and
*MRC Reproductive Biology Unit,
Centre for Reproductive Biology,
37 Chalmers St,
Edinburgh EH3 9EW UK
ABSTRACT
Mifepristone is an effective abortifacient in combination with an exogenous
prostaglandin but its mechanism of action is unknown. Mifepristone stimulates
prostaglandin production from decidua in tissue culture. To determine whether this effect
also operates in vivo, we treated women with mifepristone 24, 36 and 48 hours prior to
surgical termination. Decidua was removed at operation and the ability of the tissue to
generate prostaglandin in culture subsequently assessed. Prctreatment with mifepristone
36 hours prior to termination of pregnancy resulted in an increased production of PGF2a
in tissue culture (p<0.01). A significant decrease in PGFM production was seen 24
hours after pretreatment with mifepristone in vivo (p < 0.01). These results suggest that
the increased uterine activity observed after administration of mifepristone may be due to
stimulation of endogenous prostaglandin production and inhibition of prostaglandin
metabolism.
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INTRODUCTION
The antiprogestin mifepristone (RU486) is an effective abortifacient in early pregnancy
with a success rate in inducing complete abortion of around 62% when used alone up to
56 days amenorrhoea, and around 95% when used in conjunction with an exogenous
prostaglandin at the same gestation1. The mechanism of action of mifepristone in
inducing bleeding and abortion is however unknown. There is an increase in the
production of prostaglandins following the addition of mifepristone to decidual cells in
vitro2. The following studies were undertaken to investigate the mechanism of action of
mifepristone in inducing abortion, and in particular to determine whether treatment with
mifepristone in vivo results in an increase in endometrial prostaglandin production.
In this study we have measured the decidual concentrations of PGE2, PGF2a. and
metabolites of PGF2a (PGFM), and the production of these prostaglandins in culture,
following pretreatment with mifepristone in vivo. The effects of the duration of tissue
culture on prostaglandin production, and the effects of in vitro treatment with
progesterone were also investigated.
MATERIALS AND METHODS
Materials
Mifepristone (RU 486 (17ahydroxy lip -[4 dimethyl amino phenyl] 17p-[l-propynyl]
estra 4, 9 dien-3-one)}tablets (200 mg each) were a gift from Miss Angela Davey,
Roussel Laboratories Ltd, Uxbridge, UK. RPMI 1640 medium (Gibco Ltd, Paisley,
Scotland UK) was supplemented with 200 (ig/ml gentamycin and fungizone 2 pg/ml
(both from Sigma Chemical Co., USA) and used as "transport medium". Tissues were
cultured in "complete medium": RPMI 1640 supplemented with 2 pg/ml fungizone and
50 pg/ml gentamycin with 5% (v/v) calf serum (Gibco Ltd, Paisley, Scotland UK)
which had previously been stripped with charcoal (1 mg/ml). Progesterone (Sigma Ltd,
Poole, Dorset, UK) in ethanol,2g progesterone / litre ethanol.was added to complete
media in some of the wells, to a Final concentration of 50 ng/ml or 500 ng/ml
progesterone. The final concentration of ethanol in these wells was 1 part in 400,000
and 1 part in 40,000.respectively.
Patients
Twenty-four women requesting termination of pregnancy with a normal intrauterine
pregnancy of less than 56 days gestation were recruited into the study. All women
satisfied the conditions of the 1967 Abortion Act, and written informed consent was
obtained from each patient. The protocol was approved by the Reproductive Medicine
Ethical Subcommittee of Lothian Health Board. Women were randomised into one of
four groups. Group 1 (the control group, n=8) received no treatment prior to surgical
termination, the remaining women were given 600 mg (3 tablets) of mifepristone 24
hours (group 2, n=7), 36 hours (group 3, n=4) or 48 hours (group 4, n=5) prior to
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termination of pregnancy. At operation under general anaesthesia, decidua was obtained
by gentle curettage and placed in liquid nitrogen (for measurement of endogenous levels)
or ice cold transport media as described above for removal to the laboratory and
subsequent tissue culture. Pregnancy termination was completed using suction curettage.
Endogenous levels
A portion of decidua was stored in liquid nitrogen until analysis. When ready to be
assayed, the tissues were removed from the liquid nitrogen. A piece of decidua weighing
about 60 mg was homogenised in 5 ml ice cold ethanol at full speed (Polytron) for 5 sees
to extract the prostaglandins. After homogenisation, a 1 ml aliquot of the homogenate
was spun at 12000 g for 2 minutes. To 0.5 ml of the supernatant, an equal volume of
methyl oximating solution (0.12M methoxyamine hydrochloride and 1.0M sodium
acetate, pH 5.6-5.8 ) was added. The sample was then stored until ready to be assayed
in the manner described below.
Tissue culture
Decidua from five patients in each of groups 1 and 2 and four patients in each of groups
3 and 4 was set up in tissue culture. On arrival at the laboratory, the decidua was washed
twice in complete medium. The tissue was then divided into small pieces of around 1
mm3. Several pieces were then placed into each of 9 wells of a 24-well culture plate
(Nunc, Denmark) with 1 ml of complete medium, or medium supplemented with
progesterone to a final concentration of 50ng/ml or 500 ng/ml. Three replicates of each
culture treatment were used. The culture plates were sealed with micropore tape and
placed in an incubator at 37°C in 95% air and 5% CO2. Media was changed daily and the
spent media stored at room temperature after the immediate addition of methyl oximating
solution in a 1:1 ratio. At the end of three days of culture, protein content of each of the
wells was measured using the protein estimation technique of Lowry3- PGF2a levels
were measured on only the third day of culture in one patient in group 3. PGE2 levels
were measured in groups 1 and 2 only. PGFM levels were measured in only four
patients in group 2, but on all cultured samples in the other groups.
Radioimmunoassay
Radioimmunoassay was used to determine the PGE2, PGF2a. and PGFM content of
the media. The method used has already been reported4 5-6 Prostaglandin results are
expressed as a ratio of protein content of the decidua. PGE2 levels were only measured
in media from control subjects and patients pretreated with mifepristone 24 hrs
previously since repeat measurements for PGF201 and PGFM used all the media.
Statistics
Statistically significant differences were found using analysis of variance using Newman-
Keuls procedure. Within subject variables were analysed using analysis of variance
using the t-test. The data were log transformed before analysis to normalise the
distribution.




Decidual concentrations of PGF2a> PGE2 and PGFM varied greatly with each group
(Fig 1). PGF2a concentration was greater in group 2 than in group 3 or 4 (p<0.05).
Decidual concentrations of PGE2 and PGFM mirrored PGF2a. but no significant




Fig. 1: Decidual concentration of prostaglandin following mifepristone in vivo.
a > b ( p<0.05)
In vitro culture data
In order to investigate the effect of tissue in culture and of steroid hormones, decidua
from group 1 (control untreated) was cultured for up to 3 days in vitro. PGF2o, PGE2
and PGFM production from decidua harvested from women in the control group is
shown in Fig. 2. The production of prostaglandins from decidua of women in the
control group was low and unaffected by the addition of progesterone to the medium.
Decidual PGF2a production (Fig. 2a) was greater on the second and third day in culture
than on the first day, when cultured in the absence of progesterone (complete media
only) (p<0.05) or in the presence of a small dose of progesterone (50 ng/ml) (p<0.01).
PGF2a production did not change significantly when tissue was cultured in the presence
of a higher dose of progesterone (500 ng/ml). Progesterone had no effect on production
of PGE2 or PGFM in culture, and there was no significant change in PGE2 or PGFM
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production over the three-day culture period whether or not progesterone was added to
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Figure 2: Decidual prostaglandin production from control tissue (group 1) in culture.
The production of prostaglandins by control decidua was extremely low and unlikely to
be suppressed by progesterone. Accordingly, the effect of progesterone was tested on
decidua removed from women who had been pretreated 24 hours previously with
mifepristone (group 2). It was hypothesised that the mifepristone-induced increase in
prostaglandin synthesis might be reversed by the addition of progesterone in vitro. In
women pretreated with mifepristone 24 hours previously (group 2), the addition of
progesterone (500 ng/ml) significantly reduced PGF2a production by day 3 of culture
(p<0.05) (Fig. 3a). A lower dose of progesterone (50 ng/ml) had a smaller inhibitory
effect on PGF2a production, suggesting a dose-related suppression of PGF2a
production by progesterone, although we were not able to establish statistical
significance for this. Progesterone had a similar (non-significant) effect on PGE2
production (Fig. 3b). There was no significant change in production of PGF2a. PGE2
or PGFM from decidua throughout the three-day culture period, either when cultured in
control media only, or when cultured in the presence of progesterone.
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Figure 3 : Decidual prostaglandin production in culture 24 hours after mifepristone in
vivo (group 2).
Effect of mifepristone in vivo
To assess the effects of pretreatment with mifepristone in vivo on the output of
prostaglandins in vitro, decidual explants were cultured for 24 hours in the presence of
progesterone (50 ng/ml) which simulated the concentration seen in the plasma in
pregnancy. The production of PGF2a was significantly higher in group 3 (p<0.01),
but had declined to control levels in group 4 (Fig.4a). The production of PGFM was
significantly reduced in group 2 compared with group 1 (p<0.01) (Fig. 4b). However
in group 3, PGFM production was significantly increased in comparison with group 1
(p<0.01). The ratio of PGFM to PGF2a shows a biphasic response, with a decrease in
groups 2 and 3 and an increase in group 4 (data not shown).
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Group Group
Figure 4: Prostaglandin production in culture following mifepristone in vivo.
a < b (p<0.01)
c > d (p<0.01)
c < e (p<0.01)
DISCUSSION
This study demonstrates that decidua removed from women pretreated 36 hours
previously with mifepristone releases more PGF2a than control tissue when cultured in
vitro for 24 hours. There was a (non-significant) trend for an increase in the production
of PGF2a by decidua 24 hours after treatment with mifepristone in vivo. The
concentration of PGF2a in the decidua was also increased 24 hours after pretreatment
with mifepristone in vivo, compared with concentrations 36 and 48 hours after
pretreatment. It is unlikely that concentration as measured in vitro reflects the
endogenous levels of prostaglandin in the tissue; rather it reflects the ability of the tissue
to generate prostaglandins in response to the trauma of collection7. Thus the production
of prostaglandins from explants of tissue in vitro may be a better reflection of the relative
production of prostaglandins in vivo than the measured concentration of prostaglandin in
a sample of decidua.
The output of prostaglandin E2 and F2a by explants of decidua from women in group 1
was low. Decidual "concentrations" of PGF2a and PGE2 are lower in pregnancy8
probably due to an inhibitory effect of progesterone on prostaglandin production9.
Progesterone inhibits prostaglandin production even in the presence of excess
arachidonic acid10 The increased release of PGF2a in tissue recovered from women
pretreated with mifepristone in vivo may reflect partial antagonism of the suppressive
effect of progesterone. This correlates with previous reports where mifepristone in vitro
has been shown to stimulate decidual PGF2a and PGE2 production from progesterone-
treated explants in a similar culture system u.
The increase in decidual prostaglandin production from day 1 to day 2 and 3 of tissue
culture in group 1 suggests a decreasing effect of endogenous progesterone as culture
progresses. This hypothesis is supported by the lack of a change in prostaglandin
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production when progesterone (500 ng/ml) is added to the culture medium, and by the
lack of a change in prostaglandin production with duration of culture in group 2, where
the effects of endogenous progesterone are already partially antagonised by treatment
with mifepristone in vivo.
In the present study, the addition of progesterone to the culture medium resulted in a
suppression of the release of PGF2a by the third day of culture in women pretreated
with mifepristone in vivo (group 2) bringing production down to the levels seen in the
first 24 hours for the control group. A suppressive effect of progesterone in culture was
not seen in decidua from women in the control group. Prostaglandin production is low
in the control group and further suppression may be difficult to detect. In group 2,
prostaglandin production had been stimulated by mifepristone in vivo (Fig. 1 and 4a).
This effect was partially reversed by the addition of progesterone in vitro and a
suppressive effect of progesterone on prostaglandin production was seen.
Twenty-four hours of pretreatment with mifepristone in vivo (group 2) resulted in a
significant reduction in PGFM production in culture despite an increase in its precursor,
PGF2a- In both group 2 and group 3, the ratio of PGFM to PGF2a (which represents
the ability of the tissue to metabolise PGF2a) was reduced, compared with group 1.
This implies mifepristone antagonizes the stimulatory effects of progesterone on
prostaglandin metabolism5. Again this confirms data with mifepristone in vitro showing
an inhibitory effect of mifepristone on prostaglandin metabolism2.
During pregnancy the myometrium shows little spontaneous activity which is reflected
by the absence of uterine contractions. By 24 hours after administration of mifepristone,
there is an increase in spontaneous uterine activity12, and a markedly enhanced
sensitivity to exogenous prostaglandins. The present findings of increased generation of
PGF2a in vitro by decidua collected from women pretreated with mifepristone in vivo is
compatible with the hypothesis that the increased uterine contractility is due to increased
release of prostaglandins by the decidua in vivo. Moreover,the fall in the output of
PGFM at 24 hr may reflect a relative decrease in the metabolism of PGF2a which would
make the effective local concentration of the hormone higher. However,the fall in the
concentration of PGF2a in the tissue collected from women treated 48 hours previously
(group 4) is more difficult to explain because bleeding and abortion is often occurring at
this time. Possible reasons for the decrease in PGF2a and production include the
development of decidual necrosis following mifepristone13 so that only a portion of the
tissue is functional by 48 hours after mifepristone. Alternatively, the decrease in
prostaglandin production in group 4 may represent antagonism by mifepristone of the
accumulation of cellular stores of prostaglandin precursor, since progesterone appears
necessary to prime the cells with arachidonic acid14. It is likely that factors other than
increased prostaglandin production, such as increased number of gap junctions between
myometrial cells'5 or increased number of receptors for prostaglandins,are important in
the increase in uterine activity seen 48 hours after mifepristone.
In summary, this study confirms that mifepristone stimulates decidual prostaglandin
production and inhibits prostaglandin metabolism. These effects are in keeping with the
action of mifepristone as a progesterone antagonist, and partially explain its abortifacient
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activity. However, it appears that factors other than an increased production of
prostaglandins may also be responsible, at least in the later stages of the abortion
process, and further work is needed to clarify this.
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Uterine contractility and induction of abortion in
early pregnancy by misoprostol and mifepristone
J. E. Norman K. J. Thong D. T. Baird
A combination of the antiprogestagen
mifepristone and an exogenous prostaglandin given
by intramuscular injection or intravaginal pessary is a
highly effective means of inducing abortion in early
pregnancy. However, the search for a stable oral
prostaglandin preparation has been largely
unsuccessful.
The effect of misoprostol, an orally active
prostaglandin used to treat peptic ulcer, on uterine
contractility was investigated in 33 women in early
pregnancy (under 56 days' amenorrhoea). After
administration of misoprostol in doses ranging from
200 ng to 600 pg, there was a significant increase in
uterine pressure. In a second group of women who
were given 200-1000 pg misoprostol 48 h after the
administration of 200 mg mifepristone, there was a
significant increase in the amplitude and frequency
of uterine contractions. Complete abortion took
place in 18 of the 21 women who received
misoprostol after mifepristone, but in only 2 of 40
women given misoprostol alone.
Our findings show that misoprostol increases
uterine activity in early pregnancy and suggest that,
in combination with mifepristone, it may be a highly
effective method of inducing therapeutic abortion.
Lancet 1991; 338: 1233-36.
Introduction
The antiprogestagen, mifepristone, will induce abortion
in early pregnancy.1 When mifepristone is combined with a
synthetic prostaglandin given by vaginal pessary
(gemeprost)2 or an intramuscular injection (sulprostone)3 36
to 48 h later, the complete abortion rate is about 95%.
However, neither route ofadministration ofprostaglandin is
ideal. Reports ofcardiovascular compromise and even death
from myocardial infarction4 after intramuscular sulprostone
are probably related to high peak blood concentrations of
drug. Gemeprost, as part of a vaginal pessary, must be
refrigerated before use, and absorption from the vagina is
variable between individuals; gemeprost has also been
reported to cause cardiovascular complications.5
A stable, orally active prostaglandin that could be used in
combination withmifepristone has been sought. Oral PGE2
has proved disappointing,6 but Swahn and colleagues7
have shown that the combination of mifepristone and
9-methylene PGE2 results in complete abortion rates of
around 95%. Although that study showed the feasibility of
using an orally active prostaglandin, the 9-methylene PGE^
was given in solution and would be impracticable for routine
clinical use. An orally active prostaglandin in tablet form
would bemore acceptable to women and could be important
in developing countries where access to medical facilities is
limited.
Misoprostol is an orally active prostaglandin ([ 15-S]-15-
methyl-PGE2 methyl ester) marketed for the treatment of
peptic ulcer. The manufacturers claim that the structure
of misoprostol leads to fewer gastrointestinal side-effects
than other prostaglandins.8,9 The unauthorised use of
misoprostol as an abortifacient is widespread in some
countries, including Brazil.10
The aims of this study were to determine the effects of
misoprostol alone on uterine tone and contractility in
pregnant women at an early gestation (under 56 days).
Misoprostol (200-1000 jig) was also given to women
pretreated with mifepristone (200mg) to determine whether
enhanced sensitivity to misoprostol could be seen after
mifepristone administration. The clinical effects of
combination abortifacient therapy were also assessed.
Subjects and methods
Women with a normal intrauterine pregnancy of up to 56 days'
gestation and who requested termination ofpregnancy were invited
to take pan in the study. All women satisfied the conditions of the
1967 Abortion Act and gave written informed consent. The
protocol was approved by the Reproductive Medicine Ethical
Subcommittee of Lothian Health Board.
Part 1
The effects of different doses of misoprostol alone on uterine
activity were studied in 12 women scheduled for suction
termination of pregnancy. 3 women were given one 200 fig
misoprostol tablet, 6 women received two misoprostol tablets (total
dose 400 pg), and the remaining 3 women received three
misoprostol tablets (total dose 600 pg). Intrauterine pressure was
monitored for 30 min before misoprostol was given and for the next
3 h. At the end of the monitoring period, suction termination was
completed in the usual way.
Part 2
40 women were given 400 pg misoprostol seven days before
surgical termination of pregnancy. They were asked to record any
symptoms or bleeding. Seven days later, immediately before
ADDRESS: Department of Obstetrics and Gynaecology (J. E.
Norman, MB, K. J. Thong, MRCOG, D. T. Baird, FRCOG), Centre for
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CLINICAL DETAILS OF SUBJECT GROUPS





Pari 1 12 29(19-38) 50 (42-56) 6
Pan 2 40 26 (17-42) 49 (39-56) 26
Pan 3 21 25(18-35) 50 (39-56) 17
termination, a clinical assessment, an ultrasound scan, and a
measurement of serum human chorionic gonadotropin
concentrations were completed to find out whether there was either
an ongoing pregnancy or an incomplete or complete abortion. The
pregnancy was then ended by suction termination.
Part 3
21 women were recruited to determine the effect ofmifepristone
and misoprostol on uterine contractility in early pregnancy (under
56 days' amenorrhoea) and to assess the clinical outcome of this
therapy. Intrauterine pressuremonitoring was started 48 h after oral
treatment with 200 mg mifepristone. Baseline readings were taken
over 30 min, and then a single dose ofmisoprostol was given orally.
4 women received 200 pg misoprostol (one tablet), 10 received
400 pg misoprostol (two tablets), and 7 received 600 pgmisoprostol
(three tablets). Intrauterine pressure monitoring was continued
either for a further 3 h or until abortion occurred, whichever was the
shorter time period.
3 h aftermisoprostol was given, subjects were examined to assess
whether abortion had taken place. In 3 women who received 600 pg
misoprostol, a further dose of 400 pg misoprostol was given after
examination, because no products of conception had been passed
vaginally. Surgical termination of pregnancy was not carried out in
these women but a follow-up appointment ensured that abortion
was complete. Complete abortion was defined as an empty uterus
on ultrasound scan with falling concentrations of human chorionic
gonadotropin. Women in whom abortion was not complete by the
second follow-up were scheduled for surgical termination of
pregnancy.
In parts 1, 2, and 3, a short symptom questionnaire was
completed before and 3 h after misoprostol was given.
Intrauterine pressure recordings
A flexible catheter with a pressure transducer at its tip (Gaeltec,
Dunvegan, Isle of Skye) was passed through the cervix to record
intrauterine contractions and then connected to an amplifier and
pen recorder. The transducer and amplifier were calibrated for each
subject. Details of calibration, catheter insertion, and calculation of
uterine activity in Montevideo units have been described
previously."
Uterine activity
The effects of exogenous prostaglandins on the uterus are
qualitatively and quantitatively different in women pretreated with

















Fig 1—Intrauterine pressure (mm Hg) in 3 women in early
pregnancy who received 200 ng, 400 ng, or 600 pg oral
misoprostol.
30 60 90 120 150 180
Time after misoprostol
■ 600m9 n = 3 • 400ug n = 6 □ 200ng n»3
Fig 2—Mean (SE) intrauterine pressure (untransformed data)
after three doses of misoprostol.
pretreated with mifepristone, a small dose of exogenous
prostaglandin leads to an increase in uterine tone only. Discrete
uterine contractions occur only with large doses of exogenous
prostaglandin. In women pretreated with mifepristone,
spontaneous uterine activity can be recorded. Exogenous
prostaglandin increases the frequency and amplitude of this uterine
activity. Uterine pressure tracings from women in part 1 were
therefore analysed differently from those in pan 3: intrauterine tone
before and at various times after misoprostol was calculated for
women in pan 1, whereas recordings from women in part 3 were
expressed in Montevideo units."
Statistics
The effects of both misoprostol dose and the time after
misoprostol administration on intrauterine pressure and uterine
activity were calculated by analysis of variance (Newman-Keuls
procedure). Data were log transformed before analysis, although
the values were given as means (and standard errors) of
untransformed data for the sake of clarity.
Results
The clinical characteristics of women in each group are
shown in the table.
Part 1
Beforemisoprostol was given, there was negligible uterine
activity and the mean (SE) intrauterine pressure (all three
doses ofmisoprostol combined) was 19-1 (2-6) mm Hg. In
10 of the 12 patients, there was an increase in intrauterine
pressure after misoprostol but, despite this increase in
intrauterine tone, regular uterine activity did not develop
(fig 1). In the other 2 patients (both treated with 400 pg
misoprostol), misoprostol caused no change in intrauterine
pressure. Analysis of the effect of time after misoprostol
administration on mean intrauterine pressure (all three
doses of misoprostol combined) showed a greater
intrauterine pressure after misoprostol administration: 49 7
(6 0) mm Hg at 30 min; 47-5 (6 0) mm Hg at 60 min; and
40-8 (8-4) mm Hg at 120 min (p<001, p<001, and
p < 0 05, respectively, compared with time zero). Analysis of
the effects of different dose regimens showed a greater
intrauterine pressure in women given 600 pg misoprostol
than in women given 400 pg or 200 pg misoprostol (all time
points compared simultaneously; fig 2).
No patient given misoprostol alone complained of
prostaglandin-related side-effects such as nausea, vomiting,
or diarrhoea. 1 patient (who had received 400 pg
misoprostol) had mild abdominal pain that was relieved by
paracetamol. 3 patients reported abdominal pain that did not
require analgesia.
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Fig 3—Intrauterine pressure (mm Hg) in 3 women in early
pregnancy who received 200 ng, 400 ng, or 600 |ig oral
misoprostol 48 h after 200 mg mifepristone.
Part 2
21 of the 40 women studied had some bleeding in the
seven days after administration of misoprostol, although
only 2 (42 and 44 days' amenorrhoea) aborted completely,
6 h and 72 h, respectively, after prostaglandin intake. The
remainder required surgical evacuation seven days later
because of either ongoing pregnancy (32 women) or
incomplete or missed abortion (6 women). Side-effects were
few,with only 1 woman having either diarrhoeaor vomiting.
10 women felt abdominal discomfort in the 4 h after
misoprostol administration and 3 described the pain as
severe.
Part 3
In the group treated with mifepristone, there was an
expected apparent increase in uterine contractility
compared with those in part 1 (fig 3). There was an increase
in uterine activity (in Montevideo units) after prostaglandin
administration; the significance of the increase during
different time periods (all three doses of misoprostol
combined) is shown in fig 4. There were no significant
differences in uterine activity among the three doses of
misoprostol. In 4 women, uterine recordings were not
r p < 0.05 1
0 J
Before 0-30 30-60 60 - 90
Minutes after misoprostol
I 200|ig n = 3 CD 400ng n = 8 I 600ng n = 6
Fig 4—Mean uterine activity (untransformed data) before and
at varying times after misoprostol at three doses after
pretreatment with mifepristone.
possible because of technical limitations. In 3 of the
remaining 17 women, the recording was ended prematurely
(before 90 min) because of passage of the fetus (2 women
given 600 pg and 1 woman given 200 pg). In 18 of 21
women, complete abortion took place after treatment with
misoprostol and mifepristone. Of the remaining 3 women
who required surgical evacuation, 2 (1 given 200 pg and 1
given 400 pg misoprostol in combination with 200 mg
mifepristone) were found to have an ongoing pregnancy at
follow-up 14 days later. The third woman (given 400 pg
misoprostol in combination with 200 mg mifepristone)
passed a gestational sac and placental tissue aftermisoprostol
and appeared to have an empty uterus one week later.
However, she was subsequently admitted to another
hospital with continuing vaginal bleeding. An ultrasound
scan showed the presence of somematerial in the uterus and
uterine evacuation was therefore completed. The material
obtained was not sent for histological examination. Side-
effects of combination therapy were minor. 3 patients
vomited aftermisoprostol, but 1 had vomited earlier that day
and reported an improvement in symptoms after taking the
drug.
None of the women had diarrhoea, although 9 women (2
after 200 pg misoprostol, 6 after 400 pg misoprostol, and 1
after 600 pgmisoprostol) required analgesia (paracetamol or
dihydrocodeine) and 3 (2 after 400 pg misoprostol and 1
after 600 pg misoprostol) required opioid analgesia.
Discussion
The effects of misoprostol on uterine tone are
qualitatively similar to those seen with other prostaglandins.
When prostaglandins are given orally, a high frequency of
side-effects are reported at doses sufficient to cause a change
in uterine tone." In our study, misoprostol led to a
significant increase in uterine tone without important
adverse effects; this low frequency of side-effects after
misoprostol is in keeping with previous reports.13
Misoprostol is known to have some uterine effects. In a
study of pregnant women of 9-12 weeks gestation, 800 pg
misoprostol induced vaginal bleeding in 45% of women,
and a partial or complete abortion in 11 % ofwomen, within
12 h of tablet administration.14 In the UK, the Committee
on Safety of Medicines has urged caution over the use of
misoprostol in premenopausal and postmenopausal women
and advises against its use in women who are pregnant or
planning a pregnancy because of risk of vaginal bleeding.1S
Although misoprostol led to an increase in uterine tone
when given alone, pregnancy continued in 80%, indicating
that it would have little use as an abortifacient at this dose.
Congenital malformations have been reported in babies
born to women who have taken misoprostol in early
pregnancy in an unsuccessful attempt to induce abortion.10
Whether these abnormalities can be directly attributed to
misoprostol remains unclear. The increased efficacy of
misoprostol in women who had been pretreated with
mifepristone reflects the enhanced sensitivity to
prostaglandins induced by antiprogestagens.3
The increased uterine activity after misoprostol
administration in women pretreated with mifepristone is
qualitatively similar to the effects of other prostaglandin
analogues, whether given by the intramuscular3 or oral7
route. However, the only other available orally active
9-methylene PGE2 is not available in a form that would
enable large-scale commercial production. Natural PGE2
given orally in doses small enough to be free of
1236 the lancet VOL 338: NOV 16, 1991
gastrointestinal side-effects does not seem to induce uterine
activity in early pregnancy, despite the increase in uterine
sensitivity after pretreatment with mifepristone.7
The rate of complete abortion with mifepristone
combined with exogenous prostaglandin ranges from
85%-l00%.16,17 The clinical value of mifepristone and
misoprostol therapy cannot be fully evaluated from our
small study, but the finding that complete abortion took
place in 18 of 21 patients is encouraging. Furthermore, 95%
ofwomen in early pregnancy (under 49 days' amenorrhoea)
aborted completely after administration of 600 mg
mifepristone in combination with 600 pg misoprostol.18
Arbaprostil, an orally active PGE2 analogue (15[R]15-
methyl PGE2) that is used to treat peptic ulcers, has been
shown to have little or no effect on uterine activity or
baseline uterine tone when a single dose (similar to that
recommended for treatment) is given to pregnant women in
the first trimester.19 At larger doses (up to 1200 pg), vaginal
spotting is induced in some women, but the frequency of
side-effects in association with this dose of prostaglandin is
high. If our encouraging clinical results are confirmed in a
larger series, the combination of mifepristone and
misoprostolmay prove to be a safe, effective, and reasonably
inexpensive means of medical termination of early
pregnancy.
We thank Sister Maria Dewar and Sister Heideh Hillier for the excellent
nursing care and data collection in this study, and Sister Doreen Wills and her
staffon Ward 54, Simpson Memorial Maternity Pavilion for their continuing
help. The secretarial assistance ofMargaret Harper and the assistance ofMr
T. McFetters and Mr E. Pinner in our Graphics Department is gratefully
acknowledged.
REFERENCES
1.Van Look PFA, Bygdemman M. Antiprogestational steroids: a new
dimension in human fertility regulation. OxfRev ReprodBiol 1989; 11:
1-60.
2. Rodger MW, Baird DT. Induction of therapeutic abortion in early
pregnancy with mifepristone in combination with prostaglandin
pessary. Lancet 1987; ii: 1415-18.
3. Bvgdeman M, Swahn ML. Progesterone receptor blockade: effect on
uterine activity in early pregnancy. Contraception 1985; 32: 45-51.
4. Anon. A death associated with mifepristone sulprostone. Lancet 1991;
337: 969-70.
5. Kalra PA, Litherland D, Sallomi DF, Critchley HOD, Falconer GF,
Holmes AM. Cardiac standstill induced by prostaglandin pessaries.
Lancet 1989; i: 1460-61.
6. Swahn ML, Ugocsai G, Bygdeman M, Kovacs L, Belsey EM, Van Look
PFA. Effect of oral prostaglandin E^ on uterine contractility and
outcome of treatment in women receiving RU 486 (mifepristone) for
termination of early pregnancy. Hum Reprod 1989; 4: 21-28.
7. Swahn ML., Gottlieb C, Green K, Bygdeman M. Oral administration of
RU 486 and 9-mcthylene PGE2 for termination of early pregnancy.
Contraception 1990; 41: 461-73.
8. Dajani EZ, Driskell DR, Bianchi RG, Collins PW, Pappo R. Influence of
the position of the side chain hydroxy group on the gastric antisecretory
and antiulcer actions of E, prostaglandin analogs. Prostaglandins 1975;
10: 733-45.
9. Collins PW, Pappo R, Dajani EZ. Chemistry and synthetic development
ofmisoprostol. Dig Dis Sci 1985; 30: 114S-17S.
10. Fonscca W, Alencar AJC, Mota FSB, Coelho HLL. Misoprostol and
congenital malformations. Lancet 1991; 338: 56.
11. Norman JE, Kelly RW, Baird DT. Uterine activity and decidual
prostaglandin production in women in early pregnancy in response to
mifepristone with or without indomethacin in vivo. Hum Reprod (in
press).
12. Krim SMM. Effects of oral administration of prostaglandins E2 and F2
on the human uterus. J Obstet Gynaecol Br Comtnv 1971; 78: 289-93.
13. Sontag SJ, Mazure PA, Pontes JF, Beker SG, Dajani EZ. Misoprostol in
the treatment of duodenal peptic ulcer: a multicenter double-blind
placebo-controlled study. Dig Dis Sci 1985; 30: 159S-63S.
14. RabeT, Basse H,ThuroH, Kiesel L, Runnebaum B. Action of the PGE,
methyl analogue misoprostol on the pregnant human uterus in the first
trimester. Geburtshilfe Frauenheilkd 1987; 47: 324—31.
15. Committee on Safety of Medicines. Misoprostol (Cytotec) reports of
uterine bleeding and diarrhoea. Cur Problems 1989; 27: 2-3.
16. Ji G, Gen-Mei Q, Yu-Ming W, et al. Pregnancy interruption with RU
486 in combination with dl-15-methyl-prostaglandin-F2a-methyl
ester: the Chinese experience. Contraception 1988; 38: 675-83.
17. Dubois C, Ulman A, Aubeny E, et al. Contragestation par le RU 486:
interet de 1'association a un derive prostaglandine. C R Acad Sci (III)
1988;306:57-61.
18. Aubeny E, Baulieu EE. Contragestation with RU 486 and an orally active
prostaglandin. C R Acad Sci (III) 1991; 312: 539-46.
19. Euler AR, Leodolter S, Huber J, et al. Arbaprostil's [15(R)-15-methyl
PGEJ effects on intrauterine pressure in the non-pregnant and
pregnant human female—a report of four clinical trials. Prostaglandins
Leucot Essent Fatty Acids 1989; 38: 91-98.
SHORT REPORTS
Safety and immunogenicity of
Pseudomonas aeruginosa
conjugate A vaccine in cystic
fibrosis
Urs B. Schaad Alois B. Lang
Joanna Wedgwood Anna Ruedeberg
John U. Que Emil Furer
Stanley J. Cryz Jr
To assess the safety and immunogenicity of a
Pseudomonas aeruginosa octavalent 0-
polysaccharide-toxin A conjugate vaccine, 22
patients (mean age 7 years) with cystic fibrosis who
had no history of colonisation with P aeruginosa
were immunised with the vaccine. Adverse reactions
were mild and self-limiting. IgG antibody
concentrations to all vaccine antigens were
significantly raised after vaccination and remained so
for 12 months. Immunisation produced opsonic and
toxin A neutralising antibodies. A booster dose given
at 12 months led to an anamnestic response. There
was no significant change in clinical status after
vaccination. Further work to assess efficacy in
patients with cystic fibrosis can now be considered
since our findings support the safety and
immunogenicity of the vaccine.
lancer 1991; 338: 1236-37.
Bronchopulmonary infections due to Pseudomonas
aeruginosa are a leading cause ofmorbidity and mortality in
patients with cystic fibrosis (CF).1 Once established in the
lower respiratory tract, the organism is virtually impossible
to eradicate. Repeated pulmonary exacerbations, which
often are fatal, are common. The acquisition of antibiotic
resistance by infecting strains also greatly complicates
treatment.
We have recently described the safety and
immunogenicity of a P aeruginosa octavalent O-
polysaccharide (O-PS)-toxin A conjugate vaccine in man.2
Strains of P aeruginosa that initiate colonisation are
recognised by anti-lipopolysaccharide (LPS) antibodies,
which eradicate the organism via opsonophagocytic killing;
such antibodies could potentially prevent or impede
control patients also took 500 mg of calcium daily throughout one study and during the eti-
dronate-free periods in the other (T Storm et al, N Engl J Med, 322:1265, May 3, 1990; NB
Watts et al, N Engl J Med, 323:73, July 12, 1990).
ADVERSE EFFECTS — With 400 mg of etidronate per day in women with postmenopaus¬
al osteoporosis, no definite adverse effects were detected. After two or three years at this
dosage, defects in bone mineralization have not been observed. In patients with Paget's dis¬
ease, allergic skin rashes have been reported.
DOSAGE AND COST — The dosage of etidronate used in these studies for treatment of
postmenopausal osteoporosis was 400 mg once daily two hours before or after a meal for 14
days, every 3 to 3% months. Sixty 400-mg tablets cost the pharmacist $145.67, according to
Drug Topics MicREData, Nov 1990.
CONCLUSION — Although not approved for such use by the US Food and Drug Adminis¬
tration, etidronate appears to be effective and well tolerated for treatment of postmenopausal
osteoporosis, at least for two or three years. How it compares in effectiveness to other drugs
for this indication and whether concurrent use with one or more of the other drugs would pro¬
vide additional benefit remain to be determined.
MIFEPRISTONE (RU 486)
Recent articles in the press have suggested that mifepristone (RU 486 - Roussel Uclaf)
can effectively and safely induce an abortion. The drug is currently available only in France
and China, but the manufacturer has also applied for a license in the United Kingdom. Mi¬
fepristone has been used on an investigational basis in the USA as an abortifacient and for
treatment of Cushing's disease and breast cancer, but no manufacturer has applied to the US
Food and Drug Administration for approval to market the drug in this country.
MECHANISM OF ACTION — Mifepristone is a 19-norsteroid analog with a high affinity for
progesterone receptors that acts as an antiprogestin (A Ulmann et al, Sci Am, 262:42, 1990).
The drug also binds strongly to glucocorticoid receptors and, to a lesser extent, to androgen
receptors, and stimulates synthesis of prostaglandins by cells of the early human decidua.
Both the prostaglandins and withdrawal of progesterone stimulate uterine contractility. Treat¬
ment with mifepristone during early pregnancy leads to detachment and expulsion of the pro¬
ducts of conception.
PHARMACOKINETICS — After oral administration, plasma concentrations of mifepristone
generally reach a peak within one to two hours, with an elimination half-life of about 20 hours
(ML Swahn et al, Contraception, 34:469, 1986). The drug is extensively metabolized and ex¬
creted mainly in bile. Serum concentrations of active metabolites, but not the parent drug,
are generally dose-dependent (O Heikinheimo et al, Hum Reprod, 2:379, 1987).
EFFECTIVENESS — Clinical studies have shown that treatment with mifepristone alone
can terminate early pregnancy. In one study, 400 to 800 mg in divided doses was 82% to 89%
effective (B Couzinet et al, N Engl J Med, 315:1565, 1986). Another study found an 82% inci¬
dence of complete abortion after a single 600-mg dose (DA Grimes et al, Am J Obstet Gyne¬
col, 162:910, 1990). A summary of studies found that the incidence of complete abortion fol-
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lowing a single 600-mg dose was 84% with less than 42 days of amenorrhea, and 58% if the
duration of amenorrhea was longer (A Ulmann, Contraception, 36 suppl:27, 1987).
The incidence of complete abortion increases if a small dose of a prostaglandin analog is
added (withdrawal of progesterone increases the sensitivity of the myometrium to prostaglan¬
dins). A study in women with less than 56 days of amenorrhea found that mifepristone (150
mg daily for four days) led to complete abortion in 12 (60%) of 20 women, but given with an
intravaginal suppository of the prostaglandin gemeprost (Cervageme - not available in the
USA), complete abortion occurred in 18 (95%) of 19 women (IT Cameron et al. Contraception,
34:459, 1986). A Chinese clinical trial in 283 women found that the incidence of abortion was
slightly more than 50% with mifepristone alone and more than 90% with mifepristone plus a
prostaglandin (SR Zheng, Acta Obstet Gynecol Scand, suppl 149:19, 1989).
In an uncontrolled multicenter survey conducted in France, a single 600-mg dose of mife¬
pristone followed 36 to 48 hours later by intramuscular sulprostone (Nalador - not available
in the USA) or intravaginal gemeprost induced complete abortion in 96% of about 2000 wom¬
en with up to 49 days of amenorrhea. Differences in effectiveness between different doses or
routes of prostaglandins were small, but the mean time to expulsion of the products of con¬
ception ranged from 4.5 hours after the highest dose of sulprostone (0.5 mg) to 22.7 hours
after intravaginal gemeprost (L Silvestre et al, N Engl J Med, 322:645, 1990). Another multi-
center survey found that mifepristone given with intravaginal gemeprost was effective at
inducing abortion in 95% of about 600 women with up to 63 days of amenorrhea (UK Multi¬
centre Trial, Br J Obstet Gynaecol, 97:480, 1990). Mifepristone regimens have been reported
to be ineffective in aborting ectopic pregnancies (JH Levin et al, Am J Obstet Gynecol, 163:543,
August 1990).
BLEEDING — The bleeding pattern is similar with mifepristone alone or given with a
prostaglandin; bleeding starts, in general, one to two days after treatment and lasts one to
two weeks. In one study, patients started to bleed between 10 and 58 hours (median 35
hours) after being given the drugs, with a median duration of 13 days (range one to 44 days)
(MW Rodger and DT Baird, Contraception, 40:439, 1989). The amount of blood loss tends to
be more than during a normal menstrual period. About 1% of patients have required curet¬
tage, and a few have had transfusions.
ADVERSE EFFECTS — Except for bleeding, adverse effects with mifepristone plus a pros¬
taglandin have generally been mild. Crampy abdominal pain occurs in most patients for a
few hours after administration of the prostaglandin. Transient nausea, vomiting, diarrhea, and
headache can also occur. Prostaglandins can cause adverse cardiovascular effects; among
more than 20,000 patients, the manufacturer reports that one myocardial infarction and one
ventricular arrhythmia occurred within three hours after injection of the prostaglandin, but no
maternal deaths have been reported. Endometritis and salpingitis have occurred rarely. No
fetal abnormalities have been observed, and three apparently healthy children were recently
born to women who had taken mifepristone alone early in pregnancy (BH Lim et al, Lancet,
336:257, July 28, 1990).
CONCLUSION — A single oral dose of mifepristone followed by an intramuscular or
intravaginal dose of a prostaglandin can terminate early intrauterine pregnancy in about 95%
of women. The drugs commonly cause transient abdominal pain and one to two weeks of




Jane Norman, Edinburgh University
Inhibitors of progesterone synthesis, antibodies to circulating
progesterone and progesterone receptor antagonists all act
as antiprogesterones. Epostane, azastene and trilostane all
inhibit 3(5 hydroxy steroid dehydrogenase, an essential en¬
zyme in the pathway to synthesis of progesterone. Prelimi¬
nary clinical trials using the antiprogestogenic activity of
these drugs have shown some promise (van der Spuy et al,
1983; Birgerson et al, 1987). As yet only trilostane has a
product licence, for its antiglucocorticoid properties.
Mifepristone (RU486), ZK 98 299 and ZK 98 734 are all
progesterone receptor antagonists. They offer a revolutionary
approach to fertility control, but the very success of
mifepristone has attracted adverse attention from the anti-
abortion lobby. Mifepristone, which has undergone the most
clinical trials, is at present only available in France and
China. Antibodies to circulating progesterone, although ef¬
fective at terminating pregnancy in mice, have not yet been
developed clinically.
This article will concentrate on the progesterone receptor
antagonists and in particular on mifepristone.
Progesterone receptor antagonists
Mifepristone is a progesterone receptor antagonist, i.e. it
binds to the progesterone receptor to exert its effect. It binds
more strongly to the progesterone receptor and to the
glucocorticoid receptor than do progesterone and dexa-
methasone respectively, but binds only weakly to the
androgen receptor (Philibert et al, 1981). Binding to the
glucocorticoid receptor confers antiglucocorticoid properties.
Structure
Mifepristone is derived from the synthetic progestin
norethindrone, with a dimethylaminophenyl side chain at the
11(3 position which confers antagonistic activity. In addition
a propynyl side chain at the 17a position increases the affinity
of the drug for the progesterone receptor (Teutsch, 1985)
(Fig. 1). ZK 98 299 and ZK 98 734 (Schering) are structur¬
ally similar and differ from mifepristone in their in-vitro ac¬
tion only in their relative antiglucocorticoid and
antiprogestogenic activities. However, these last two sub¬
stances have not yet undergone extensive clinical trials in
humans.
Mechanism of receptor interaction
Two mechanisms have been invoked to explain how
mifepristone interacts with the progesterone receptor to pro¬
duce an antagonistic effect. Mifepristone may stabilize a non-
DNA-binding form of the receptor either by stabilizing the
Dr Norman is ClinicaJ Research Fellow in the Department of Obstetrics
and Gynaecology at Edinburgh University
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Fig. 1. Molecular structures of progesterone and mifepristc
progesterone receptor-heat shock protein complex, or
allowing the heat shock protein to dissociate but prevent
the necessary conformational change in the receptor for oj
mal binding to the hormone response elements of D1
(Baulieu, 1988). Transcription cannot then occur.
Pharmacology
Following oral administration the half-life of mifepristi
in the human is around 20-24 h. Mifepristone circula
bound to an alpha-1 acid glycoprotein which is saturated
fairly low doses of the drug (Philibert et al, 1986). Unboc
mifepristone is rapidly metabolized and excreted in the 1
(90%) or in the urine (10%). Metabolism ofmifepristone p
ceeds along two main pathways: mono- and then
demethylation of the diaminophenyl side chain, and c
dation of the propynyl side chain (Deraedt et al, 1985). Th
metabolites also have antiprogestogenic and at
glucocorticoid activity — around 30% that of the origi




Administration of mifepristone in the luteal phase of I
menstrual cycle has been shown to induce luteolysis and v;
inal bleeding (Schaison et al, 1985; Shoupe et al, 1987). V;
inal bleeding may occur independently of luteolysis and
thought to be due to a direct effect of mifepristone
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the endometrium, possibly mediated via an increase in
prostaglandin production by glandular cells (Kelly et al,
1986) or a decrease in endometrial aromatase activity (Tseng
et al, 1986). In these women a second episode of vaginal
bleeding may occur at the end of the luteal phase at the
time of luteolysis. Luteolysis appears to be secondary to
changes in gonadotrophin secretion, such that a decrease in
amplitude (Schaison et al, 1985; Shoupe et al, 1987) and
frequency (Critchley and Baird, 1986) of pulsatile
gonadotrophin release is seen following mifepristone admin¬
istration. These effects are similar to those following
exogenous progesterone administration, and mifepristone
may be acting as a progesterone agonist on the
hypothalamic-pituitary axis in this instance. Factors influ¬
encing luteolysis include dosage of mifepristone and riming
of administration; luteolysis is more likely to occur when
mifepristone is given in the mid to late luteal phase, and
when high doses are given (Nieman and Loriaux, 1988).
Follicular phase administration
Administration of mifepristone in the follicular phase delays
ovulation and disrupts folliculogenesis (Liu et al, 1987). On
ultrasound scanning, collapse of the dominant follicle is seen
with a new wave of follicle formation starting when treatment
is discontinued. Unlike the effects of mifepristone in the
luteal phase, these effects do not seem to be mediated via
a change in gonadotrophin secretion.
Effects on fertilization and embryogenesis
In the rat, administration ofmifepristone results in accelerat¬
ed ovum transport along the fallopian tube (Roblero et al,
1987). The receptive period available for implantation is de¬
layed and widened (Sarantis et al, 1988). In the human,
mifepristone does not appear to affect the final stages of
oocyte development or to affect the in-vitro fertilization rate
of these oocytes when given to women 35 h before egg collec¬
tion (Messinis and Templeton, 1988).
Effects on early pregnancy
Progesterone is essential for the maintenance of early preg¬
nancy. Removing the source of progesterone (Csapo et al,
1973), inhibiting progesterone synthesis using a 3(3 hydroxy
steroid enzyme inhibitor such as epostane (Webster et al,
1985), and blocking the action of progesterone at the receptor
level using mifepristone (Swahn and Bygdeman, 1988) all
result in the development of uterine activity. In a proportion
Fig. 2. Effects of mifepristone on the early pregnant uterus.
C = cervical dilatation; decidual necrosis; PG \ increased
prostaglandin production from endometrium; P4 1 = decreased
progesterone production from corpus luteum; hCG 1 =
decreased placental production of human chorionic
gonadotrophin; E= embryo.
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of cases, abortion occurs {Fig. I). An increased sensitiv
to exogenous prostaglandin has also been demonstrated f
lowing pretreatment with epostane or mifepristone.
The use ofmifepristone or epostane in the second trimesi
also results in the development of spontaneous uterine act
ity and increased sensitivity to exogenous prostaglanc
(Selinger, 1988; Hill et al, 1990a).
Effects on the cervix
When given in the first trimester, mifepristone results in
variable degree of cervical dilatation and ripening (Radest
et al, 1988; World Health Organisation, 199(
Morphologically, dissolution of the collagen fibres, accum
lation of mast cells and ingrowth of blood capillaries c
be seen (Van Look and Bygdeman, 1989). These effects we
initially thought to be due to increased local prostagland
E2 release. In a recent study, however, homogenates of cen
cal biopsies from women pretreated with mifepristone h;
no greater ability to generate prostaglandin E2, prostagland
F2„, thromboxane B2 or 6-keto prostaglandin Fla fro
radiolabeled arachidonic acid than did homogenates of cen
cal biopsies from a control group of women (Radestad
al, 1990). This suggests that cervical effects may be median
by factors other than an increase in prostaglandin productio
Effects on pregnancy at term
The use ofmifepristone to induce labour has been investiga
ed in monkeys. In one study, mifepristone appeared to pr
voke cervical ripening but this was insufficient to induce 1
bour (Wolf et al, 1989). However, the combination i
mifepristone and oxytocin was very effective, with 12 oi
of 14 fetuses being delivered within 48 h. Interestingly, moi
keys delivered to the mifepristone-treated animals showe
a transient increase in weight gain compared with contr
animals; this effect appeared to be secondary to accelerate
colostrum production and immunoglobulin appearance i
breast milk. Evidence from a previous study on the use i
mifepristone to induce labour is less encouragini
mifepristone induced uterine activity in five macaques bi
cervical ripening did not occur, and delivery by caesarea
section (for disproportionate labour) was necessary (Halusl
et al, 1987).
Clinical use
The proven and potential uses of mifepristone are show
in Tables 1 and 2 respectively.
Contraceptive agent
Induction of labour at term
Treatment of progesterone-dependent cancers
Manipulation of the implantation window in in-vitro fertilization
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Abortifacient activity
It is as an abortifacient that mifepristone has been most wide¬
ly investigated, and it is for this application that it is poten¬
tially most useful. Used alone in women at up to 56 days
gestation, mifepristone induces abortion in around 62% (Van
Look and Bygdeman, 1989). However, when used in combi¬
nation with exogenous prostaglandin given 2-4 days after
mifepristone therapy, the complete abortion rate can be im¬
proved to 95-100% (Rodger and Baird, 1987; Dubois et al,
1988; Silvestre et al, 1990). The minimum effective dose of
mifepristone and the optimal dose and type of prostaglandin
are unknown. Studies in Edinburgh on women of less than
56 days gestation have used 600 mg mifepristone followed
48 h later by 0.5-1 mg of vaginal gemeprost (a prostaglandin
Ei analogue) to achieve a complete abortion rate of 95%
(Rodger and Baird, 1987). Vaginal bleeding lasted a median
of 12 days and median blood loss (measured objectively) was
72 ml (range 15-398 ml). Ten per cent of women required
opiate analgesia.
In the second trimester, priming with mifepristone for
24-36 h significantly reduced the induction-abortion interval
when abortion was subsequently induced with prostaglandins
(Urquhart and Templeton, 1987; Rodger and Baird, 1990).
The dose of prostaglandin required and the necessity for opi¬
ate analgesia were also significantly reduced.
Mifepristone can also be used to ripen the cervix in women
at an intermediate stage of gestation undergoing surgical ter¬
mination of pregnancy.
Inhibition of ovulation
Mifepristone has been shown to inhibit ovulation
(Luukkainen et al, 1988), but the minimum dose required
is as yet unknown. Further studies in this area are currently
being undertaken by the World Health Organisation. The
use of mifepristone to inhibit ovulation would potentially be
useful for contraception, but this has not yet been addressed
directly. Unopposed oestrogenic stimulation of the
endometrium might be a problem with long-term daily use.
Postcoital contraception
Three studies to date have examined the effectiveness of
mifepristone as a contraceptive in the luteal phase (Ulmann,
1987; van Santen and Haspels, 1987; Lahteenmaki et al,
1988). A mean failure rate of 4% per treated cycle is compar¬
able with that of other postcoital contraceptive methods (Van
Look, 1987). In addition mifepristone does not seem to have
the same high frequency of side effects (nausea and vomiting)
as other hormonal regimens. A WHO-sponsored study to
compare 600 mg mifepristone with the Yuzpe regimen is on¬
going. In addition to its lower incidence of side effects,
mifepristone may be effective for a longer period after inter¬
course than are the current hormonal methods.
Labour induction
The ability of mifepristone to induce labour at term has not
yet been fully evaluated in the human. A recent French study
has reported on the use of mifepristone to induce labour
in humans and has shown some success (Frydman et al,
1991). Animal work suggests it has potential in this area.
Mifepristone in combination with an oxytocic agent might
induce labour in a more controllable manner than do the
current available agents. Mifepristone was effective in induc¬
ing labour in some patients following fetal death in the third
trimester (Cabrol et al, 1985; Padayachi et al, 1988).
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If mifepristone is to be used to induce labour, it has i
be shown to be harmless to the fetus. Mifepristone does cro:
the placenta and studies in the second trimester have show
a significant increase in fetal aldosterone levels (but r
change in fetal progesterone, oestradiol or Cortisol levels) 4
after maternal administration of 600 mg mifepristone (Hi
et al, 1990b). The significance of this is unclear.
Non-reproductive effects
The antiprogesterones, by virtue of their antiglucocorticoi
activity, also have potential outwith the field of human reprt
duction. In a patient with Cushing's syndrome due to ectopi
secretion of adrenocorticotrophic hormone, treatment wit
mifepristone resulted in a resolution of all symptoms an
signs of the disease (Nieman et al, 1985). Mifepristone hi
been shown to lower intraocular pressure in rabbits and ma
be of benefit in the treatment of glaucoma (Phillips et a
1984). In women with breast cancer resistant to convention;
therapy, mifepristone may be useful as adjuvant treatmer
(Romieu et al, 1987).
Availability
Mifepristone is at present only available in France and Chin;
Roussel have applied for a product licence for mifepriston
m the UK, and it is to be hoped that this revolutionary dru
will be available in the UK soon.
Conclusion
Mifepristone is the first of a number of antiprogesterone
being developed. It is of proven use as a medical abortifacien
(in combination with prostaglandins), as a cervical ripene
in the late first trimester and as a postcoital contraceptiv
agent. Further studies are needed to evaluate its use to indue
labour and as a contraceptive. As with other antihormones
the use of mifepristone provides a unique opportunity to in
vestigate the effects of the natural hormone (progesteron
in this case) in a variety of physiological situations.
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